| Excerpt | Reference |
|---|
| "A review of 352 patients with primary liver cell carcinoma treated by the author is presented." | ( Balasegaram, M, 1975) |
| "We now report another patient with hepatoma with initial near-normal, unsaturated B12-binding capacity that increased 400-fold as the disease progressed and then fell 50% with response to chemotherapy." | ( Helson, L; Liu, CK; Schreiber, C; Waxman, S, 1977) |
| "alpha-BHC inhibited the induction of hepatocellular carcinomas and oval cells infiltration in rats treated with 2-FAA for 5 months." | ( Hiasa, Y; Murata, Y; Ohmori, T; Ohshima, M, 1978) |
| "Survival period of rats bearing ascites hepatoma, AH-60C, which was less sensitive to bis (3-methylsulfonyloxypropyl)amine (864-T) and 6-mercaptopurine each alone, was prolonged by the combined treatment with these two agents." | ( Imamura, H; Okumoto, T, 1975) |
| "Both the unusual avascularity of the hepatoma, and its association with anabolic steriod therapy are discussed." | ( Gnarra, DJ; Holder, LE; Lampkin, BC; Nishiyama, H; Perkins, P, 1975) |
| "among rat liver cells untreated, hepatoma cells produced by back-transplantation of rat liver cells after the treatment with a chemical carcinogen in tissue culture, and the hepatoma cells passaged serially through rats." | ( Akatsuka, T; Katsuta, H; Takaoka, T, 1975) |
| "A rat hepatoma cell line in tissue culture (HTC cells) was treated with hypophyseal extracts from adult male and female rats." | ( Gustafsson, JA; Larsson, A; Skett, P; Stenberg, A, 1975) |
| "The guinea pig hepatoma (line-1) treated with anti-Forssman antibody (TA) and GPC sequentially released 86Rb, 14C from 14C aminoidobutyric acid and failed to exclude trypan blue." | ( Borsos, T; Boyle, MD; Ohanian, SH, 1976) |
| "Thus, benign and malignant tissues from hepatoma-bearing rats exposed to the hepatic carcinogen DL-ethionine have elevated rather than depressed cAMP, compared to control liver, and parenteral administration of this drug increases hepatic cAMP within hours." | ( Craven, PA; DeRubertis, FR, 1976) |
| "Rat hepatocytes and AS-30 D hepatoma cells were treated in vitro with phallolysin, the toxic haemolysin from the death cap fungus Amanita phalloides." | ( Petzinger, E; Seeger, R, 1976) |
| "Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule." | ( Bateman, JR; Durkin, WJ; Link, JS; Paroly, WS; Peters, RL, 1977) |
| "In the case of hepatoma AH109A, radioactivity of mitochondrial fraction was increased with the passage of time after administration, and about 30% of total activity was concentrated in this fraction at 24 hours after administration." | ( Ando, A; Ando, I; Hiraki, T; Hisada, K; Takeshita, M, 1977) |
| "The binding of Line 10 hepatoma cells to normal syngeneic guinea pig macrophages is increased when the tumor cells are treated with neuraminidase and galactose oxidase (NAGO) before they are added to the macrophage monolayers." | ( Piessens, WF, 1977) |
| "This has been investigated in cultured hepatoma (HTC) cells in which N6,O2'-dibutyryladenosine 3':5'-monophosphate increases the activity of tyrosine transaminase only after glucocorticoid treatment." | ( Rousseau, GG, 1977) |
| "The incidence of hepatomas in the phorbol-treated offspring of AAF-injected mothers was 8/74 (11%), as compared with 2/80 (2." | ( Armuth, V; Berenblum, I, 1977) |
| "In a different type of hepatoma cell which is less malignant and forms a small tissue mass or island, cell surface ATPase activity at cell-cell contacts in an island is very weak or scarcely detected even when cells are not treated with dibutyryl cyclic AMP and theophylline." | ( Ohnishi, T; Yamaguchi, K, 1977) |
| "Two types of ascites hepatoma cells, AH 66 and AH 130 FN, were treated with trypsin to observe the release of complex carbohydrates constituting the plasma membranes." | ( Nakada, H; Yamashina, I, 1978) |
| "Two patients with hepatoma of the liver were treated with ligation of the hepatic artery and continuous infusion of adriamycin into the distal arterial branch." | ( Irwin, L; Lee, YT, 1978) |
| "A 45-year-old man with hepatocellular carcinoma who developed intravascular coagulation following complete tumor regression by chemotherapy is described." | ( Harada, T; Makisaka, Y; Nishimura, H; Okuda, K, 1978) |
| "The incidences of malignant tumors, hepatomas or modular hyperplasias, and benign tumors in halothane-treated mice were 7, 6, and 20 per cent, respectively; there were similar incidences of these lesions in control animals." | ( Baden, JM; Kosek, JC; Mazze, RI; Rice, SA; Wharton, RS, 1979) |
| "A total of 18 patients with hepatocellular carcinoma (HCC) were treated by transcatheter arterial embolization (TAE) with a 4'-epi-doxorubicin (EDX)-lipiodol emulsion." | ( Aiba, N; Aoyama, K; Higuchi, K; Miyabayashi, C; Nambu, S; Okada, K; Tsuchida, T; Tsukishiro, T; Watanabe, A; Yasuyama, T, 1992) |
| "Twenty-nine small hepatocellular carcinomas (sHCCs) less than 5 cm in diameter were treated with percutaneous ethanol injection (PEI) under US guidance in 24 cirrhotic patients." | ( Bagnolesi, P; Bartolozzi, C; Caramella, D; Cilotti, A; Lencioni, R; Mazzeo, S; Pinto, F; Vignali, C, 1992) |
| "In 207 cirrhotic patient carriers of hepatocellular carcinoma (HCC), percutaneous ethanol injection (PEI) was administered with ultrasound guidance." | ( Bolondi, L; Lazzaroni, S; Livraghi, T; Marin, G; Morabito, A; Rapaccini, GL; Salmi, A; Torzilli, G, 1992) |
| "Fourteen patients with hepatocellular carcinoma (HCC) and five patients with metastatic liver cancer were treated with this "pile-up" arterial infusion therapy by anticancer agents without gelatin sponge TAE." | ( Abeyama, K; Hiraki, Y; Nakajo, M; Ogita, M; Onohara, S; Shimada, J, 1992) |
| "Patients affected by hepatocellular carcinoma (HCC) with unfavorable prognostic factors have limited therapeutic options due to moderate responsiveness to chemotherapeutic agents and lack of compliance with such treatments." | ( Bajetta, E; Colleoni, M; de Braud, F; Di Bartolomeo, M; Nole, F, 1992) |
| "Ten patients with primary hepatocellular carcinoma were treated with intraarterial instillation of yttrium-90 (Y-90) microspheres, including eight men and two women (median age, 52 years; range, 29-69 years)." | ( Houle, S; Paul, K; Rotstein, LE; Shepherd, FA; Sniderman, KW; Yip, TC, 1992) |
| "Among 44 patients with hepatocellular carcinoma (HCC), combination treatment with both transhepatic arterial embolization (TAE) and ethanol injection therapy (EIT) was performed in 10 patients." | ( Furukawa, J; Hasuike, Y; Kinuta, M; Maruyama, H; Naoi, M; Oi, H; Okamoto, S; Okamura, J; Takata, N; Yayoi, E, 1992) |
| "A total of 135 patients with hepatocellular carcinoma (HCC) were treated by intra-arterial injection of an Adriamycin/mitomycin C oil (lipiodol) suspension (ADMOS) alone or of ADMOS plus cis-diammine-dichloroplatinum (CDDP)." | ( Ikeda, K; Inoue, H; Kobayashi, H; Nakajo, M; Yano, T, 1992) |
| "Nine patients with inoperable hepatoma were treated by using hepatic arterial embolization 131I and chemotherapeutic agent gelatin microsphere (131I-CA-GM)." | ( Chen, X; Li, L; Li, X; Tan, T; Wu, Y; Xie, X; Yan, C; Zhong, D, 1992) |
| "Although hepatic resection for hepatocellular carcinoma is the only known modality that offers an opportunity for cure, the practicing oncologist must be aware of alternative modes of therapy." | ( Demers, ML; Ellis, LM; Roh, MS, 1992) |
| "Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy)." | ( Desai, DC; Desouza, LJ; Dhir, V; Dinshaw, KA; Jagannath, P; Mohandas, KM; Nagral, A; Sharma, V; Swaroop, VS, 1992) |
| "Seventeen patients with hepatocellular carcinoma were treated by intraarterial injection of CTL suspension." | ( Harada, O; Hori, A; Inoue, H; Kanetsuki, I; Miyazono, N; Nishida, H; Sagara, K; Satake, M; Shinmaki, H; Takeshita, T, 1992) |
| "A patient with primary hepatoma, treated with doxorubicin and presenting with atypical electrocardiographic findings, was investigated with myosin-specific monoclonal antibody radiolabelled with indium-111." | ( Athanassiadis, P; Gerali, S; Kostamis, P; Lekakis, J; Moulopoulos, S; Psichoyiou, H; Vassilopoulos, N, 1991) |
| "Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery." | ( Gotoda, A; Kamiyama, T; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Saito, M; Sato, N; Uchino, J; Une, Y, 1991) |
| "Twenty-six cases of hepatocellular carcinoma were divided randomly into 3 groups, treated by transcatheter hepatic arterial chemo-embolizations with agents of MMC 20 mg, MMC 20 mg plus lipiodol 10 ml, and MMC 20 mg plus MTXmc 150 mg, respectively, 2 to 3 weeks before surgery." | ( Chen, H, 1991) |
| "Sixty-three patients with unresectable hepatocellular carcinoma (HCC) were treated with cisplatin-phosphatidyl-choline-Lipiodol (CPL) suspension." | ( Aoki, Y; Hirai, K; Izyuin, H; Noguchi, H; Okano, Y; Ono, N; Sakata, K; Tanikawa, K; Tomita, Y, 1991) |
| "Two patients with recurrent hepatocellular carcinoma underwent reoperation following percutaneous ethanol injection therapy (PEIT) and transarterial embolization (TAE)." | ( Imaoka, S; Ishikawa, O; Iwamoto, S; Iwanaga, T; Kasugai, H; Masutani, S; Ogawa, A; Ohashi, I; Ohigashi, H; Sasaki, Y, 1991) |
| "We describe a man who developed a hepatocellular carcinoma after 24 years of androgen treatment, whose tumour initially showed partial regression after withdrawal of androgens but subsequently pursued an aggressive and fatal course." | ( Gleeson, D; Leahy, BC; McMahon, RF; Newbould, MJ; Taylor, P; Warnes, TW, 1991) |
| "The tumours treated were hepatocellular carcinoma (n = 35), metastatic adenocarcinoma (n = 14), intrahepatic cholangiocarcinoma (n = 3) and leiomyosarcoma (n = 1)." | ( Dick, R; Dusheiko, G; Hobbs, KE; Markham, NI; Novell, JR; Reddy, K, 1991) |
| "Ten patients with unresectable hepatomas were treated by intraarterial high dose ADR (100-150mg/m2) using HVI." | ( Iwasaki, T; Ku, Y; Maekawa, Y; Saitoh, M; Saitoh, Y; Shiki, H; Tominaga, M, 1991) |
| "The therapeutic effect of hepatocellular carcinoma (HCC) was assessed by the serial change of serum AFP value before and after treatment." | ( Hayashi, S; Inagaki, Y; Kaneko, S; Kobayashi, K; Matusushita, E; Terada, M; Terasaki, S; Unoura, M; Urabe, T; Yoneshima, M, 1990) |
| "The survival of hepatocellular carcinoma patients is very low, mainly due to the lack of effective treatments." | ( Chi, CW; Liu, TY; Lui, WY; P'eng, FK, 1991) |
| "Treatment of rat hepatoma cells (H4 cells) with various DNA-damaging agents increases the number of O6-methylguanine-DNA-methyltransferase (transferase) molecules per cell." | ( Habraken, Y; Laval, F, 1991) |
| "Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)." | ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990) |
| "We treated a patient in whom a hepatocellular carcinoma and a hyperplastic nodule of the liver concomitantly grew in association with long term phosphate diethylstilbestrol therapy for a carcinoma of the prostate." | ( Ishibashi, H; Koga, T; Miyamoto, Y; Miyanaga, O; Sakakibara, N; Takata, T, 1990) |
| "From 1986 to 1988, 35 patients with a hepatoma judged either inoperable or unresectable because of coexistent cirrhosis were treated with hepatic arterial embolization of mitomycin C microcapsules." | ( Audisio, RA; Bellegotti, L; Damascelli, B; DeFazio, C; Doci, R; Marchianò, A; Mazzaferro, V; Montalto, F; Piva, A; Tommasini, M, 1990) |
| "In patients with hepatocellular carcinoma who do not sufficiently respond to transcatheter chemoembolization, the combined use of ethanol injection therapy can improve therapeutic results." | ( Akaji, H; Nakamura, H; Suyama, Y; Takayasu, Y, 1990) |
| "In 55 hepatocellular carcinoma patients treated with transcatheter arterial embolization or one shot therapy, the prognosis of patients treated with UFT (group A; n = 23) were historically compared with those of patients treated without UFT (group B; n=32)." | ( Hayashi, K; Ishikawa, T; Ishinoda, Y; Iwaki, Y; Kisanuki, H; Kitamura, T; Maruyama, T; Nakamura, H; Okamoto, T; Shigehira, M, 1990) |
| "In 36 patients with hepatocellular carcinoma treated with transcatheter arterial infusion and embolization, the arithmetic mean survival time after treatment was 412." | ( Akai, S; Kato, K; Kato, T; Nashimoto, A; Niwa, M; Ogoshi, K; Saito, Y; Shimizu, K, 1990) |
| "Sixty cirrhotic patients without hepatocellular carcinoma were included as controls in the same sclerotherapy program for the same period." | ( Etienne, JP; Ink, O; Lascar, G; Pelletier, G; Schoux, JB, 1990) |
| "Six patients with resectable hepatocellular carcinoma received this treatment, which in 3 of them was followed by embolization with Gelfoam of the segmental artery." | ( Furui, S; Hashimoto, T; Mizumoto, S; Monden, M; Nakamura, H; Oi, H; Sawada, S, 1990) |
| "Reported is the case of a hepatocellular carcinoma with a complete remission of the bone metastasis by arterial chemotherapy." | ( Aoki, Y; Fujimoto, T; Fukushima, H; Hirai, K; Iwai, I; Majima, Y; Nakashima, O; Shimada, M; Tanaka, M; Yamashita, K, 1990) |
| "10 patients with hepatocellular carcinoma were treated with intratumoral injection of OK432." | ( Nishioka, M; Shirai, M; Watanabe, S, 1990) |
| "One hundred nine patients with hepatocellular carcinoma were treated with intravenous (IV) Adriamycin (doxorubicin)." | ( Le Moli, S; Pagliaro, L; Sciarrino, E; Simonetti, RG, 1985) |
| "A case of hepatocellular carcinoma was treated with anti-alpha-fetoprotein (AFP) antibody-adriamycin via the hepatic artery with induced hypertension by angiotensin II." | ( Asai, T; Kitamura, T; Mai, M; Ogino, T; Ohta, T; Sawaguchi, K; Suga, T; Takahashi, Y; Ueda, H; Ueno, M, 1986) |
| "Twenty-one patients with nonresectable hepatocellular carcinoma (HCC) received intraarterial infusion chemotherapy of Adriamycin (Adria Laboratories, Columbus, Ohio) via an indwelling catheter in the hepatic artery." | ( Imaoka, S; Ishiguro, S; Ishikawa, O; Iwanaga, T; Koyama, H; Ouhigashi, H; Sasaki, Y, 1986) |
| "This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol (DES) therapy for prostatic cancer." | ( Endo, H; Murakami, T; Nishimoto, I; Sekine, I; Yokoyama, M, 1987) |
| "For the treatment of small hepatocellular carcinoma, intratumor injection of absolute ethanol under ultrasound guidance was performed in 27 tumors in 23 patients, with a tumor diameter of between 1." | ( Chen, DS; Huang, GT; Lai, MY; Lee, CZ; Sheu, JC; Su, CT; Sung, JL; Tsang, YM; Wei, TC; Yang, PM, 1987) |
| "Twenty patients with malignant hepatoma were treated with sequential intraarterial doxorubicin (72-hour continuous infusion) followed by systemic 5-fluorouracil (5-FU) and semustine (methyl CCNU)." | ( Hahn, RG; Moertel, CG; O'Connell, MJ; Rubin, J, 1988) |
| "Thirty-six patients with hepatocellular carcinoma were treated by hepatic arterial chemoembolization of microencapslated mitomycin C (MMCmc)." | ( Fujii, M; Kamata, R; Sakabe, T; Takano, S; Tanaka, T; Yamaguchi, T, 1988) |
| "Lacking a treatment for nonresectable hepatocellular carcinoma (HCC), we have utilized the androgen antagonist properties of ketoconazole in treating eight patients, seven men and one woman, with HCC, which, in view of a higher prevalence of HCC in men, seems to be androgen dependent." | ( Gupta, S; Korula, J, 1988) |
| "Twenty-four patients with hepatocellular carcinoma were treated with 80 mg etoposide/m2 for five consecutive days at 4-week intervals." | ( Hashimoto, N; Hayashi, S; Kanda, Y; Miki, M; Oda, H; Okazaki, N; Sasagawa, Y; Yoshida, T; Yoshino, M, 1989) |
| "A new immunotherapy for hepatocellular carcinoma (HCC) using Freund's adjuvant and recombinant interleukin-2 (IL-2) combined with conventional transarterial chemoembolization therapy was performed." | ( Higashi, T; Ikeda, N; Ito, T; Nouso, K; Ohsawa, T; Okamoto, T; Sue, K; Tsuji, T; Ukida, M; Watanabe, A, 1989) |
| "Twenty-seven patients with unresectable hepatocellular carcinoma (HCC) were treated with Cisplatin-Phosphatidyl-choline-Lipiodol (CPL) suspension." | ( Aoki, Y; Hirai, K; Hitoshi, T; Inoue, H; Majima, Y; Noguchi, H; Okano, Y; Sakai, T; Tanikawa, K; Yamashita, K, 1989) |
| "The surgical treatment for hepatocellular carcinoma must be chosen by considering some factors such as liver function, position and involved area of the tumor." | ( Kato, T; Okamoto, E; Yamanaka, N, 1989) |
| "chemotherapy of hepatocellular carcinoma, were investigated." | ( Hirai, S; Ikeda, N; Itakura, T; Iwamoto, K; Katagiri, Y; Kawai, T; Mabuchi, K; Naora, K; Nozu, Y, 1989) |
| "Our multimodal treatment of hepatocellular carcinoma (HCC) has brought about a significant improvement of the survival rate." | ( Ishii, M; Kitai, Y; Kitaya, T; Shima, Y; Shimamura, Y; Sugai, S; Takashi, A; Takenaka, Y; Taniguchi, H; Watanabe, H, 1989) |
| "Three cases of ruptured hepatocellular carcinomas were treated: one case by emergency hepatectomy, and two cases by hepatectomy following TAE." | ( Itoh, H; Kaiho, T; Kanno, Y; Kimura, F; Koshikawa, H; Matsumoto, J; Miyazaki, M; Nakajima, T; Teramoto, O; Udagawa, I, 1989) |
| "In 24 cases of unresectable hepatocellular carcinoma, we performed hepatic arterial catheterization and intra-arterial infusion chemotherapy." | ( Amioka, K; Hara, H; Iga, C; Ishibashi, T; Isozaki, H; Morita, S; Nakata, E; Nishimura, J; Okajima, K; Tanimura, M, 1989) |
| "Of the 8 patients having hepatoma with increased AFP, all the patients showed a decrease of AFP following the therapy with an average ratio of 65% decrease." | ( Haida, K; Miura, T, 1989) |
| "When these hepatoma cell lines were pretreated with the IgG fraction of a monospecific antibody to the rat liver membrane fatty acid binding protein (MFABP), initial uptake of [3H]oleate was selectively inhibited compared to controls pretreated with the IgG fraction of the preimmune serum." | ( Diede, HE; Stremmel, W, 1989) |
| "Heat shock treatment of human Hep 3B hepatoma cells led to the induction of mRNA for microsomal heme oxygenase." | ( Fujita, H; Kappas, A; Mitani, K; Sassa, S, 1989) |
| "We experienced a case of hepatocellular carcinoma with adrenal metastasis that was effectively treated with ultrasonographically guided percutaneous ethanol injection." | ( Kano, T; Kawashima, S; Kubota, Y; Kunieda, K; Kunieda, Y; Mizuno, T; Sameshima, Y; Seki, Y, 1989) |
| "A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen." | ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989) |
| "Among 37 patients with hepatocellular carcinoma given systemic chemotherapy, 12 (32 percent) lived 14 to 37 months from initiation of treatment whereas the remainder died within five months." | ( Eddy, JL; Ihde, DC; Makuch, RW; Matthews, MJ; McIntire, KR; Seeff, LB, 1985) |
| "Of 66 patients with hepatocellular carcinoma, 32 were treated by intraarterial injection of mitomycin C microcapsules (group A) and 34 patients by intraarterial injection of mitomycin C microcapsules followed by transcatheter hepatic artery embolization (group B)." | ( Iida, S; Nomura, F; Ohnishi, K; Sugita, S; Tanabe, Y, 1987) |
| "In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | ( Suenaga, M, 1987) |
| "Primary hepatoma with infiltration of the inferior vena cava was diagnosed by various imaging techniques and the subject was started on a program of daily oral administrations of 800 mg of tegafur." | ( Hayashi, K; Ishizaki, J; Kitamura, T; Maruyama, T; Nakamura, H; Shigehira, M; Tsuda, K, 1988) |
| "For the group of patients studied, hepatoma volumes at the time of treatment ranged from 135 to 3442 cm3." | ( Frenkel, TL; Hawkins, WG; Klein, JL; Leichner, PK; Loudenslager, DM; Order, SE; Yang, NC, 1988) |
| "One patient with hepatocellular carcinoma shunted only 24% of the macroaggregated albumin, and flow through the liver was reduced to 48% by DSM therapy." | ( Giles, GR; Mavor, AI; O'Brien, T; Parkin, A; Riley, A; Robinson, PJ; Smye, S, 1987) |
| "Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)." | ( Suenaga, M, 1988) |
| "In 23 patients with hepatocellular carcinoma, accumulating patterns of Lipiodol on CT and therapeutic effects in combination therapy with adriamycin/mitomycin C-oil suspension (ADMOS) and Cis-diamminedichloroplatinum II (CDDP)two-route infusion were evaluated." | ( Hiraki, Y; Ikeda, K; Itoh, Y; Kobayashi, H; Shinohara, S; Sonoda, T; Yano, T, 1988) |
| "Of the 8 patients with hepatoma with increased AFP, all the patients showed a decrease of AFP following therapy with an average decrease ratio of 64%." | ( Haida, K; Miura, T, 1988) |
| "Adriamycin + DSM was administered for hepatocellular carcinoma, and Mitomycin C + DSM was used for metastatic liver cancer." | ( Hattori, T; Kodama, H; Kuninobu, H; Niimoto, M; Nishiyama, M; Saeki, T; Toge, T; Yoshinaka, K, 1988) |
| "A 24h pretreatment of the human hepatoma cell line HepG2 with dibutyryl cyclic AMP in the presence of theophylline induced a dose dependent decrease in low density lipoprotein binding, uptake and degradation." | ( Auclair, M; Maziere, C; Maziere, JC; Mora, L; Moreau, M; Polonovski, J; Salmon, S, 1988) |
| "Fifteen patients with hepatocellular carcinoma were administered elliptinium acetate in a phase II trial." | ( Droz, JP; Rougier, P; Ychou, M, 1988) |
| "Human hepatoma cells, HuH-6 Cl-5, were treated with 12-O-tetradecanoylphorbol-13-acetate at concentrations of 1 ng/ml to 10 micrograms/ml for 6 h in the presence of [35S]methionine." | ( Fujiki, H; Moore, RE; Uchida, T; Yoneda, Y, 1985) |
| "A multidisciplinary treatment for hepatocellular carcinoma including preoperative chemo-embolization with resection treatment was introduced." | ( Kuroda, C; Monden, M; Mori, T; Okamura, J; Sakon, M; Sakurai, M; Wakasa, K; Yoshioka, H, 1985) |
| "Twenty-two patients with hepatocellular carcinoma were treated with transcatheter arterial embolization therapy." | ( Fujii, H; Iwai, M; Miyoshi, M; Suyama, Y, 1985) |
| "A total of 850 patients with hepatocellular carcinoma seen during the last 8 years were analyzed retrospectively for survival in relation to treatment and disease stage." | ( Hasegawa, H; Nakajima, Y; Obata, H; Ohnishi, K; Ohtsuki, T; Okazaki, N; Okuda, K; Tomimatsu, M, 1985) |
| "407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy." | ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985) |
| "Thirty-five patients with hepatocellular carcinoma (HCC) have been treated with the Anthracenedione derivative, Mitozantrone." | ( Dunk, AA; Johnson, PJ; Lok, AS; Melia, W; Murray-Lyon, I; Scott, SC; Thomas, HC; Williams, R, 1985) |
| "Most hepatomas developed in rats treated for 480-640 days, and 5 rats had both forestomach carcinoma and hepatoma (Table 2)." | ( Li, MX, 1985) |
| "As liver tumors, adenoma, hepatocellular carcinoma, cholangioma and hemangioma were observed only in the mice treated with DHPN." | ( Yamamoto, H, 1985) |
| "The authors report a patient with hepatocellular carcinoma associated with diarrhea mediated by prostaglandins, surviving 30 months after receiving treatment with indomethacin and Adriamycin." | ( Barcena, R; Boixeda, D; Moreno, A; Saban, J; Serrano-Rios, M, 1986) |
| "Four patients with advanced hepatocellular carcinoma, but with stage I functional disease, were treated with intrahepatic arterial lipoidal mixed with small doses of Adriamycin (20 mg) and Mitomycin C (10 mg)." | ( Chin, JH; Oon, CJ; Tan, L; Yong, YM, 1986) |
| "Fourteen lesions (nine hepatocellular carcinomas, four hepatic metastases from gastric carcinoma, and one peritoneal metastasis from transitional cell carcinoma) in 12 patients were treated with percutaneous injection of 95% ethyl alcohol under guidance with ultrasound." | ( Festi, D; Livraghi, T; Monti, F; Salmi, A; Vettori, C, 1986) |
| "A small (less than 3 cm) inoperable hepatocellular carcinoma was treated with percutaneous interstitial chemotherapy (PIC)." | ( Livraghi, T; Ravetto, C; Solbiati, L; Suter, F, 1986) |
| "Exposure of cultured human hepatoma cells (Hep G2) to medium containing 2% (v/v) dimethyl sulphoxide resulted in an approximate doubling in the activity of delta-aminolaevulinate dehydratase, an increase in the haem content and a decreased growth rate; induced enzyme activity was decrease by 50% after treatment with alpha-amanitin." | ( Galbraith, RA; Kappas, A; Sassa, S, 1986) |
| "He was diagnosed as having primary hepatocellular carcinoma with bone metastasis by his high titer (111,683 ng/ml) of serum alpha-fetoprotein, computed tomography and abdominal angiography, and so UFT therapy, 400 mg daily, was instituted." | ( Imai, Y; Inada, M; Inui, Y; Kawata, S; Matsuda, Y; Minami, Y; Miyoshi, S; Noda, S; Saito, R; Tamura, S, 1987) |
| "Between 1984 and 1986, 63 patients with hepatocellular carcinoma were treated by TAE with the use of Gelfoam." | ( Akamatsu, K; Miyauchi, S; Mogami, H; Nishimura, N; Ohshima, K; Ohta, Y; Yasuhara, Y, 1987) |
| "Preparations of rat hepatoma-associated virus obtained from cultures treated with this compound were deficient in DNA polymerase activity." | ( Axel, R; Gebert, R; Orenstein, JM; Stadler, UC; Weinstein, IB, 1972) |
| "Twelve patients with unresectable hepatocellular carcinoma associated with cirrhosis were treated with Doxorubicin which was given intravenously (30 to 50 mg/m2) every three weeks." | ( Ballet, F; Barbare, JC; Darnis, F; Petit, J; Poupon, R, 1984) |
| "Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
| "Thirteen patients with primary hepatocellular carcinoma were treated with this Lipiodol-Urografin system containing antitumor agents." | ( Furuta, T; Hasuo, K; Inokuchi, K; Kanematsu, T; Sonoda, T; Sugimachi, K; Tamura, S, 1984) |
| "Sixty-seven patients with advanced hepatoma were treated with intra-arterial MMC-mc during the period from 1978 to 1982." | ( Kato, T; Tamakawa, Y; Unno, K, 1984) |
| "Of 20 patients with inoperable hepatocellular carcinoma (HCC) treated with one or more courses via a hepatic arterial catheter, a change in tumor size could be measured in 16." | ( Goto, N; Hiyama, Y; Iwama, S; Kono, K; Nakajima, Y; Nakayama, T; Ohnishi, K; Ohtsuki, T; Takashi, M; Tsuchiya, S, 1984) |
| "A 57-year-old man with hepatocellular carcinoma and liver cirrhosis combined with Dubin-Johnson syndrome was successfully treated by extensive right hepatic lobectomy." | ( Horikawa, S; Kosaki, G; Kuroda, C; Monden, M; Okamura, J; Sakurai, M; Seki, K; Sikujara, O, 1980) |
| "An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs." | ( Gerok, W; Holstege, A; Keppler, D; Pausch, J, 1981) |
| "Twenty-one patients with unresectable hepatocellular carcinoma (hepatoma) were treated with adriamycin (15-45 mg/m2 q21 D) and methyl-CCNU (75-150 mg/m2 q 63 D) with dosage adjusted for hepatic dysfunction." | ( Bateman, JR; Chan, KK; Chlebowski, RT; Ryden, VM; Tong, MJ; Weiner, JM, 1981) |
| "A 69-year-old man with a large hepatoma of the right lobe extending in part to the medial segment of the left lobe was treated by ligation of the right hepatic artery combined with continuous infusion of a total dose of 5500 mg og 5-fluorouracil (5-FU) into the left hepatic artery." | ( Hiraoka, T; Konno, T; Nakakuma, K; Tashiro, S; Yokoyama, I, 1981) |
| "One patient with hepatocellular carcinoma had compete disappearance of all disease with chemotherapy alone." | ( Siegel, MM; Siegel, SE; Stanley, P; Weinblatt, ME; Weitzman, JJ, 1982) |
| "Patients with hepatocellular carcinoma can be treated with intraarterial doxorubicine and floxuridine infusions." | ( Balch, CM; Urist, MM, 1983) |
| "A 9-year-old boy with non-resectable hepatocellular carcinoma was treated with irradiation and intra-hepatic arterial infusion of antitumor agents." | ( Hamawaki, M; Ito, Y; Iwata, K; Kikkawa, K; Kubonishi, S; Kuroiwa, Y; Matsuoka, K; Ohmura, T; Okano, K, 1983) |
| "Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0." | ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982) |
| "Forty patients with hepatoma and metastatic tumors of liver were treated with rapid arterial infusion administered simultaneously using 30-40 mg of adriamycin and 10-20 mg of mitomycin C into the hepatic artery by Seldinger catheter." | ( Aiba, K; Domyo, M; Ezaki, K; Horikoshi, N; Inagaki, J; Inoue, K; Miyamoto, H; Nagata, T; Ogawa, M, 1982) |
| "Twenty-two cases of non-operable hepatocellular carcinoma (HCC) were treated with three types of chemotherapy mainly with Adriamycin (ADM)." | ( Adachi, N; Aoyama, M; Hirose, H; Kobayashi, S; Nonaka, T; Oshima, K; Udo, K; Yamada, T, 1982) |
| "Fifteen patients with inoperable hepatoma were treated with NCS by the selective intra-hepatic arterial infusion method." | ( Fujita, S; Koizumi, T; Mitsutani, N; Sasaki, Y; Takimoto, C; Yoshioka, H, 1982) |
| "Experimental hepatocellular carcinoma (HCC) in rats did not take up intravenously administered indocyanine green (ICG) and trypan blue, while surrounding tissue did." | ( Hattori, S; Ito, T; Itoshima, T; Kita, K; Kitadai, M; Koide, N; Mizutani, S; Ogawa, H; Tanaka, R; Ukida, M, 1984) |
| "Interventional treatment of hepatocellular carcinoma is indicated if surgical treatment is impossible." | ( Duda, SH; Huppert, PE; Lauchart, W; Viebahn, R, 1994) |
| "Forty patients with hepatocellular carcinoma were treated with percutaneous ethanol injection therapy." | ( Kotoh, K; Morotomi, I; Nawata, H; Sakai, H, 1995) |
| "Human hepatocellular carcinoma (HCC) cell lines, HEP-G2, J5, and SK-HEP-1, which differ in their differentiation status, were compared for their trans-activating activities after treatment with cytokines or 12-O-tetradecanoylphorbol-13-acetate (TPA)." | ( Chang, KS; Chen, SW; Hsu, ML; Liao, SK; Lin, KH, 1995) |
| "We report here a case of hepatocellular carcinoma (HCC) with multiple lung metastases, which were disappeared by treatment of OK-432." | ( Ashida, K; Fujio, K; Hasui, T; Higashi, T; Hino, N; Nakatsukasa, H; Ooguchi, S; Takaki, A; Ueki, T; Yonei, T, 1993) |
| "Twenty patients with unresectable hepatocellular carcinoma were treated by intra-arterial subsegmental injection of Cisplatin/4-0-Tetrahydro-Pyranyl-adriamycin Lipiodol suspension (CTLS)." | ( Fukukura, Y; Hori, A; Inoue, H; Kanetsuki, I; Matsumoto, Y; Miyazono, N; Nakajo, M; Nishida, H; Tanaka, D; Ueno, K, 1993) |
| "Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days." | ( Harvey, WH; Macdonald, JS; Poplin, EA; Tangen, CM, 1994) |
| "We studied 710 patients with hepatocellular carcinoma(HCC) who underwent non-surgical treatment." | ( Ebara, M; Kita, K; Ohto, M; Sugiura, N; Yoshikawa, M, 1995) |
| "Treatment of hepatocellular carcinoma with bone metastasis is often ineffective, but this is a rare case showing the clinical effectiveness of oral administration of UFT." | ( Chao, C; Imada, T; Maehara, T; Matsumoto, A; Miyazaki, T; Morinaga, S; Takehana, T, 1995) |
| "A 62-year-old male patient with hepatocellular carcinoma (HCC) received percutaneous ethanol injection therapy (PEIT) four times following fine needle biopsy (FNB)." | ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Nakamori, S; Nakano, H; Ohigashi, H; Sasaki, Y, 1994) |
| "Eighteen patients with inoperable hepatocellular carcinoma (HCC) were treated with intrahepatic arterial yttrium-90 microspheres." | ( Chan, M; Ho, S; Johnson, P; Lau, WY; Leung, NW; Leung, WT; Li, AK; Lin, J; Metreweli, C, 1994) |
| "It has been hypothesized that hepatocellular carcinoma might be a long-term adverse effect of tamoxifen therapy." | ( Cook, LS; Mühlemann, K; Weiss, NS, 1994) |
| "Thirty-two tumors in 30 patients with hepatocellular carcinoma (HCC) were studied preoperatively using PET with 18F-labeled 2-fluoro-2-deoxy-D-glucose (FDG) to evaluate the metabolic activity of the lesions after interventional therapy." | ( Inokuma, T; Konishi, J; Magata, Y; Tamaki, N; Tanaka, A; Torizuka, T; Yamamoto, K; Yamaoka, Y; Yonekura, Y, 1994) |
| "Twenty patients with unresectable hepatocellular carcinoma (HCC) were followed up to 5 years after transarterial radiotherapy with 90Y-resin particles." | ( Baer, HU; Becker, C; Beer, HF; Blumgart, LH; Geiger, L; Rösler, H; Triller, J, 1994) |
| "The diagnosis of hepatocellular carcinoma was made 3 months after the initiation of a hormonal treatment with cyproterone acetate (for 1 month) and an LH-RH agonist." | ( Culine, S; Droz, JP; Elias, D; Kattan, J; Spatz, A; Terrier-Lacombe, MJ, 1994) |
| "A case of hepatocellular carcinoma (HCC), which developed during chemotherapy for chronic myelogenous leukemia (CML), is presented." | ( Endo, Y; Hara, M; Katoh, M; Murashima, N; Nakajima, M; Takeuchi, K; Yamaguchi, H, 1994) |
| "In both bacteria and hepatoma cells two DNA adducts could be detected after treatment with 2-phenoxy-4H-1,3,2-benzodioxaphosphorin 2-oxide." | ( Dekant, W; Henschler, D; Mentzschel, A; Vamvakas, S, 1993) |
| "We describe a case of hepatoma, a 66-year-old woman, presenting with obstructive jaundice, whom we treated with intra-arterial infusion of the anticancer drug, MMC." | ( Kato, S; Kobayashi, H; Nakagawa, T, 1993) |
| "Of 136 patients with hepatoma 78 (57%) were not eligible, eight (6%) refused to take part, and 50 entered the trial (chemotherapy: n = 25, symptomatic treatment: n = 25)." | ( Bailey, S; Beningfield, SJ; Geddes, C; Krige, JE; Madden, MV; Terblanche, J; Werner, ID, 1993) |
| "In 10 patients with infiltrating hepatocellular carcinoma, about 70-90% necrosis was achieved; in six of these patients, the alpha-fetoprotein level, which had been more than 200 ng/ml, decreased during treatment." | ( Lazzaroni, S; Livraghi, T; Pellicanò, S; Ravasi, S; Torzilli, G; Vettori, C, 1993) |
| "A 79-year-old female with hepatocellular carcinoma with portal invasion and right adrenal gland metastasis was treated by low dose UFT (200 mg/day)." | ( Itoh, Y; Ohkawa, S; Tamai, S; Tarao, K, 1994) |
| "Nine patients with biopsy-proved hepatocellular carcinoma underwent percutaneous ethanol ablation therapy (PEAT) with computed tomographic (CT) guidance." | ( Baumgarten, DA; Bernardino, ME; Joseph, FB, 1993) |
| "On the other hand, the CNR of hepatocellular carcinoma was significantly increased after CSIC administration on both T1- and T2-weighted images (p < 0." | ( Kamba, M; Kato, T; Matsuo, T; Nakamura, K; Ohta, Y; Ohuchi, Y; Shimatani, Y; Suto, Y, 1993) |
| "Eighty patients with inoperable hepatocellular carcinoma (HCC) were treated by transcatheter arterial chemoembolization using an emulsion of Lipiodol and Cisplatin." | ( Fan, ST; Lai, CL; Lai, EC; Ngan, H; Tso, WK; Yuen, WK, 1993) |
| "One hundred thirty-five patients with hepatocellular carcinoma (HCC) were treated by intraarterial injection of adriamycin/mitomycin C oil suspension (ADMOS) alone (59 cases) and ADMOS plus cis-diaminodichloroplatinum (CDDP) (76 cases)." | ( Fukukura, Y; Hokotate, H; Hori, A; Ida, K; Ikeda, K; Inoue, H; Kanetsuki, I; Miyazono, N; Tanaka, D; Tsuchimochi, S, 1993) |
| "125 cases of hepatocellular carcinoma (HCC) were treated by transarterial approach." | ( Luo, PF, 1993) |
| "A 67-year-old man with an extensive hepatocellular carcinoma (HCC) was treated successfully with intraarterial infusion of high-dose adriamycin (ADR), 150 mg/m2, five minutes continuous infusion using an extra-corporeal system consisting of direct hemoperfusion (DHP) under hepatic venous isolation (HVI)." | ( Fukumoto, T; Iwasaki, T; Ku, Y; Kuroda, Y; Maekawa, Y; Saitoh, M; Sako, M; Samizo, M; Shiki, H; Tominaga, M, 1993) |
| "In 304 patients with hepatocellular carcinoma who underwent hepatic resection, 162 patients received chemoembolization before surgery (group A) and the remaining 142 patients received no therapy before surgery (group B)." | ( Hiratsuka, M; Imaoka, S; Ishikawa, O; Iwamoto, S; Kameyama, M; Kishimoto, S; Masutani, S; Nakamori, S; Ohigashi, H; Sasaki, Y, 1993) |
| "Twenty-two patients with unresectable hepatocellular carcinoma were treated by intra-arterial infusion chemotherapy using an implantable reservoir." | ( Kosaka, A; Maruo, H, 1993) |
| "Patients with hepatocellular carcinoma and metastatic colorectal carcinoma with liver only or liver-predominant disease were eligible for therapy." | ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "Its systematic use to treat hepatocellular carcinoma must be proceeded by further comparative studies with PEI." | ( Bonenti, G; Cirillo, S; Dore, D; Fava, C; Grosso, M; Martina, C; Veltri, A, 1995) |
| "We cultured human hepatoma Hep3B cells in the presence of RA (10(-5) M) for 30 days; the expression of both alpha-fetoprotein and hepatitis B virus surface antigen were suppressed over 70% at the transcriptional level by RA treatment." | ( Chou, CK; Hsu, SL; Lin, HM, 1996) |
| "In patients with hepatocellular carcinoma (hepatoma), the rate of recurrent and second primary hepatomas is high despite surgical resection and percutaneous ethanol-injection therapy." | ( Adachi, S; Kojima, T; Moriwaki, H; Muto, Y; Nakamura, T; Ninomiya, M; Okuno, M; Saito, A; Takasaki, KT; Tanaka, T; Tomita, E; Tsurumi, K, 1996) |
| "A 60-year-old male with hepatocellular carcinoma was treated by repeated intra-arterial injection of epirubicin, carboplatin and doxorubicin." | ( Deguchi, S; Fujita, M; Honda, K; Kikuchi, T; Miyata, A, 1996) |
| "A 46-year-old male with unresectable hepatocellular carcinoma (HCC) comprised of severe liver dysfunction was treated by intra-arterial infusion chemotherapy through an implantable reservoir." | ( Misawa, K; Nagabuchi, E; Sato, Y; Sunahara, M; Uchino, J; Une, Y, 1996) |
| "When human hepatocellular carcinoma cell lines displaying different levels of AFP and albumin and nonhepatocyte tumor cell lines were infected with the recombinant AAV virus, ganciclovir treatment caused only AFP and albumin-positive hepatocellular carcinoma cells death, but not nonhepatocyte tumor cells or AFP and albumin-negative hepatic tumor cells." | ( Chang, JC; Kan, YW; Su, H; Xu, SM, 1996) |
| "Twenty patients with unresectable hepatoma, recurrent hepatoma or metastatic liver cancer were treated by intra-hepatic arterial injection of mitoxantrone, and its effectiveness and side effects were studied." | ( Hiraki, S; Maeda, Y; Nakashima, K; Nishida, M; Oka, M; Suzuki, T; Takao, K; Takao, T, 1996) |
| "A patient with hepatocellular carcinoma (HCC) who underwent successfully percutaneous ethanol injection therapy (PEIT) with etoposide was reported." | ( Aoki, T; Dohno, K; Gotoh, M; Higaki, N; Kishimoto, S; Monden, M; Okuyama, M; Osato, H; Sakon, M; Shimizu, J; Sugimoto, K; Takeda, H; Taniguchi, K; Umeshita, K; Yamada, T, 1996) |
| "Dexamethasone treatment of hepatoma cells enhances the DNA binding activity of nuclear factors that bind this site." | ( Chan, J; Dionne, JM; Lawless, DE; Raymond, J; Romney, J; Taylor, AH; Wanke, IE; Wong, NC, 1996) |
| "Progress in the treatment of hepatocellular carcinoma (HCC), a common tumor worldwide, has been disappointing." | ( Adjei, PN; Gores, GJ; Kaufmann, SH; Leung, WY; Mao, F, 1996) |
| "A human hepatocellular carcinoma cell line, SMMC-7721, was treated with all-trans-retinoic acid (RA) and phorbol 12-myristate 13-acetate (PMA) to induce its differentiation and proliferation respectively." | ( Gu, J; Jiang, S; Shen, Z; Zhou, D, 1996) |
| "Virally-induced hepatocellular carcinomas (HCC) are intrinsically resistant to cancer chemotherapy partly due to increased expression of p-glycoprotein (pgp)." | ( Cullen, JM; Dunn, SE, 1996) |
| "A total of 22 patients (11 with hepatocellular carcinoma and 11 with cholangiocarcinoma) were treated." | ( Andrews, JC; Ensminger, WD; Kessler, ML; Lawrence, TS; Robertson, JM; Walker, S, 1997) |
| "Since 1988, 124 patients with hepatocellular carcinoma were treated in our departments." | ( Kinuta, M; Maruyama, H; Masuda, N; Matsui, S; Oi, H; Okamura, J; Tateishi, H; Yano, H; Yayoi, E, 1997) |
| "Twenty patients with unresectable hepatocellular carcinoma were treated by zinostatin stimalamer-transcatheter arterial embolization (SMANCS-TAE)." | ( Hirai, T; Hirashima, N; Itazu, I; Kano, H; Kumada, K; Matsuura, H; Nemoto, A; Nojiri, O; Sakakibara, K, 1997) |
| "Thirty-two patients with hepatocellular carcinoma (HCC) were treated with YNK-01, a prodrug of cytarabine for oral administration." | ( Miyazawa, J; Sakata, Y; Suto, K; Suto, T; Watanabe, Y; Yoshida, Y, 1997) |
| "A 47-year-old man with hepatocellular carcinoma (HCC) at anterior and medical segment in the liver was treated with hepatic arterial infusion of Zinostatin Stimalamer-lipiodol suspension (SMANCS)." | ( Fukuhara, K; Iwasashi, H; Kodama, H; Matsuno, S; Rikiyama, T; Sakamoto, N; Suzuki, M; Takeuchi, H; Uchiyama, T; Unno, M; Yamaki, T, 1997) |
| "Chemotherapy of hepatocellular carcinomas is hampered by the insufficient accumulation of cytostatic drugs within the tumor cells." | ( Beuers, U; Böker, C; Glasa, J; Grützner, U; Hagenbuch, B; Kramer, W; Kullak-Ublick, GA; Meier, PJ; Oswald, M; Paumgartner, G; Stieger, B; Wess, G, 1997) |
| "Approximately 80% of hepatocellular carcinoma (HCC) patients in Japan have associated liver cirrhosis, which increases the difficulty of surgical treatment." | ( Ikai, I; Ozaki, N; Sakai, Y; Shimahara, Y; Yamamoto, Y; Yamaoka, Y, 1997) |
| "Treatment of HepG2 hepatoma cells with bleomycin induced the production of reactive oxygen intermediates and, as an additional parameter of oxidative stress, resulted in glutathione (GSH) depletion." | ( Galle, J; Galle, PR; Grambihler, A; Hack, V; Hug, H; Krammer, PH; Strand, S; Stremmel, W, 1997) |
| "Treatment of the human hepatoma cell line HuH-7 with H2O2 caused dose-dependent necrosis as determined by light microscopy, fluorescent staining, and an absence of DNA fragmentation." | ( Bradham, C; Brenner, DA; Czaja, MJ; Xu, Y, 1997) |
| "Treatment of rats bearing established hepatoma ascites with 500 microg RH1-betaG followed 2 hr later with a single i." | ( Chan, LY; Chen, BM; Chern, JW; Roffler, SR; Wang, SM; Wu, MF, 1997) |
| "The outcome in 3225 patients with hepatocellular carcinoma (HCC) was studied in groups with equivalent prognosis treated with resection, transcatheter arterial embolization (TAE), and percutaneous transhepatic ethanol injection (PEI)." | ( Furuse, J; Iwasaki, M; Kawano, N; Kinoshita, T; Konishi, M; Moriyama, N; Ryu, M; Shimamura, Y; Sugita, M; Yoshino, M, 1997) |
| "In patients with cirrhosis and hepatocellular carcinoma, treated with percutaneous ethanol injection, survival depends on: the severity of the underlying liver disease, uni/multifocality of the tumor and basal alpha-fetoprotein." | ( Calandra, M; Castellano, L; de Sio, I; Del Vecchio Blanco, C, 1997) |
| "Forty-four patients with hepatocellular carcinoma were treated with oily anticancer agent SMANCS dissolved in Lipiodol (SMANCS-LPD)." | ( Doai, K; Hasebe, S; Honda, M; Kuniyasu, Y; Matsuoka, S; Obuchi, M; Satoh, S; Shima, H; Takizawa, K; Uchiyama, K, 1997) |
| "A rat hepatocellular carcinoma cell line AH 60C (5 x 10(5) cells) was administered into the portal vein under general anesthesia." | ( Hirai, T; Iwata, T; Kuwahara, M; Toge, T; Yamashita, Y; Yoshimoto, A, 1997) |
| "MRI was performed on 14 patients with hepatocellular carcinoma (45 nodules) before and after administration of chondroitin sulphate iron colloid (CSIC)." | ( Sugihara, S; Suto, Y; Yoshida, K, 1997) |
| "Eleven rats with chemically induced hepatocellular carcinoma underwent unenhanced T2-weighted fast spin-echo imaging followed by T1-weighted spin-echo imaging before and at 5 minutes, 30 minutes, 3 hours, 1 day, and 3 days after intravenous administration of 60 micromol/kg gadoxetate disodium at 4." | ( Delos, M; Demeure, R; Goudemant, JF; Grandin, C; Pringot, J; Van Beers, BE, 1998) |
| "Fifty-five patients with hepatocellular carcinoma were treated with oily anticancer agent SMANCS dissolved in Lipiodol (SMANCS-LPD)." | ( Doai, K; Hasebe, S; Honda, M; Kuniyasu, Y; Matsuoka, S; Obuchi, M; Satoh, S; Shima, H; Takizawa, K; Uchiyama, K, 1998) |
| "Four patients with advanced hepatocellular carcinoma were treated by repeated arterial infusion of zinostatin stimalamer (SMANCS)." | ( Ebara, M; Fukuda, H; Saisho, H; Sugiura, N; Yoshikawa, M, 1998) |
| "A total of seventeen patients with hepatocellular carcinoma (HCC), nineteen HCCs, who underwent as an initial treatment transcatheter hepatic segmental or subsegmental arterial administration of SMANCS alone for hepatocellular carcinoma (HCC), were studied to evaluate the efficacy and complication of that treatment." | ( Inoue, Y; Nakamura, H; Oi, H; Tomoda, K, 1998) |
| "Patients with unresectable hepatocellular carcinoma (hepatoma) with hypervascularity were treated by SMANCS-TAE, which was performed by a superselective catheterization technique to inject gelatin sponge particles after administration of SMANCS." | ( Hirashima, N, 1998) |
| "Human RPE cells, human hepatoma cells, and human fibroblast cells were treated with 5-fluoromethylornithine (5-FMOrn), a specific irreversible inhibitor of OAT." | ( Ando, A; Del Monte, MA; Ito, S; Maeda, H; Masu, Y; Ueda, M; Uyama, M, 1998) |
| "When the human RPE cells, HepG2 hepatoma cells, and WI-38 fibroblast cells were treated with 0." | ( Ando, A; Del Monte, MA; Ito, S; Maeda, H; Masu, Y; Ueda, M; Uyama, M, 1998) |
| "We report a case of advanced hepatocellular carcinoma (HCC) successfully controlled by the suppository administration of Tegafur alone." | ( Arakawa, A; Kudo, K; Nishimura, R; Takagi, Y; Takahashi, M; Yamashita, Y, 1998) |
| "For 6 patients with advanced hepatocellular carcinoma (HCC) in whom TAE was inefficacious, we tried hepatic arterial infusion chemotherapy." | ( Aoyama, H; Asano, T; Fukunaga, T; Isono, K; Iwasaki, K; Kenmochi, T; Kobayashi, S; Kouno, T; Matsuzaki, H; Nakagouri, S; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1998) |
| "Patients with unresectable hepatocellular carcinoma (hepatoma) with hypervascularity were treated by SMANCS-TAE." | ( Hasegawa, I; Hirashima, N; Itazu, I; Kimura, H; Nemoto, S; Nukaya, H; Sakakibara, K; Yoshimizu, T, 1998) |
| "Treatment of HuH-7 human hepatocellular carcinoma (HCC) cells with 1-10 mM sodium butyrate (SB) resulted in growth inhibition in a dose-dependent manner." | ( Fujimoto, J; Furuyama, J; Hashimoto-Tamaoki, T; Okamoto, E; Tamaoki, T; Yamamoto, H, 1998) |
| "A 56-year-old male had suffered from hepatocellular carcinoma treated by operation, PHoT and TAE since 1994." | ( Ando, A; Asano, N; Bamba, T; Fujiyama, Y; Fukano, M; Inoue, T; Ito, A; Koyama, S; Kubo, M; Sasaki, M; Sato, J; Tsujikawa, T; Yoshioka, U, 1998) |
| "The growth of hepatoma cells can be inhibited by treatment with TGFbeta1 or with exogenous reducing agents." | ( Cabibbo, A; Consalez, GG; Rubartelli, A; Sardella, M; Sitia, R, 1998) |
| "Selection of local therapy for hepatocellular carcinoma achieved long survival in our case considering the QOL and frequent therapy administration." | ( Akazawa, K; Hata, S; Hayashi, N; Hayashida, H; Ikeda, K; Kitada, M; Niinobu, T; Ogawa, M; Shibata, N; Shibata, T; Takada, T; Takami, M; Tsukahara, Y, 1998) |
| "The majority of patients with hepatocellular carcinoma will develop either unresectable or metastatic disease and, therefore, are candidates for systemic chemotherapy." | ( Eberhardt, W; Erhard, J; Harstrick, A; Klaassen, U; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1998) |
| "Twenty-four cirrhotic patients with hepatocellular carcinoma undergoing subsegmentectomy under ischemia induced only by Pringle's maneuver were divided into two groups (patients given prostaglandin E1 by injection and untreated controls) and postoperative results were compared." | ( Esumi, H; Inoue, K; Kubota, K; Makuuchi, M; Ogura, T; Sugawara, Y; Takayama, T, 1998) |
| "The findings suggest that, in FOCUS hepatocellular carcinoma cells, which overexpress IRS-1, ethanol treatment substantially inhibits IRS-1 and MAP kinase signaling and growth-associated gene expression, but has no effect on Shc phosphorylation, which activates p21ras through an IRS-1 independent pathway." | ( Banerjee, K; de la Monte, SM; Mohr, L; Wands, JR, 1998) |
| "Nine of 20 hepatomas were detected at baseline US, whereas 17 were detected after administration of SHU 563A (P = ." | ( Forsberg, F; Goldberg, BB; Liu, JB; Merton, DA; Rawool, NM; Shi, WT, 1999) |
| "Rats bearing the Zajdela hepatoma tumor and T3-treated hypothyroid rats were used to study the role of protein degradation in the process of mitochondrial biogenesis." | ( Chloupkova, M; Luciakova, K; Nelson, BD; Sokolikova, B, 1999) |
| "The patient was diagnosed as having hepatocellular carcinoma, and was treated by arterial administration of anticancer drugs (epirubicin hydrochloride, mitomycin C and carboplatin) and TAE." | ( Fujii, S; Manabe, T; Matuo, R; Murata, K; Oda, J; Sato, T; Tanaka, S; Yamada, A; Yamada, K, 1999) |
| "Human and murine hepatoma cells were treated with berberine (0." | ( Chi, CW; Lin, HL; Liu, TY; Lui, WY, 1999) |
| "Inoperable hepatocellular carcinoma is an incurable malignancy with no accepted standard therapy." | ( Clendennin, N; Johnston, A; Rudy, J; Stuart, K; Tessitore, J, 1999) |
| "Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1." | ( Der, CJ; Kong, AN; Lei, W; Mandlekar, S; Weber, MJ; Wu, J; Yu, R, 1999) |
| "Advanced hepatocellular carcinoma (HCC) with extensive tumour growth through the hepatic vein still has an extremely poor prognosis, even after cancer chemotherapy and/or transarterial embolization." | ( Ambiru, S; Furuya, S; Ito, H; Kaiho, T; Kashima, Y; Miyazaki, M; Nakagawa, K; Nakajima, N; Shimizu, H, 1999) |
| "Treatment of the hepatoma bearing rats with 5-azacytidine, a demethylating agent, induced basal as well as heavy metal-activated MT-I gene expression in the hepatoma, implying that methylation was indeed responsible for silencing the gene." | ( Dong, X; Ghoshal, K; Jacob, ST; Li, Z; Majumder, S, 2000) |
| "The frequency of apoptotic hepatoma cells in TNP-470-treated rats was higher than in control rats." | ( Kin, M; Nakamura, T; Ogata, R; Sakamoto, M; Sata, M; Tamaki, S; Torimura, T; Ueno, T, 2000) |
| "Forty-seven nodules of hepatocellular carcinoma (size, 28 +/- 7 mm [mean +/- standard deviation]; range, 20-40 mm) in 38 patients were treated with transarterial embolization (n = 6), percutaneous ethanol injection therapy (n = 23), and transarterial embolization plus percutaneous ethanol injection therapy (n = 9)." | ( Hareyama, M; Hirata, K; Hirokawa, N; Ichimura, T; Katsuramaki, T; Koito, K; Namieno, T; Nishi, M; Syonai, T, 2000) |
| "Treatment of hepatocellular carcinoma (HCC) with percutaneous ethanol injection (PEI) is established for tumors up to 3 cm." | ( Bleck, JS; Caselitz, M; Gebel, M; Lange, P; Manns, MP; Ockenga, J; Ostertag, H; Wagner, S, 1999) |
| "Sixty-five patients with 65 solitary hepatocellular carcinoma nodules < or =6 cm in diameter underwent initial treatment with percutaneous ethanol injection and were examined to ascertain the factors related to recurrence, local and distant, within the liver." | ( Inoue, O; Khan, KN; Koga, M; Yamasaki, K; Yamasaki, M; Yano, M; Yatsuhashi, H, 2000) |
| "The main therapeutic options for hepatocellular carcinoma (HCC) are hepatic resection, transcatheter arterial embolization (TAE), percutaneous ethanol injection therapy (PEIT) and regional chemotherapy (RC)." | ( Iwai, S; Kono, S; Kubota, N; Nakamura, M; Ohishi, H; Takano, S; Watanabe, Y, 2000) |
| "Treatment results of advanced hepatocellular carcinoma have remained unsatisfactory; the response rates to intravenous doxorubicin are no better than 20%." | ( Lochs, H; Plauth, M; Schachschal, G, 2000) |
| "A patient with advanced hepatocellular carcinoma was treated with PLD and a pharmacokinetic study was performed." | ( Chang, FH; Hong, RL; Tseng, YL, 2000) |
| "Its role in treating advanced hepatocellular carcinoma is worthy of further study." | ( Chang, FH; Hong, RL; Tseng, YL, 2000) |
| "Gene therapy for hepatocellular carcinoma (HCC) has shown some promise, but its evaluation requires relevant experimental models." | ( Bilbao, R; Bralet, MP; Bréchot, C; Gérolami, R; Prieto, J; Qian, C; Tennant, B; Tran, PL, 2000) |
| "Four cases of gigantic hepatocellular carcinoma, considered by surgeons to be inoperable, were treated with repeated transcatheter chemoembolization (TOCE) until the serum alfafetoprotein reduced to normal or less than half of the original level or until the tumor reduced to less than half of the original size documented by CT scan and angiogram." | ( Eurvilaichit, C; Kanjanapitak, A; Leopairut, J, 2000) |
| "We report a rare case of hepatocellular carcinoma (HCC) for which intravenous administration of cisplatin (CDDP) was effective." | ( Fukuda, Y; Harada, M; Ishikawa, M; Miyake, H; Tashiro, S; Wada, D; Yogita, S, 2000) |
| "Nineteen patients with hepatocellular carcinoma (HCC) underwent PD with and without Levovist and spiral CT at diagnosis and 1 month after PEI treatment." | ( Civiletti, C; Daniele, B; De Vivo, R; Fiore, F; Izzo, F; Pignata, S; Ricchi, P; Sandomenico, F; Tambaro, R; Vallone, P; Ziviello, M, 2000) |
| "We found that treatment of hepatoma cells with 300 mM ethanol results in disruption and aggregation of the keratin network in the vicinity of the nucleus as well as a hypophosphorylation of keratin subunits from ethanol-treated cells compared with non-ethanol-treated controls." | ( Eckert, BS; Negron, G, 2000) |
| "Treatment of human hepatoma cells (HepG2) with NO-donors for 24 h inhibited hypoxia-induced erythropoietin (EPO) gene activation." | ( Fandrey, J; Genius, J, 2000) |
| "Indeed, pretreatment of human hepatocellular carcinoma HepG2 cells with IL-1beta suppressed IFN-alphabeta-induced antiviral activity and antiviral protein MxA mRNA expression." | ( Feng, H; Gao, B; Shen, X; Tian, Z, 2000) |
| "Treatment for nonresectable hepatocellular carcinoma (HCC) is palliative." | ( Dancey, JE; Gabrys, J; Goin, JE; Hendler, AL; Houle, S; Paul, K; Shepherd, FA; Sniderman, KW, 2000) |
| "Survival of patients with hepatocellular carcinoma treated by percutaneous ethanol injection is related to baseline albumin level." | ( Albanese, M; Cammà, C; Cottone, M; D'Antoni, A; Livraghi, T; Maringhini, A; Orlando, A; Pagliaro, L; Sciarrino, E; Simonetti, RG; Torzilli, G; Virdone, R, 2000) |
| "Because hepatocellular carcinomas (HCCs) are one of the most resistant tumors to systemic chemotherapy, we investigated the activation of NFkappaB and the consequence of its inhibition by an IkappaBalpha-super repressor during tumor necrosis factor alpha (TNFalpha)- and chemotherapy-induced apoptosis in HCC cell lines." | ( Kubicka, S; Manns, MP; Paul, Y; Tietze, MK; Trautwein, C; Wuestefeld, T; Zender, L, 2000) |
| "We describe a case of hepatocellular carcinoma (HCC) after long term tamoxifen therapy in a 71-year-old woman." | ( Dickson, J; Habeshaw, T; McLellan, DR; Moffat, DF; Oien, KA, 2000) |
| "Cultured mouse hepatoma Hepa-1c1c7 cells were treated with either bisphenol A or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or in combination to assess the role of bisphenol A in the process of Cyp1a-1 induction." | ( Choi, CY; Jeong, HG; Kimand, JY, 2000) |
| "We developed a human hepatoma cell model that faithfully reproduces the responsiveness of the CYP2E1 gene to IL-4 at least in part through transcriptional activation, upon treatment with 150 U/ml of IL-4." | ( Corcos, L; Galisteo, M; Guillouzo, A; Joannard, F; Lagadic-Gossmann, D; Lerche, C; Rissel, M, 2000) |
| "We report a case of advanced hepatocellular carcinoma (HCC), successfully treated by a combination therapy of alpha-interferon (IFN-alpha) and tegafur/uracil (UFT)." | ( Dono, K; Eguchi, H; Gotoh, M; Kishimoto, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K, 2000) |
| "Thirty-two hepatocellular carcinoma lesions in 26 patients (age range, 44-85 years; mean age, 66 years) were examined with Levovist-enhanced intermittent harmonic imaging before and after therapy." | ( Ding, H; Kudo, M; Maekawa, K; Minami, Y; Onda, H; Suetomi, Y, 2001) |
| "Intratumoral flow signals in hepatocellular carcinoma after therapy on harmonic imaging were used as a guide to target additional percutaneous therapy." | ( Ding, H; Kudo, M; Maekawa, K; Minami, Y; Onda, H; Suetomi, Y, 2001) |
| "Recent advances in the treatment of hepatocellular carcinoma (HCC) have prolonged patient survival." | ( Aratani, T; Doi, K; Komori, T; Narabayashi, I; Ogura, Y; Shimidzu, T; Sueyoshi, K; Utsunomiya, K, 2001) |
| "Chemotherapy is not effective for hepatocellular carcinoma (HCC)." | ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001) |
| "Treatment of a human hepatocellular carcinoma cell line, QGY-7703, with Taxol induced apoptosis and Bcl-2 protein phosphorylation." | ( Cheng, SC; Luo, D; Xie, Y, 2001) |
| "Mice inoculated with hepatoma cell (H22) suspension subcutaneously at right axilla were orally administered with glutamine (GLN) solution." | ( Liu, SL; Shen, ZH; Shi, DY; Wu, YD, 2000) |
| "In the treatment of hepatocellular carcinoma, the range of indications for percutaneous ablation techniques is becoming wider than surgery and intra-arterial therapies." | ( Livraghi, T, 2001) |
| "We report the successful treatment of hepatocellular carcinoma (HCC) associated with an intraductal tumor thrombus in a 67-year-old male." | ( Furuse, J; Hasebe, T; Ishikura, S; Ogino, T; Satake, M; Tanizaki, H; Yoshino, M, 2001) |
| "The increase in the incidence of hepatomas with treatment was thought to be related to the high fat content of the diets." | ( Baldrick, P; Carthew, P; Hepburn, PA, 2001) |
| "Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients." | ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001) |
| "We report that HepG2 hepatoma cells displayed only a modest apoptotic response to doxorubicin treatment, accompanied by a substantial elevation of ceramide levels only at toxic drug concentrations." | ( di Bartolomeo, S; Spinedi, A, 2001) |
| "This study suggests that treatment of hepatocellular carcinoma requires multidisciplinary expertise and that ablation and operation can be performed safely." | ( Adams, MB; Christians, KK; Franco, J; Pitt, HA; Quebbeman, EJ; Quiroz, FA; Rilling, WS; Wallace, JR, 2001) |
| "In gene therapy for hepatocellular carcinoma (HCC), gene transfer is efficient for small tumors, but not for large tumors." | ( Eto, Y; Futagawa, Y; Ohashi, T; Okamoto, T; Shiba, H, 2001) |
| "We report a patient with advanced hepatocellular carcinoma (HCC) who was successfully treated with multi-ablation therapy by the surgical method of laparotomy and partial thoracotomy." | ( Beppu, T; Fujimura, M; Hirota, M; Ishiko, T; Ogawa, M; Yoshida, N, 2001) |
| "Untreated patients with small, single hepatocellular carcinoma (HCC) in compensated cirrhosis are characterized by a relatively good prognosis." | ( Fagiuoli, S; Farinati, F; Gianni, S; Marin, G; Naccarato, R; Rinaldi, M, 2001) |
| "Two human hepatoma cell lines, HepG2 (with wild-type p53) and Hep3B (with deleted p53), were treated with different concentrations of cisplatin." | ( Ng, IO; Qin, LF, 2002) |
| "A patient with advanced hepatocellular carcinoma was treated with intravenous infusion of pegylated liposomal doxorubicin (PLD, Caelyx) in combination with ultrasound hyperthermia of the liver." | ( Dvorák, J; Jandík, P; Kalousová, D; Melichar, B; Mergancová, J; Motycková, I; Petera, J; Zoul, Z, 2002) |
| "Treatment of hepatocellular carcinoma (HCC) by chemotherapy is often impeded by the intrinsic multidrug resistance (MDR) of this frequent primary cancer of the liver." | ( Hofmann, WJ; Keppler, D; Klar, E; König, J; Nies, AT; Pfannschmidt, M, 2001) |
| "Mice bearing sarcoma 180 and solid hepatoma were treated with HCPT (0." | ( Liu, J; Xu, B; Zhou, JJ, 2001) |
| "These tumors included 29 hepatocellular carcinomas in patients with no previous treatment, 26 treated hepatocellular carcinomas, and 38 hemangiomas." | ( Chen, PH; Chen, RC; Chen, WT; Cheng, NY; Liao, LY; Tu, HY; Wang, CK; Wang, CS, 2002) |
| "Tumorigenicity of H22 hepatoma was examined in purified hsp70-treated C3H mice." | ( Gao, Y; Liu, K; Wu, W, 2000) |
| "In C3H mice challenged with H22 hepatoma, tumor developed in 6 of 6 mice while in hsp70 pretreated mice, none of the 6 H22 challenged mice developed tumor." | ( Gao, Y; Liu, K; Wu, W, 2000) |
| "In HBVx transgenic rats, hepatocellular carcinoma was induced by the joint administration of aflatoxin B1 and cyanotoxin." | ( Yu, S; Zhao, N; Zi, X, 2001) |
| "Effective treatment for hepatocellular carcinoma is urgently needed." | ( Ganslmayer, M; Geerts, A; Hahn, EG; Hermann, M; Herold, C; Ocker, M; Schuppan, D, 2002) |
| "TSA inhibits hepatoma cell growth in vitro, which are otherwise particularly resistant to chemotherapy." | ( Ganslmayer, M; Geerts, A; Hahn, EG; Hermann, M; Herold, C; Ocker, M; Schuppan, D, 2002) |
| "Eighty-seven patients with hepatocellular carcinoma were divided into two groups: Group A, 45 patients were treated with TACE only, group B, 42 patients were treated with TACE plus PEI." | ( Hao, Y; Li, C; Shi, Z, 2001) |
| "Patients with hepatocellular carcinoma no longer amenable to established forms of treatment were eligible for the study." | ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002) |
| "We studied 3 cirrhotic patients with hepatocellular carcinoma > 3 cm and < 8 cm who underwent transarterial embolization and percutaneous ethanol injection as combination coadjuvant therapy while on the waiting list for liver transplantation." | ( Callado França, AV; Lescano Lescano, MA; Martinelli Canadolo, AL, 2002) |
| "We treated four hepatocellular carcinoma cell lines, HLE, HLF, HuH7, and HepG2 with ATO and demonstrated that arsenic trioxide (ATO) at low doses (1--3 muM) induced a concentration-dependent suppression of cell growth in HLE, HLF, and HuH7." | ( Akao, Y; Kito, M; Nozawa, Y; Ohishi, N; Yagi, K, 2002) |
| "Treatment of hepatocellular carcinoma (HCC) is different from that of other solid tumors, in that surgery plays a limited role while nonsurgical therapies are very instrumental." | ( Hamamura, K; Koike, Y; Obi, S; Omata, M; Shiina, S; Teratani, T, 2002) |
| "Prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein (MPV), inferior vena cava (IVC), or extrahepatic bile duct (EBD) treated by conventional therapies has been considered poor." | ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002) |
| "Systemic treatment for hepatocellular carcinoma is indicated in locally advanced or metastatic disease." | ( Treiber, G, 2001) |
| "Treating hepatoma cells with 2-AAF activated phosphoinositide 3-kinase (PI3K) and its downstream effectors Rac1, and NAD(P)H oxidase." | ( Kuo, MT; Lin-Lee, YC; Liu, Z; Mills, GB; Tatebe, S; Unate, H; Wei, Y, 2002) |
| "A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)." | ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002) |
| "Human hepatoma-derived cell lines, PLC/PRF/5, HuH-7, and JHH-7, were treated in vitro with AR." | ( Adachi, S; Moriwaki, H; Muto, Y; Obora, A; Okuno, M; Seishima, M; Shidoji, Y; Shiratori, Y; Takemura, M; Yasuda, I, 2002) |
| "The human hepatoma cells SMMC-7721 were treated with different concentrations of ascorbic acid (50-800 mumol/L) and FeSO4 (2." | ( Li, JF; Ren, JG; Zheng, RL, 1998) |
| "Cotreatment of HepG2 human hepatoma cells with the proteasome inhibitor N-acetyl-Leu-Leu-norleu-al did not prevent the ACR-induced decrease in cyclin D1 protein, in contrast to the protective effect of N-acetyl-Leu-Leu-norleu-al on the cyclin D1 protein in cells treated with all-trans-retinoic acid." | ( Albanese, C; Lim, JT; Masuda, M; Pestell, RG; Suzui, M; Weinstein, IB, 2002) |
| "EBB can enhance the anti-hepatoma ability of 5-Fu treatment." | ( Li, Z; Liu, J; Qi, S; Wang, T; Zhang, J; Zhu, H, 2002) |
| "Effective therapy of advanced hepatocellular carcinoma remains a major clinical problem." | ( Koorey, DJ; McCaughan, GW; Strasser, SI, 2002) |
| "Sixty-seven patients with nonresectable hepatoma were treated with hepatic artery infusions (HAI) of 50 mg/m2 cisplatinum on a monthly basis." | ( Court, WS; DeNittis, AS; Johnson, E; Martz, K; Order, SE; Principato, R; Siegel, JA; Zeiger, LS, 2002) |
| "We report a case of multicentric hepatocellular carcinoma that developed in a 74-year-old man 3 and 6 years after interferon (IFN) treatment for chronic hepatitis C, despite sustained virologic, biochemical, and histological improvement." | ( Ando, K; Fukuda, K; Hayashi, Y; Hirai, M; Ikawa, H; Imoto, S; Kim, KI; Kim, SR; Koterazawa, T; Kudo, M; Maekawa, Y; Matsuoka, T; Mita, K; Nakaji, M; Ninomiya, T; Shintani, S; Yano, Y, 2002) |
| "We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
| "HuH-7 hepatoma cells were transplanted into nude mice and the growth of xenograft tumors was compared to and without administration of trientine." | ( Kagawa, K; Katagishi, T; Kimura, H; Mitsumoto, Y; Moriguchi, M; Nakajima, T; Okanoue, T; Takashima, H; Watanabe, T, 2002) |
| "Treatment of hepatocellular carcinomas (HCCs) with chemotherapy has generally been disappointing and it is most desirable to have more effective new drugs." | ( Chen, CC; Ho, CK; Huang, YL, 2002) |
| "Patients with small hepatocellular carcinoma (HCC) are usually treated with hepatic resection or percutaneous ethanol injection (PEI)." | ( Aiello, A; Andreana, A; Capuano, G; Daniele, B; De Sio, I; Fiore, F; Gaeta, GB; Gallo, C; Izzo, F; Mazzanti, R; Perrone, F; Pignata, S; Vallone, P, 2003) |
| "Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)." | ( Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002) |
| "To introduce an animal model of hepatocellular carcinoma (HCC) in ACI-rats, and to evaluate the therapeutic effects of Poly-lactide-co-glycolide (Plcg) -microspheres in the transarterial chemoembolization (TACE) in this model, as well the value of this model in the experiments of interventional therapy." | ( Claussen, C; Eul, T; Graepler, F; Huppert, P; Pereira, P; Qian, J; Truebenbach, J; Wiemann, G, 2003) |
| "The results of tamoxifen treatment in hepatocellular carcinoma have been disappointing and randomized studies have shown conflicting results." | ( Auriault, ML; Boivin, JF; Chayette, C; Cheaib, S; Deplus, R; Macaigne, G, 2002) |
| "Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis." | ( Bae, MA; Song, BJ, 2003) |
| "In the present study, hepatocellular carcinomas were induced in male A/J mice by the intraperitoneal injection of bleomycin (120 mg/kg) followed by the intraperitoneal administration of 1-nitropyrene (total dose: 1,575 mg/kg)." | ( Bai, F; Hara, N; Harada, T; Inoue, K; Izumi, M; Nakanishi, Y; Pei, XH; Takayama, K, 2003) |
| "Treatment of rat hepatoma AH136B cells with the HO inhibitor zinc protoporphyrin IX (ZnPP IX) or tin protoporphyrin IX resulted in extensive apoptotic changes of tumour cells both in vivo and in vitro." | ( Akaike, T; Beppu, T; Fang, J; Maeda, H; Miyamoto, Y; Ogawa, M; Tamura, F; Tanaka, S, 2003) |
| "Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC." | ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Malogolowkin, MH; Newman, K; Ortega, JA; Qu, W; Quinn, JJ; Reynolds, M; Sensel, MG, 2003) |
| "Chemotherapy of advanced hepatocellular carcinoma (HCC) is frequently limited by unacceptable toxicity." | ( Hong, RL; Tseng, YL, 2003) |
| "The majority of patients with hepatocellular carcinoma (HCC) cannot be treated with surgery." | ( Becker, D; Bernatik, T; Frieser, M; Hahn, EG; Hänsler, J; Kutschall, C; Müller, W; Schaber, S; Strobel, D, 2003) |
| "In early stage hepatocellular carcinoma (HCC), liver transplantation, surgical resection and percutaneous techniques are classified as radical treatments, and may be offered to about 25% of all patients with HCC evaluated in referral centres." | ( Bolondi, L; Cecilioni, L; Celli, N; Gaiani, S; Piscaglia, F, 2003) |
| "The optimal treatment for hepatocellular carcinoma (HCC) is surgical resection." | ( Bertolini, E; Bruno, S; Cornalba, GP; Costa, M; Montorsi, M; Podda, M; Santambrogio, R; Zuin, M, 2003) |
| "Before treatment, all examined 107 hepatocellular carcinoma nodules were found to be hypervascular on contrast-enhanced imaging with coded harmonic angio." | ( Chung, H; Kawasaki, T; Kitano, M; Kudo, M; Maekawa, K; Minami, Y; Onda, H; Suetomi, Y; Wen, YL; Zheng, RQ, 2003) |
| "In the treatment group, cell cycle of hepatoma cells was mainly arrested at S phase, but in group D, G0/G1 phase cells were significantly decreased and S phase cells significantly increased." | ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003) |
| "When the human hepatoma cells were pretreated with HAb18 antibody and incubated with immunonanoparticles, few immunonanoparticles were seen in cytoplasm of the cells, suggesting antibody-specific internalization of the immunonanoparticles." | ( Cai, M; Li, G; Liu, X; Wang, X; Wei, D, 2003) |
| "The human hepatoma cell line BEL-7402 was cultured and treated with HAP nanoparticles at various concentrations." | ( Ai, ZL; Liu, ZS; Tang, SL, 2003) |
| "Fifty-eight patients with 68 hepatocellular carcinomas and 6 metastases who were treated with interventional procedures were evaluated with SH U 508A-enhanced agent detection imaging and helical computed tomography." | ( Kim, CS; Lee, JM; Youk, JH, 2003) |
| "Keywords were Hepatocellular carcinoma, liver metastases, percutaneous ethanol injection, cryotherapy, microwave coagulation therapy, radiofrequency ablation, interstitial laser photocoagulation, focused high-intensity ultrasound, hot saline injection, electrolysis and acetic acid injection." | ( Aylott, C; Berry, DP; Garcea, G; Lloyd, TD; Maddern, G, 2003) |
| "Human hepatoma HepG2 cells were treated with 5-Fu at the concentrations of 1X10(-1), 1X10(-2), 1X10(-3), 1X10(-4), 1X10(-5) mol/L and for 1, 2, 4, 8, 16, 24 hours, respectively." | ( Yang, LY; Yi, TB, 2003) |
| "Nineteen patients with far advanced hepatocellular carcinoma received transarterial hepatic chemotherapy." | ( Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kitamura, S; Masuda, F; Masutani, S; Obana, T; Ohnishi, H; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M, 2003) |
| "In 10 (12%) of the 81 treated hepatocellular carcinomas, contrast-enhanced ultrasonography showed either nodular or crescentic enhancing foci at the margins of ablation zones, suggesting residual unablated tumors." | ( Choi, D; Kim, SH; Kim, YH; Lee, WJ; Lim, HK; Lim, JH, 2003) |
| "Four patients with inoperable hepatocellular carcinoma were treated with a magnetic targeted carrier bound to doxorubicin (MTC-DOX) by using a joint magnetic resonance (MR) imaging/conventional angiography system consisting of a 1." | ( Fidelman, NA; Gordon, RL; Kerlan, RK; Koda, J; LaBerge, JM; Venook, AP; Wilson, MW, 2004) |
| "HuH-7 human hepatoma cells were either synchronized in G1, S and G2/M phases, or treated with 1 nM TGF-beta1." | ( Fan, G; Ma, X; Rodrigues, CM; Steer, CJ; Wong, PY, 2004) |
| "Effective therapy for advanced hepatocellular carcinoma (HCC) is lacking." | ( Ganslmayer, M; Hahn, EG; Herold, C; Leitner, S; Ocker, M; Schuppan, D; Zopf, S, 2004) |
| "One approach to treatment of primary hepatocellular carcinoma (HCC) is intraarterial injection of (131)I-lipiodol." | ( Bacher, K; de Ridder, L; De Ruyck, K; De Vos, F; Dierckx, RA; Gemmel, F; Lambert, B; Thierens, H; Vral, A, 2004) |
| "A standard treatment for hepatocellular carcinoma with extrahepatic metastasis is not established and chemotherapy is ineffective." | ( Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K, 2004) |
| "In patients with hepatocellular carcinoma, trientine hydrochloride therapy may significantly reduce copper content in liver tissue." | ( Ebara, M; Fukuda, H; Kondo, F; Okabe, S; Saisho, H; Sugiura, N; Yoshikawa, M; Yukawa, M, 2004) |
| "Treatment of hepatocellular carcinoma before liver transplantation can curb local tumor progression and thereby prolong patients' transplantation eligibility." | ( Holck, PS; Johnson, EW; Levy, AE; Yeh, MM; Yeung, RS, 2004) |
| "Treatment of hepatoma cells with retinoic acid and 1alpha,2,5-dihydroxyvitamin D(3) (Vit-D(3)) resulted in an increase in GlcNAc-transferase-V activity, while treatment with dimethyl sulfoxide and cytosine-arabinoside resulted in decrease in the enzyme activity." | ( Kim, CH, 2004) |
| "L-FABP expressing 1548-rat hepatoma cells were treated with 0." | ( Burczynski, FJ; Rajaraman, G, 2004) |
| "Large hepatocellular carcinoma tumors are being treated increasingly with a combination of transcatheter arterial chemoembolization (TACE) and radiofrequency (RF) ablation." | ( Ahrar, K; Newman, RA; Pang, J; Vijjeswarapu, MK; Wallace, MJ; Wright, KC, 2004) |
| "Histologic analysis of the hepatoma tissue revealed prominent tumor cell death in the dox-RGD-4C treated group and complete tumor cell necrosis in 40% of cases." | ( Kim, JW; Lee, HS, 2004) |
| "Human hepatoma cell line SMMC-7721 was cultured and treated with Sch B at various concentrations." | ( Cao, MF; Chen, F; Gao, YP; Qian, KX; Wang, T; Wu, YF; Zumbika, EP, 2004) |
| "Unresectable hepatocellular carcinoma is extremely difficult to treat." | ( Carr, BI; Geschwind, JF; Goin, JE; Goin, KA; Roberts, CA; Salem, R; Soulen, MC; Thurston, KG; Van Buskirk, M, 2004) |
| "Human hepatoma cell lines HepG2, Huh7, and Hep3B were stably transfected with beta 1-integrin, and the parental, and mock- and beta 1-integrin-transfected hepatoma cells were treated with TGF-beta 1." | ( Eguchi, Y; Hisatomi, A; Matsuhashi, S; Mizuta, T; Ozaki, I; Sakai, T; Yamamoto, K; Yasutake, T; Yoshimura, T; Zhang, H, 2004) |
| "Treatment of either H4IIE or MH1C1 rat hepatoma cell lines as well as primary rat or human hepatocytes with FXR agonists led to stimulation of PEPCK mRNA expression to levels comparable to those obtained with glucocorticoid receptor agonists." | ( Bramlett, KS; Burris, TP; Christe, ME; Cook, T; Ficorilli, J; Michael, LF; Savkur, RS; Stayrook, KR, 2005) |
| "To find a new method of treating hepatocellular carcinoma with melittin by way of using the melittin gene." | ( Gu, W; Huang, XQ; Li, B; Li, SX; Ling, CQ; Zhang, C; Zhang, YN, 2004) |
| "Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy." | ( Ikeda, M; Okusaka, T; Ueno, H, 2004) |
| "The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents." | ( Abbruzzese, JL; Brown, TD; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Zeldis, JB, 2005) |
| "Treatment of rat hepatoma cells as well as human primary hepatocytes with FXR agonists stimulates the expression of PDK4 to levels comparable to those obtained with glucocorticoids." | ( Bramlett, KS; Burris, TP; Michael, LF; Savkur, RS, 2005) |
| "Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor." | ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005) |
| "Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory." | ( Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S, 2005) |
| "Although the incidence of hepatocellular carcinoma (HCC) has been shown to be reduced after interferon (IFN) monotherapy in chronic hepatitis C, the risk factors for the development of HCC have not been fully understood." | ( Inoue, K; Izumi, N; Kurosaki, M; Miyake, S; Nakanishi, H; Nishimura, Y; Onuki, Y; Tsuchiya, K; Uchihara, M; Ueda, K; Yasuhiro, A, 2005) |
| "Treatment of hepatocellular carcinoma raised on cirrhotic liver represents a major endeavor because surgery and chemotherapeutic management fail to improve the clinical course of the disease." | ( Carloni, V; Pantaleo, P; Vizzutti, F, 2005) |
| "We studied two cases of primary, hepatocellular carcinoma (HCC) that occurred following hormone therapy (estrogen therapy in one case and total androgen blockade therapy in another) for stage D2 prostate cancer." | ( Asano, K; Hasegawa, N; Hasegawa, Y; Ikemoto, I; Ishikawa, T; Ohishi, Y; Onodera, S; Tomita, M, 2005) |
| "We show that TRAIL is upregulated in hepatoma cells upon treatment with TGF-beta, whereas TRAIL receptor levels remain unchanged." | ( Ganten, TM; Grosse-Wilde, A; Herzer, K; Koschny, R; Krammer, PH; Schulze-Bergkamen, H; Walczak, H, 2005) |
| "Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | ( Wang, HD; Zheng, JF, 2005) |
| "In Huh-7 hepatoma cells, low dose (LD) doxorubicin treatment induces cell death through mitotic catastrophe accompanying the formation of large cells with multiple micronuclei, whereas high dose (HD) doxorubicin induces apoptosis." | ( Choi, KS; Eom, YW; Park, SS, 2005) |
| "Present chemotherapy for hepatocellular carcinoma (HCC) is not effective." | ( Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY, 2005) |
| "Forty-two advanced hepatocellular carcinoma patients with baseline alpha-fetoprotein levels above 200 ng/mL and thalidomide therapy were included." | ( Chang, JY; Chao, Y; Chen, LT; Chen, SC; Chin, YH; Chuang, TR; Juang, SH; Liu, TW; Shiah, HS; Whang-Peng, J, 2005) |
| "We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)." | ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005) |
| "Judging tumor residue of hepatocellular carcinoma (HCC) after treatment of transcatheter arterial chemo-embolization (TACE) combined with radiofrequency ablation (RFA) by computed tomography (CT) scan is difficult; while 18-fluorodeoxyglucose-positron emission tomography/CT ((18)FDG-PET/CT) has some advantages in this aspect." | ( Fan, WJ; Gu, YK; Huang, JH; Lin, YE; Tan, ZB; Wu, PH; Zeng, YX; Zhang, FJ; Zhang, L; Zhao, M, 2005) |
| "Human hepatoma cell lines HepG2, Hep3B, human breast cancer cell line MCF-7, and human lung adenocarcinoma cell line AGZY-83-a were treated with As(2)O(3) together with ATRA." | ( Li, BX; Lin, DH; Lin, LM; Xiao, JB; Yang, BF, 2005) |
| "However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established." | ( Araki, Y; Fujio, K; Fujioka, S; Hashimoto, K; Iwasaki, Y; Kaneyoshi, T; Kobashi, H; Nishida, T; Piao, CY; Sakaguchi, K; Senoh, T; Shiratori, Y; Terada, R, 2005) |
| "Human hepatocellular carcinoma cell line was tested in vitro for cytotoxicity, colony formation inhibition, and cell cycle distribution through flow cytometry after treatment with water-soluble crude ethanolic extract (CEE) from LFP." | ( Liu, G; Wang, W; Wang, X; Wei, Y; Yuan, S; Zhang, YL, 2006) |
| "For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33." | ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005) |
| "No effective chemotherapy for advanced hepatocellular carcinoma (HCC) exists." | ( Dobritz, M; Eckel, F; Fend, F; Hosius, C; Lersch, C; Mayr, M; Schleyer, E; Schmid, RM; Schulte-Frohlinde, E; von Delius, S, 2005) |
| "The majority of patients with hepatocellular carcinoma are not eligible for surgical radical treatment (resection or liver transplantation) and lipiodol chemoembolisation is an efficient alternative procedure in this indication." | ( Berger, F; Boillot, O; Borson, O; Chapuis, F; Davril, B; Dumortier, J; Henry, L; Mion, F; Paliard, P; Partensky, C; Poncet, G; Scoazec, JY; Valette, PJ, 2006) |
| "We report a case of hepatocellular carcinoma (HCC), initially treated by carbon ions, then subsequently by protons for marginal recurrence." | ( Abe, M; Hishikawa, Y; Igaki, H; Kagawa, K; Kawaguchi, A; Mayahara, H; Murakami, M; Oda, Y; Tokuuye, K, 2005) |
| "It is desirable to diagnose hepatocellular carcinoma (HCC) in the early stages during its development since its treatment is usually difficult." | ( Ebara, M; Fukuda, H; Kawata, T; Minami, T; Nagamine, T; Nakamura, S; Nakayama, A; Sakurai, H, 2006) |
| "One hundred and two patients with hepatocellular carcinoma were evaluated for treatment between 1999 and 2000." | ( Andreani, T; Arrive, L; Chazouillères, O; Fartoux, L; Poupon, R; Rosmorduc, O; Serfaty, L; Tubiana, JM, 2005) |
| "Human hepatoma cells were treated with different concentrations of ethanolic extract of T." | ( Balasubramanian, MP; Sivalokanathan, S; Vijayababu, MR, 2006) |
| "To assess treatment response of hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) with use of diffusion and dynamic contrast medium-enhanced magnetic resonance (MR) imaging." | ( Bluemke, DA; Eng, J; Geschwind, JF; Kamel, IR; Liapi, E; Messersmith, W; Reyes, DK, 2006) |
| "All reported cases of hepatocellular carcinoma in association with Crohn's disease involve patients treated previously with azathioprine or both azathioprine and steroids." | ( Chen, SC; Cho, WK; Cummings, OW; Filomena, CA; Hartley, MP, 2006) |
| "Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment." | ( Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cillo, U; Cingarlini, S; Farinati, F; Marchese, F; Mattiazzi, M; Pastorelli, D; Salmaso, F; Sanavio, C; Zanus, G; Zovato, S; Zustovich, F, 2006) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) remains poor, and new alternative treatments are needed." | ( Caselmann, WH; Gonzalez-Carmona, MA; Kornek, M; Leifeld, L; Rabe, C; Raskopf, E; Sauerbruch, T; Schmitz, V; Vogt, A, 2007) |
| "Treatment of hepatocellular carcinoma cell lines (HepG(2) and Bel-7402) with cAMP inhibited proliferation, with HepG(2) cells showing lower sensitivity to cAMP." | ( Lou, L; Zhao, Y, 2006) |
| "Pre-treatment of human hepatoma Huh7." | ( Boriskin, YS; Pécheur, EI; Polyak, SJ, 2006) |
| "Early detection of the response of hepatocellular carcinoma (HCC) to yttrium-90 radioembolization therapy may be important to permit repeat radioembolization or alternative treatment options." | ( Deng, J; Kulik, LM; Larson, AC; Miller, FH; Mulcahy, MF; Omary, RA; Rhee, TK; Salem, R; Sato, KT, 2006) |
| "Data from 24 consecutive patients with hepatocellular carcinoma (HCC) treated by radioembolization in the period from September 2003 to February 2005 were reviewed." | ( Benito, A; Bilbao, JI; Boan, J; Gil, B; Herrero, I; Inarrairaegui, M; Martinez-Cuesta, A; Panizo, A; Prieto, J; Quiroga, J; Rodriguez, J; Sangro, B, 2006) |
| "L-FABP expressing 1548-hepatoma cells, treated with dexamethasone or clofibrate, decreased and increased intracellular L-FABP levels, respectively." | ( Burczynski, FJ; Gong, Y; Jiang, P; Rajaraman, G; Wang, GQ; Yan, J, 2007) |
| "The outcome of surgical treatment of hepatocellular carcinoma (HCC) could be improved by applying patient selection criteria based on tumoral aggressiveness." | ( Fabregat, J; Figueras, A; Figueras, J; Lastra, R; Lladó, L; Rafecas, A; Ramos, E; Serrano, T; Torras, J, 2006) |
| "In rat hepatoma (Fao) cells, treatment with WY-14,643 also increased the mRNA concentration of OCTN-2." | ( Eder, K; Geissler, S; Hirche, F; Koch, A; König, B; Luci, S; Stangl, GI, 2006) |
| "We report a case of large-size hepatocellular carcinoma (HCC) successfully treated with transarterial chemoembolization (TACE) followed by the combination therapy of percutaneous ethanol-lipiodol injection and radiofrequency ablation (PELI-RFA) and percutaneous ethanol-lipiodol injection (PELI) therapy." | ( Hosomi, N; Kiuchi, T; Kohi, F; Kuriyama, S; Kurokohchi, K; Maeta, T; Masaki, T; Matsumoto, I; Ohgi, T; Ono, M; Yoneyama, H; Yoshitake, A, 2006) |
| "Only one hepatocellular carcinoma developed, which was successfully treated by locoregional ablative therapy." | ( Bara, C; Böker, KH; Deterding, K; Haverich, A; Manns, MP; Meyer, S; Pethig, K; Potthoff, A; Tillmann, HL; Wedemeyer, H, 2006) |
| "To evaluate which patients with hepatocellular carcinoma (HCC) are most likely to respond to thalidomide treatment." | ( Chiou, HE; Liu, HW; Wang, TE; Wang, YY, 2006) |
| "A 38-year-old woman with multiple hepatocellular carcinoma developed refractory liver failure 2 months after the completion of the dual treatment; namely a cytoreductive right hepatectomy for bulky main tumors followed by 2 courses of percutaneous isolated hepatic perfusion for residual tumors in the remnant liver." | ( Fukumoto, T; Iwasaki, T; Kido, M; Ku, Y; Kusunoki, N; Ogata, S; Sugimoto, T; Takebe, A; Tanaka, M; Tominaga, M, 2006) |
| "We studied the incidence of hepatocellular carcinoma (HCC) and survival probability after the initiation of IFN therapy in 500 Japanese chronic hepatitis C patients >60 years." | ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Koyama, R; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y, 2007) |
| "57 patients with 72 hepatocellular carcinomas (HCC) treated with ethanol ablation were retrospectively compared with 60 new patients who had 72 HCC treated with RF ablation." | ( Beaugrand, M; Durand-Zaleski, I; N'Kontchou, G; Sellier, N; Seror, O; Tin Tin Htar, M; Trinchet, JC, 2006) |
| "The human hepatoma cell line HepG2 was treated with tanshinone IIA at various concentrations for 72 h." | ( Chen, WG; Li, QX; Liu, YH; Qiu, Y; Zhong, ZH, 2007) |
| "Percutaneous treatment of hepatocellular carcinoma (HCC) located directly under the diaphragm is problematic because ultrasonic imaging is difficult, and the lung may be injured during the procedure." | ( Fukuno, H; Ito, S; Kohno, N; Nomura, M; Saito, K; Shimizu, I; Tamaki, K; Urata, M, 2007) |
| "Two different hepatoma cell lines were incubated for 48h with chemotherapeutic drugs cisplatin, paclitaxel and 5-FU to determine their ability to induce cytotoxicity and DNA fragmentation as well as to modify the expression of some cell death-related genes that could be involved in the resistance to therapy." | ( Arce, F; Brenes, O; Díaz, C; Gätjens-Boniche, O, 2007) |
| "In rat hepatoma 7288CTC, short-term (1-2 h) treatment with eicosapentaenoic acid during perfusion in situ reduced fatty acid uptake and [(3)H]thymidine incorporation." | ( Blask, DE; Dauchy, EM; Dauchy, RT; Davidson, LK; Krause, JA; Lynch, DT; Sauer, LA; Smith, LC, 2006) |
| "We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
| "Suppressing HBV DNA to prevent hepatocellular carcinoma and cirrhosis in immune tolerant patients is very cost-effective, and treatment of these patients may be considered." | ( Campbell, MS; Enriquez, AD; Reddy, KR, 2007) |
| "Dedifferentiated hepatoma cells, in contrast to most other cell types including hepatoma cells, undergo apoptosis when treated with lipopolysaccharide (LPS) plus the protein synthesis inhibitor cycloheximide (CHx)." | ( Bulla, GA; Ellis, J; Kraus, DM; Reidy, MR; Schmitz, EA, 2007) |
| "We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
| "We report here two cases of hepatocellular carcinoma (HCC) 90 and 70 months, respectively, after successful treatment with interferon (IFN) and ribavirin for hepatitis C virus (HCV)-related cirrhosis." | ( Andreone, P; Bernardi, M; Biselli, M; Cursaro, C; Gramenzi, A; Scuteri, A; Serra, C; Vitale, G; Vukotic, R, 2008) |
| "Systemic treatments of advanced hepatocellular carcinoma (AHCC) have offered marginal clinical benefits." | ( Chang, HM; Kang, YK; Kim, KM; Kim, MK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ, 2008) |
| "The systemic treatment of advanced hepatocellular carcinoma (HCC) has produced disappointing results thus far." | ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007) |
| "The HuH-7 hepatocellular carcinoma cells were treated with various monosaccharides for 48 h and D-allose was shown to inhibit cell growth by 40% in a dose-dependent manner." | ( Dong, Y; Kamitori, K; Nonaka, M; Sui, L; Takata, M; Tokuda, M; Yamaguchi, F, 2008) |
| "Treatment of HuH7 hepatoma cells with VK(2) produced a normal liver phenotype." | ( Arii, S; Bhattacharjee, R; Kaneda, M; Morita, I; Nakahama, K; Zhang, D, 2008) |
| "Patients with advanced hepatocellular carcinoma (HCC) face a dismal prognosis, as no effective palliative chemotherapy exists." | ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
| "The proliferation of H7402 human hepatoma cells and MCF-7 human breast cancer cells was measured by the 5-bromodeoxyuridine (BrdU) incorporation assay and flow cytometry assay after the treatment with conditioned media from hMSCs culture, such as Z3 cells or BMMS-03 cells." | ( Qiao, L; Shan, CL; Wang, FZ; Ye, LH; Zhang, XD; Zhao, TJ, 2008) |
| "Pemetrexed has demonstrated activity in hepatocellular carcinoma (HCC) cell lines, and has a manageable toxicity profile in clinical trials, suggesting its potential as a treatment for HCC patients." | ( Asmar, L; Cohn, AL; Deur, C; Hood, K; Ilegbodu, D; Khan, MM; Mamus, S; Myers, JW; Nicol, S, 2008) |
| "A 73-year-old man with hepatocellular carcinoma (HCC) had been treated repeatedly with transcatheter arterial embolization (TAE) and percutaneous ethanol injection therapy (PEIT) since 2000." | ( Fukuchi, H; Ichinose, M; Kida, Y; Tanaka, H; Ueda, H, 2008) |
| "Fifteen patients with either hepatocellular carcinoma (HCC, n = 8) or hypervascular liver metastases from uveal melanoma (n = 7) underwent arterial and portal venous C-arm CT of the liver using intraarterial contrast media administration directly before TACE." | ( Borchert, M; Frericks, BB; Justiz, J; Martus, P; Meyer, BC; Voges, M; Wacker, FK; Wolf, KJ, 2008) |
| "A young patient with hepatocellular carcinoma receiving chemotherapy presented with encephalopathy." | ( Blanke, CD; Chan, JS; Harding, CO, 2008) |
| "Treatment of hepatoma cells with the selective COX-1 inhibitor SC-560, as well as with the selective COX-2 inhibitor CAY10404, was associated with activation of ERK1/2 in a time- and dose-dependent manner." | ( Azzolina, A; Cervello, M; Cusimano, A; D'Alessandro, N; Foderà, D; Lampiasi, N; Montalto, G, 2007) |
| "We treated patient-derived hepatocellular carcinoma xenografts with (i) bevacizumab; (ii) rapamycin; and (iii) bevacizumab plus rapamycin." | ( Chow, PK; Goh, BC; Hor, H; Huynh, H; Kalpana, R; Lee, CK; Lee, HS; Lee, MH; Palanisamy, N; Salto-Tellez, M; Somani, A; Soo, KC; Soong, R; Tan, P; Tan, PH; Toh, HC; Wu, J; Yu, K, 2008) |
| "To determine if larger hepatocellular carcinoma (HCC) coagulation volumes can be obtained by combining percutaneous microwave coagulation therapy (PMCT) and ethanol injection (PEI) or PEI followed by PMCT with occlusion of the feeding artery." | ( Li, R; Liu, X; Nie, W; Zhou, P, 2009) |
| "Bortezomib treatment inhibited hepatoma cell growth with IC(50) values between 2." | ( Armeanu, S; Baltz, KM; Bitzer, M; Krusch, M; Lauer, UM; Salih, HR; Smirnow, I; Steinle, A; Weiss, TS, 2008) |
| "Of 2575 patients with hepatocellular carcinoma or hepatic metastases treated with radiofrequency ablation, intrapleural fluid infusion was performed in 587 patients for tumours in the hepatic dome." | ( Kawabe, T; Kondo, Y; Omata, M; Shiina, S; Tateishi, R; Yoshida, H, 2008) |
| "Androgen effects on hepatocellular carcinoma (HCC) remain controversial and androgen ablation therapy to treat HCC also leads to inconsistent results." | ( Chang, C; Chen, CW; Hsu, CL; Jou, YS; Lai, JJ; Ma, CL; Ma, WL; Wu, CC; Wu, CT; Wu, MH; Yeh, S, 2008) |
| "In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo." | ( Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S, 2008) |
| "Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function." | ( Kim, CM; Kim, JH; Koh, DW; Lee, WJ; Park, JW, 2009) |
| "Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed." | ( Codecà, C; Di Maria, G; Fazio, N; Ferrari, D; Fiore, J; Foa, P; Luciani, A; Maggioni, M; Oldani, S, 2008) |
| "There is no standard treatment for hepatocellular carcinoma (HCC) patients with extrahepatic metastases." | ( Aikata, H; Azakami, T; Chayama, K; Jeong, SC; Kawakami, Y; Kawaoka, T; Mori, N; Takahashi, S; Takaki, S; Uka, K, 2008) |
| "NS-398 inhibited the growth of hepatoma cells by an amount dependent on the concentration and the time since treatment." | ( Kim, DW; Kim, EY; Kim, HJ; Kim, SB; Shin, HD; Shin, JE; Shin, KC; Song, IH; Yun, SY, 2008) |
| "Treatment of hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE) is known to induce vascular endothelial growth factor (VEGF) expression." | ( Ket-Horm, S; Kiatdilokrut, A; Laisupasin, P; Leelawat, K; Narong, S; Pongtongpool, T; Samkhumphim, N, 2008) |
| "AFP-producing hepatoma can be targeted and treated with radionuclides and hNIS, using AFP enhancer/promoter." | ( Chung, HK; Chung, JK; Jin, YN; Kang, JH; Kim, S; Kim, YJ; Kimm, KI; Lee, YJ, 2008) |
| "Treatment of hepatoma cells with 2." | ( Chi, CW; Ko, PH; Liu, TY; Lui, WY; Uen, YH; Yin, PH, 2008) |
| "METHODS; Hepatocellular carcinoma cells Bel-7402 and normal liver cell line L-02 were treated with NaPB at different concentrations." | ( Jiang, JJ; Jiang, JM; Jin, CJ; Meng, M; Qin, CY; Ren, HS; Wang, CT; Yu, DQ; Zhang, JC, 2008) |
| "We have treated 6 patients [5 with hepatocellular carcinoma (HCC) one with metastatic disease] with a total of 7 tumors (6 HCCs, a solitary metastasis), using a new bipolar RFA device consisting of two separate needles, each with deployable electrodes." | ( Eisele, RM; Neuhaus, P; Schumacher, G, 2008) |
| "Treatment of hepatocellular carcinoma has dramatically changed in the last years." | ( Boucher, E; Bruix, J; Forner, A; Reig, M, 2009) |
| "The human hepatocellular carcinoma SMMC-7721 cells cultured in vitro was treated with different concentrations of Tanshinone II A." | ( Chen, JH; Han, M; He, SX; Hou, HL; Ren, MD; Wang, ZL; Zhai, XM, 2009) |
| "In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed." | ( Choi, JS; Choi, SB; Han, KH; Kim, KS; Lee, JT; Lee, WJ; Park, YN; Seong, J, 2009) |
| "In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not received prior systemic therapy, received either oral sorafenib (400 mg twice daily) or placebo until radiological and symptomatic progression." | ( Rimassa, L; Santoro, A, 2009) |
| "Reported herein is a case of hepatocellular carcinoma (HCC) occurring in a 25-year-old Japanese man who was diagnosed with Crohn's disease (CD) at 14 years of age; treatment included predonisolone, azathioprine, and infliximab." | ( Enaka, M; Kawachi, K; Kunisaki, R; Morimoto, M; Murakami, A; Nagano, Y; Nozawa, A; Sasaki, T; Tanabe, M; Tanaka, Y; Ueda, M, 2009) |
| "Human hepatocellular carcinoma HepG2 cells were treated with brazilein and analyzed for survivin protein and mRNA levels by Western blotting and real-time RT-PCR, respectively." | ( Pan, YJ; Wu, B; Zheng, S; Zhong, X, 2009) |
| ": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options." | ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009) |
| "Sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by SAHA may suggest new strategies for the treatment of liver tumours." | ( Angileri, L; Carlisi, D; D'Anneo, A; Di Fazio, P; Emanuele, S; Lauricella, M; Santulli, A; Tesoriere, G; Vento, R, 2009) |
| "XN05-treatment in human hepatocellular carcinoma cells resulted in the accumulation of G2/M phase cells and finally induced apoptosis assessed by flow cytometry analysis." | ( Ding, W; He, Q; Hu, Y; Liu, T; Wu, R; Yang, B; Zhu, H, 2009) |
| "Human hepatoma cell line (Huh7) was treated with 400 miromol x L(-1) taurodeoxycholic acid (TDCA) for 48 hours to induce apoptosis." | ( Khaoustov, V; Xu, Y; Yoffe, B; Yu, J, 2009) |
| "A 58-year-old man with hepatocellular carcinoma (HCC) with liver cirrhosis type C was admitted to our division in April, 2004 to receive transarterial chemo-embolization (TACE) as a first-line chemotherapy for HCC." | ( Miura, T; Nakamura, J; Ozeki, Y; Takahashi, T; Takano, T; Tsuboi, Y; Yamada, S; Yanagi, M, 2009) |
| "These findings indicate that hepatoma cells overcome IGF-1R inhibition through HER3 activation in an EGFR-dependent mechanism, and that HER3 represents a critical mediator in acquired resistance to anti-IGF-1R therapy." | ( Baron, A; Bladt, F; Blivet-Van Eggelpoël, MJ; Desbois-Mouthon, C; Fartoux, L; Housset, C; Rosmorduc, O; Venot, C, 2009) |
| "Curative therapies for patients with hepatocellular carcinoma (HCC) are mainly invasive, and with the exception of sorafenib, no medical treatments are available for advanced or metastatic stages of HCC." | ( Antonaci, S; Fransvea, E; Giannelli, G; Lavezzari, G; Mazzocca, A, 2009) |
| "As clinicians who treat hepatocellular carcinoma move yttrium-90 intra-arterial radiotherapy from the palliative setting to the treatment of patients with potentially curable early stage disease, more intense scrutiny of the safety of that procedure is warranted." | ( Aloia, TA; Barakat, O; Connelly, J; Gaber, AO; Ghobrial, RM; Haykal, N; Michel, D, 2009) |
| "In contrast, the hepatocellular carcinoma (HCC) cell line HepG2 was resistant to BA treatment." | ( Eichenmüller, M; Kappler, R; von Schweinitz, D, 2009) |
| "The survival of patients with hepatocellular carcinoma (HCC) has improved with advancements in various diagnostic tools and treatment modalities." | ( Addeo, R; Capasso, E; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Frega, N; Guarrasi, R; Leopardo, D; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Pizza, C; Vincenzi, B, 2010) |
| "Here, we present two cases of large hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) that resulted in TLS." | ( Chen, YS; Hsieh, PM; Hung, KC, 2009) |
| "Treatment with Morris Hepatoma 7777 cells decreased the number of proliferating cells as compared to control animals." | ( Buwalda, B; Konsman, JP; Koolhaas, JM; Pourtau, L; Schagen, SB; Seigers, R; van Dam, FS, 2010) |
| "We report a 48-year-old man with hepatocellular carcinoma (HCC) treated with hepatic arterial infusion (HAI) chemotherapy followed by proton beam therapy." | ( Fujiki, R; Kitamura, T; Matsui, O; Motoo, Y; Mouri, H; Ohtsubo, K; Okai, T; Sanada, J; Sawabu, N; Tokuuye, K; Tsuchiyama, T; Watanabe, H; Yamaguchi, Y, 2009) |
| "SMMC-7721 hepatocellular carcinoma cells (HCC) were incubated with fucosylated glycoproteins that had been isolated from retinoic acid-treated cells by affinity chromatography." | ( Shi, BZ; Wu, LH; Wu, XZ; Zhao, QL, 2010) |
| "In an orthotopic hepatoma model, treatment with AZD1152 significantly decelerated tumor growth and increased survival." | ( Aihara, A; Arii, S; Ito, K; Kudo, A; Matsumura, S; Mitsunori, Y; Murakata, A; Nakamura, N; Noguchi, N; Tanaka, S; Yasen, M, 2010) |
| "He was diagnosed with hepatocellular carcinoma in June 2007 and began treatment with sorafenib 200 mg daily in September 2007." | ( Montalvo, RO; Moretti, LV, 2009) |
| "Phase III pivotal studies against hepatocellular carcinoma as monotherapy and liver-metastatic colorectal cancer in combination with chemotherapy are ongoing." | ( Bromley, E; Chen, JC; Keltner, L; Wang, S; Xu, L, 2010) |
| "We report two cases of advanced hepatocellular carcinoma( HCC) with a portal vein tumor thrombus (PVTT) responding to transcatheter arterial infusion chemotherapy (TAI) using cisplatin (CDDP)." | ( Aizawa, M; Inose, S; Katsube, T; Kim, DH; Masuda, T; Naritaka, Y; Ogawa, K; Shiozawa, S; Tsuchiya, A; Usui, T; Yoshimatsu, K, 2009) |
| "Furthermore, after hepatoma cells (Hep3B and HepG2) were treated with different concentrations of Andro (0-30 micromol x L(-1)) for 14 d, the number of colony formation was accounted under microscope." | ( Ji, LL; Liu, TY; Shen, KK; Wang, ZT; Xu, C, 2009) |
| "During starvation hepatocellular carcinoma cells exhibited characteristics of autophagy, which disappeared in serotonin-treated cells." | ( Clavien, PA; Graf, R; Jang, JH; Moritz, W; Riener, MO; Soll, C; Wild, PJ, 2010) |
| "Records of patients with advanced hepatocellular carcinoma (HCC) treated with helical tomotherapy and sunitinib after radiation therapy (RT) from March 2007 to August 2008 were retrospectively reviewed." | ( Chang, CC; Chi, KH; Ko, HL; Liao, CS; Mehta, MP; Tsang, YW; Yang, KC, 2010) |
| "Local therapy for hepatocellular carcinoma with percutaneous ethanol injection and transarterial chemoembolization partially controlled tumor evolution considering the Milan criteria in patients waiting for liver transplantation." | ( Celho, JC; Dias, JM; Freitas, AC; Matias, JE; Parolin, MB, 2009) |
| "In addition, C/EBP was upregulated in hepatoma cells after T(3) treatment and ectopic expression of MAT1A inhibited cell migration and invasion in J7 hepatoma cells." | ( Chen, WJ; Cheng, WL; Chien, LF; Huang, YH; Liao, CH; Liao, CJ; Lin, KH; Lu, YH; Tsai, MM; Wu, SM; Yeh, CT, 2010) |
| "Among 11,030 patients with unresectable hepatocellular carcinoma, 8,507 underwent TACE, and 2,523 underwent transarterial infusion therapy with an emulsion of iodized oil and an anticancer agent as initial treatment." | ( Arii, S; Ikai, I; Kojiro, M; Kudo, M; Makuuchi, M; Matsuyama, Y; Takayasu, K, 2010) |
| "He had hepatocellular carcinoma and was treated with transcatheter arterial chemoembolization (TACE) containg epirubicin (total dose: 300 mg over the last two years)." | ( Kawasaki, Y; Nakazora, T; Shinohara, K; Suzukawa, M; Tominaga, T, 2010) |
| "The current curative treatments for hepatocellular carcinoma (HCC) do not effectively prevent tumor recurrence." | ( Kaneko, S; Nakamoto, Y, 2010) |
| "The treatment for hepatocellular carcinoma with distant metastasis remains unclear." | ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2010) |
| "Major burdens in the treatment of hepatocellular carcinoma (HCC) are the high percentage of recurrence and resistance to chemotherapy." | ( Foris, V; Irimie, A; Kacsó, G; Mosteanu, O; Pintea, B; Pop, T; Rus-Ciuca, D; Soritau, O; Susman, S; Todea, D; Tomuleasa, C, 2010) |
| "Fifty-one patients with hepatocellular carcinoma and 15 patients with liver metastases were treated by RF ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles for a target lesion identified as a defect image after the administration of contrast medium." | ( Chung, H; Hagiwara, S; Hatanaka, K; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Ueshima, K, 2010) |
| "A 65-year-old woman who had diffuse hepatocellular carcinoma(HCC)with tumor thrombus of right portalvein(Vp3) and lung metastases(Stage IVB)was treated by single-agent therapy with tegafur/uracil(UFT)." | ( Adachi, K; Hiramatsu, S; Kurai, O; Miyano, M; Oka, H; Sasaki, E; Yamasaki, T, 2010) |
| "Most hepatocellular carcinomas (HCC) are diagnosed in patients with cirrhosis and/or when tumor burden is too advanced for surgical treatment." | ( Andreana, L; Chung, H; Hatanaka, K; Kudo, M; Maekawa, K; Minami, Y; Ruggiero, G, 2010) |
| "The early detection of hepatocellular carcinoma (HCC) and opportunity to select appropriate treatment are important benefits of HCC screening." | ( Chang, KC; Changchien, CS; Chen, CH; Chen, PF; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tsai, LS; Tseng, PL; Tung, HD; Wang, JH, 2010) |
| "Fifty-two patients with advanced hepatocellular carcinoma underwent intra-arterial chemotherapy with cisplatin and fluorouracil." | ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011) |
| "There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus." | ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "Human hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to its potent MDR." | ( Li, SW; Ling, X; Wen, L; Yan, B; Zhou, Y, 2010) |
| "Human hepatocellular carcinoma (HCC) is considered difficult to cure because it is resistant to radio- and chemotherapy and has a high recurrence rate after curative liver resection." | ( Gu, J; Hu, S; Jiang, H; Li, P; Li, Z; Shi, B; Tan, Z; Wang, H; Yang, L, 2011) |
| "Hepa 1-6 mouse hepatoma cells with 70% decrease in 16S/18S rRNA ratio (Rho cells) were obtained by long-term treatment with ethidium bromide." | ( Gonzalez-Buitrago, JM; Gonzalez-Loyola, A; Gonzalez-Sanchez, E; Marin, JJ; Perez, MJ, 2011) |
| "Mice bearing H22 hepatoma were treated with cisplatin or placebo by intraperitoneal injection." | ( Cao, LH; Han, F; Li, AH; Liu, M; Zheng, W; Zhou, JH, 2011) |
| "Human hepatocellular carcinoma cells in culture, as well as nude mice transplanted with hepatocellular carcinoma cells and rats given with N-diethylnitrosamine were treated with acyclic retinoid." | ( Fukaya, Y; Ishibashi, N; Kojima, S; Moriwaki, H; Okuno, M; Sano, T; Tatsukawa, H; Watanabe, M, 2011) |
| "A case of hepatocellular carcinoma, successfully treated with multimodal loco-regional treatments, is reported." | ( Akiyama, H; Amikura, K; Kawashima, Y; Nakajima, T; Nishimura, Y; Sakamoto, H; Tanaka, Y; Yamagata, Y; Yamaura, T; Yatsuoka, T; Yokoyama, Y, 2010) |
| "We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)." | ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010) |
| "Mice bearing subcutaneous H22 hepatoma were treated with different doses of thalidomide, 100 mg/kg in group B and 200 mg/kg in group C." | ( Cao, LH; Han, F; Li, AH; Liu, JB; Liu, M; Luo, RZ; Zheng, W; Zhou, JH, 2011) |
| "In patients with small hepatocellular carcinoma, sorafenib could be suggested as neoadjuvant therapy to control tumor growth during waiting time for liver transplantation." | ( Borentain, P; Durieux, O; Garcia, S; Gérolami, R; Gregoire, E; Hardwigsen, J; Le Treut, YP, 2011) |
| "Treatment of hepatoma cells with policosanol produced a 2." | ( Banerjee, S; Ghoshal, S; Porter, TD, 2011) |
| "The treatment of HepG2 hepatoma cells with mutation-inducing doses (3-5 μmol/l) of AFB1 induced DNA adducts, 8-hydroxyguanine lesions and DNA strand breaks that lasted several days." | ( Gursoy-Yuzugullu, O; Ozturk, M; Yilmaz, M; Yuzugullu, H, 2011) |
| "We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection." | ( Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M, 2011) |
| "PURPOSE Hepatocellular carcinoma (HCC) is a common and deadly malignancy with few systemic therapy options." | ( Bekaii-Saab, TS; Goff, LW; Kauh, JS; Kazi, A; Learoyd, M; Lee, RM; Lush, RM; Moore, DT; O'Neil, BH; Sebti, SM; Strosberg, JR; Sullivan, DM, 2011) |
| "Swiss mice inoculated with hepatoma HepA(22) or sarcoma 180 (S(180)) cells were treated with ShD or 5-fluorouracil (5Fu)." | ( BaoJie, G; GuangZhi, Y; LiHua, L; Long, S; Wei, X; Yang, Z; YanYong, H; YingLi, W, 2012) |
| "Human gastric carcinoma (AGS), human hepatocellular carcinoma (HepG2), and human esophageal squamous cell carcinoma (KYSE-30) cancer cell lines were treated by MSM and incubated for 24, 48, and 72 h." | ( Bohlooli, S; Jafari, N; Mazani, M; Mohammadi, S, 2012) |
| "HCC (hepatocellular carcinoma) is among the most common and lethal cancers worldwide with a poor prognosis mainly due to a high recurrence rate and chemotherapy resistance." | ( Hong, DY; Huang, HS; Liu, ZM; Tseng, JT, 2011) |
| "The rat liver epithelial WB-F344 and hepatoma RH7777 cells were treated by TPA for 48h." | ( Fukui, R; Fukushima, N; Kato, K; Mori, T; Okabe, K; Okumura, M; Teranishi, M; Tsujiuchi, T, 2011) |
| "For targeted imaging and therapy of hepatocellular carcinoma (HCC), we established a chimeric promoter (EIIAPA) containing alpha-fetoprotein (AFP) promoter and hepatitis B virus enhancer II (EIIA) to control downstream expression of reporter and therapeutic genes." | ( Chen, FD; Gelovani, JG; Hou, MF; Hsieh, YJ; Huang, CJ; Ke, CC; Lin, KP; Liu, RS; Wang, HE, 2012) |
| "We observed that baicalein suppresses hepatoma cell growth by 55%, baicalein-treated cells showed lower levels of migration than untreated cells, and cell invasion was significantly reduced to 28%." | ( Chiu, YW; Huang, CY; Huang, HI; Huang, WS; Hwang, JM; Kuo, HC; Kuo, WH; Lin, TH; Lin, WL; Liou, YS; Liu, JY; Teng, CY; Tung, JN; Wang, WH, 2011) |
| "Human hepatoma BEL-7402 cells treated with Tan IIA underwent assessment with MTT assay for cell viability, 10-day culture for colony formation, flow cytometry and fluorescence microscopy for apoptosis and cell cycle analysis." | ( Dai, ZK; Huang, JE; Luo, Y; Qin, JK; Xu, Q; Zhao, HL, 2012) |
| "A human hepatoma cell line (SK-Hep1) depleted of mtDNA (ρ0SK-Hep1) was induced by ethidium bromide treatment." | ( He, Y; Ling, X; Yan, B; Zhang, G; Zhou, Y, 2012) |
| "Patients with advanced hepatocellular carcinoma treated with sorafenib had a median survival of 11 months." | ( Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S, 2011) |
| "Growth of hepatoma xenografts, including the size and weight, was inhibited in mice treated with pAdv-AFP-HRPC and IAA, compared with that in control group." | ( Chen, DE; Dai, M; Dong, CY; Ho, WZ; Liu, J; Rao, Y; Tang, ZJ, 2012) |
| "To assess the treatment response of hepatocellular carcinoma (HCC) after transarterial chemoembolization with diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance (MR) imaging with a 3-T system." | ( Bozkaya, H; Cinar, C; Elmas, N; Harman, M; Parildar, M; Sahin, H, 2012) |
| "Assessment of the risk of hepatocellular carcinoma (HCC) development is essential for formulating personalized surveillance or antiviral treatment plan for chronic hepatitis C." | ( Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinuma, S; Kurosaki, M; Matsuura, K; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A, 2012) |
| "Fifteen hepatocellular carcinoma patients with Child-Pugh A cirrhosis, in whom sorafenib dosing remained unchanged from initiation of treatment to disease progression, were eligible for this analysis." | ( Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B, 2012) |
| "Enhanced growth inhibition in hepatoma cells treated with both NSC 74859 and cetuximab suggests that cetuximab resistance is probably mediated via STAT3." | ( Bai, X; Chen, W; Liang, T; Ma, T; Shen, X; Xia, X; Xu, G, 2012) |
| "C-arm CT helps detection of hepatocellular carcinoma (HCC) during interventional (TACE) treatment." | ( Higashihara, H; Hori, M; Kim, T; Maeda, N; Nakamoto, A; Onishi, H; Osuga, K; Tomiyama, N; Tsuboyama, T, 2012) |
| "The treatment of solitary huge hepatocellular carcinoma (SHHCC) larger than 10 cm remains a challenge." | ( Cao, B; Ding, X; Gao, J; Gao, K; Ke, S; Li, M; Qian, X; Sun, W, 2012) |
| "Eighty hepatocellular carcinoma lesions with a maximum diameter of between 1 and 3 cm that were scheduled for treatment with radiofrequency ablation were enrolled in this prospective study." | ( Fukuda, H; Kondo, M; Maeda, S; Morimoto, M; Nozaki, A; Numata, K; Okada, M; Oshima, T; Takebayashi, S; Tanaka, K, 2012) |
| "We report three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib." | ( Egawa, C; Kato, T; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Okishiro, M; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S, 2011) |
| "Forty-four hepatocellular carcinoma patients treated by TACE using epirubicin plus mitomycin C were studied." | ( Chen, SH; Chuang, WL; Hsieh, MY; Huang, CF; Lin, CI; Lin, ZY, 2011) |
| "Treatment of hepatoma cells expressing MAGE-A4 with a sublethal dose of Adriamycin increased the MAGE-A4 processing and sensitized the cells to Adriamycin-induced apoptosis." | ( Fujita, J; Higashitsuji, H; Itoh, K; Kudo, M; Ryu, U; Sakurai, T, 2011) |
| "It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%." | ( Kudo, M, 2011) |
| "Patients with post-transplant hepatocellular carcinoma recurrence were treated with sorafenib." | ( Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2012) |
| "When hepatoma cell lines HepG2 and PLC/PRF/5 were treated with sorafenib plus ATM small inhibitory RNAs, ATM inhibitor KU55933 or caffeine, Akt signaling was suppressed and the cytotoxic effects were significantly potentiated." | ( Aoyagi, Y; Fujimaki, S; Kubota, M; Matsuda, Y; Ohkoshi, S; Sanpei, A; Takamura, M; Wakai, T; Yamagiwa, S; Yano, M, 2012) |
| "Thirty-six patients with hepatocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-loaded glass microspheres." | ( Boucher, E; Clément, B; Edeline, J; Garin, E; Laffont, S; Lenoir, L; Mesbah, H; Porée, P; Raoul, JL; Rolland, Y, 2012) |
| "Recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical or ablative treatments." | ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| "BSO-treated rat hepatoma cells showed a two order of magnitude decrease in SVCT1 and SVCT2 mRNA levels, undetectable SVCT1 and SVCT2 protein expression, and lacked the capacity to transport ascorbic acid, effects that were fully reversible on glutathione repletion." | ( Angulo, C; Barra, V; Cárcamo, JG; Concha, II; Escobar, D; González, M; Maldonado, M; Mardones, L; Mendoza, P; Oñate, G; Ormazabal, V; Reyes, AM; Rivas, CI; Sotomayor, K; Vera, JC; Villagrán, M; Zúñiga, FA, 2012) |
| "The human hepatocellular carcinoma cell line HepG2 and SMMC-7721 cells were treated with different doses of Ardipusilloside I." | ( Chen, X; Chen, Y; Deng, A; He, J; Jin, L; Lou, L; Tao, X; Wang, J; Wu, S; Ye, W; Zhu, J, 2012) |
| "The rate of morbidity and mortality of hepatocellular carcinoma (HCC) in Taiwan has not lessened because of difficulty in treating tumor metastasis." | ( Chien, MH; Chiou, HL; Hsieh, MJ; Hsieh, YH; Yang, SF; Yeh, CB, 2012) |
| "The insensitivity of hepatocellular carcinoma to chemotherapy is associated with alternation in tumor cell cycling." | ( Chen, W; Fang, D; Guo, Y; Zhu, Z, 2012) |
| "Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib remain eligible for further systemic therapy." | ( Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P, 2012) |
| "Occasionally, patients with hepatocellular carcinoma (HCC) who receive radioembolization with palliative intent are downstaged for radical treatments." | ( Benito, A; Bilbao, JI; D'Avola, D; Dominguez, I; Herrero, JI; Iñarrairaegui, M; Martí, P; Pardo, F; Quiroga, J; Rodriguez, M; Rotellar, F; Sangro, B; Zozaya, G, 2012) |
| "C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously, then divided into 5 groups (14 per group), and treated with oxysophoridine (50, 100, or 150 mg/kg) or cisplatin (4 mg/kg) for 10 days." | ( Liu, PX; Long, W; Yao, XQ; Zhang, YH, 2012) |
| "The human hepatoma Huh7 cells were treated with PKC isoform-specific inhibitors and/or siRNAs against each PKC isoform with or without 12-O-tetradecanoylphorbol-13-acetate (TPA)." | ( Eguchi, Y; Fujimoto, K; Hamajima, H; Iwane, S; Kuroda, S; Matsuhashi, S; Mizuta, T; Ozaki, I; Takahashi, H; Xia, J, 2012) |
| "Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively." | ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T, 2012) |
| "We found that TR-overexpressing hepatoma cells treated with T(3) were apoptosis resistant, even when TRAIL was upregulated." | ( Chen, CY; Chen, SL; Chen, WJ; Chi, HC; Chung, IH; Huang, YH; Liao, CH; Liao, CJ; Lin, KH; Lin, YH; Tsai, CY; Tsai, MM; Tseng, YH; Wu, SM; Yeh, CT, 2012) |
| "The treatment of human hepatocellular carcinoma (HCC) cell lines with (+)-isocorydine, which was isolated and purified from Papaveraceae sp." | ( Ge, C; Hou, H; Li, J; Lu, P; Sun, H; Wang, T; Yao, M; Zhang, L; Zhao, F, 2012) |
| "The Morris Hepatoma (MH) and HepG2 cells were treated in vitro with sorafenib (1-10 μM) and erlotinib (1-5 μM) and evaluated for tumor cell viability, apoptosis, and target regulation." | ( Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W, 2012) |
| "In addition, the treatment of rat hepatoma cells with N-acetylcysteine led to a significant increase in the release of Prx-4 protein into the medium; thus, it appears likely that the secretion of Prx-4 is associated with the redox state within cells." | ( Fujii, J; Ihara, H; Ikeda, Y; Ito, R; Takahashi, M; Tsukamoto, H, 2012) |
| "Treatment of hepatocellular carcinoma (HCC) with autologous formalin-fixed tumor vaccine after primary resection has been shown to suppress the recurrence of hepatitis B virus-associated HCC, but the effect of this treatment on hepatitis C virus (HCV)-related disease has not yet been clarified." | ( Inui, T; Ohno, T, 2012) |
| "Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super- selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups." | ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012) |
| "Treatment options of recurrent hepatocellular carcinoma (HCC) after liver transplantation are limited and data on systemic compounds for advanced tumor stages in transplant recipients are sparse." | ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012) |
| "Sixty-six patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib were enrolled in this retrospective study." | ( Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K, 2012) |
| "To (a) evaluate the response of hepatocellular carcinoma (HCC) to chemoembolization after initial nonresponse, as determined with European Association for the Study of the Liver (EASL) criteria and modified Response Evaluation Criteria in Solid Tumors (mRECIST), and (b) compare posttreatment survival of initial nonresponders versus that of initial responders." | ( Frangakis, C; Georgiades, C; Geschwind, JF; Harrison, N; Hines-Peralta, A; Hong, K; Kamel, I; Liapi, E; Wu, Z, 2012) |
| "Treatment of hepatocellular carcinoma (HCC) is a major concern for physicians as its response to chemotherapy and radiotherapy remains generally poor, due, in part, to intrinsic resistance to either form of treatment." | ( Altmeyer, A; Bischoff, P; Denis, JM; Gueulette, J; Josset, E; Mutter, D; Noël, G; Slabbert, J, 2012) |
| "Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such as hepatic resection and liver transplantation." | ( Al Younis, I; Coenraad, MJ; Defreyne, L; Lam, MG; Lambert, B; Seinstra, BA; van den Bosch, MA; van Erkel, AR; van Erpecum, KJ; van Hoek, B; van Vlierberghe, H; Verkooijen, HM, 2012) |
| "Colorectal carcinoma (HT29) and human hepatocellular carcinoma (HepG2) cells were treated with spray-dried extracts of Phyllanthus niruri (SDEPN) either alone or in combination with cisplatin at different concentrations (0." | ( Araújo, AA; Araújo, RF; da Costa Porto, CR; de Aquino, RG; de Souza, TP; Guedes, HG; Guerra, GC; Petrovick, PR; Soares, LA, 2012) |
| "Finally, attenuated proliferation of hepatoma cells by over-expression of miR-1 could be partially restored by exogenous ET-1 treatment." | ( Cheng, P; Gao, H; Li, D; Li, H; Li, Y; Peng, J; Qi, Z; Rui, Y; Su, X; Tan, Y; Wei, D; Yang, P; Zhang, L; Zhang, T; Zhao, Z, 2012) |
| "We treated human hepatoma cells (HepG2) with TCDD, and subsequently exposed them to BaP to elucidate the synergistic effects on mutations." | ( Kawanishi, M; Shiizaki, K; Yagi, T, 2013) |
| "We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine." | ( Chen, SC; Feng, CW; Feng, YM; Hsu, CD, 2012) |
| "Intermediate-stage hepatocellular carcinoma (HCC) is usually treated with locoregional therapy using transarterial chemoembolization (TACE)." | ( Alberts, SR; Andrews, JC; de Groen, PC; Fleming, CJ; Gansen, DN; Gores, GJ; Harmsen, WS; Harnois, DM; Larusso, NF; Lazaridis, KN; Mettler, TA; Moreno-Luna, LE; Narayanan Menon, KV; Paz-Fumagalli, R; Roberts, LR; Sanchez, W; Slettedahl, SW; Therneau, TM; Wiseman, GA; Yang, JD, 2013) |
| "Adult patients with hepatocellular carcinoma and treated with sorafenib 800 mg/day were eligible for this multicentric retrospective observational study." | ( Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B, 2012) |
| "Treatment of hepatoma cells and Chang liver cells with IGF-IR inhibitor abrogated AFB1-induced Akt and Erk1/2 phosphorylation." | ( Hua, H; Jiang, Y; Kong, Q; Luo, T; Ma, Y, 2012) |
| "Treatment of human hepatoma cell lines HepG2 and Bel7402 with germacrone resulted in cell cycle arrest and apoptosis in a dose-dependent manner as measured by MTT assay, flow cytometric and fluorescent microscopy analysis, while much lower effect on normal human liver cell L02 was observed." | ( Chen, M; Deng, P; Fang, B; He, G; Liu, Y; Ma, F; Wang, W; Yang, G; Zhao, S; Zheng, Q, 2013) |
| "The coexistence of liver cirrhosis with hepatocellular carcinoma (HCC) and colon cancer (Ca), which is a rare clinical condition, was treated in a liver transplant recipient." | ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "Overexpression of IAPs are found in hepatocellular carcinoma (HCC), and can contribute to chemotherapy resistance and recurrence of HCC." | ( Li, D; Li, G; Liu, G; Lu, J; Ma, X; Wang, Y; Wu, Y; Zhang, S; Zhao, Y, 2012) |
| "A 69-year-old man with recurrent hepatocellular carcinoma (HCC) in S7/8 after radiofrequency ablation therapy (RFA)was admitted to our hospital." | ( Egawa, C; Hamanaka, M; Kanemura, T; Kato, T; Kawashima, H; Miki, H; Mukai, Y; Nakahira, S; Nakata, K; Okishiro, M; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H; Uchiyama, C, 2012) |
| "She was diagnosed with unresectable hepatocellular carcinoma (HCC) with PVTT, and sorafenib in combination with intermittent cisplatin(CDDP) hepatic arterial infusion chemotherapy(HAIC)was performed." | ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T, 2012) |
| "Human hepatocellular carcinoma cell line SMMC-7721 was cultured in sphere-culture system of polyhedra-treated dish and tumor stem cell specific medium." | ( Cui, HB; Jiang, JS; Liu, YH; Wang, Y, 2012) |
| "Eligibility criteria were advanced hepatocellular carcinoma; no prior chemotherapy, performance status 0-1; and Child≤B8." | ( Barone, C; Basso, M; Biolato, M; Castaldi, P; De Gaetano, AM; Grieco, A; Iaculli, A; Leccisotti, L; Miele, L; Pompili, M; Riccardi, L; Rufini, V, 2013) |
| "The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months." | ( Ambe, CM; Anderson, AJ; Avital, I; Burka, D; Chen, JQ; Goldsmith, PK; Hari, DM; Herrmann, MA; Koizumi, T; Langan, RC; Miller, TC; Mullinax, JE; Ray, S; Rudloff, U; Stojadinovic, A; Thorgeirsson, SS; Wiegand, GW; Xin, HW, 2013) |
| "Little is known about the validity of hepatocellular carcinoma (HCC) risk scores derived from treatment-naïve patients with chronic hepatitis B for patients treated with entecavir." | ( Chan, HL; Chan, HY; Ip, ZM; Iu, HW; Lam, AT; Lee, SK; Leung, JM; Mak, CW; Tse, PC; Tse, YK; Wong, GL; Wong, VW, 2013) |
| "Three hepatoma cell lines, HepG2, PLC/PRF/5, and HLF, were treated with TGF-β, and the involvement of the non-canonical TGF-β pathway was analyzed by cell migration assays." | ( Aoyagi, Y; Fujimaki, S; Kubota, M; Matsuda, Y; Osawa, M; Sanpei, A; Sato, M; Takamura, M; Wakai, T; Yamagiwa, S, 2013) |
| "Human hepatocellular carcinoma cells (HCCLM6) were treated with C." | ( Cui, P; Guo, S; Ji, X; Li, G; Liu, Y; Ma, H; Qian, Y; Tadashi, H; Zhang, H; Zhu, Y, 2012) |
| "Twenty patients with hepatocellular carcinoma treated with chemoembolization were included in the study." | ( Beilner, J; Chen, JJ; Chi, JC; Kowarschik, M; Xu, JR; Ye, H; Zhang, XB; Zhuang, ZG, 2013) |
| "In the present study, we induced hepatocellular carcinoma in Wistar rats by diethylnitrosamine (DENA) and treated it with ursolic acid stearoyl glucoside." | ( Afzal, M; Ahmad, A; Al-Abbasi, FA; Anwar, F; Kazmi, I; Narooka, AR; Singh, R, 2013) |
| "Three different hepatoma cell lines (Huh7, HepG2, and Hep3B) were treated with different concentrations of UCN-01, and the anti-tumour effects of UCN-01 were evaluated." | ( Feitelson, MA; Lin, N; Liu, B; Wu, G; Xu, L, 2013) |
| "We treated human hepatoma cell lines (Huh7 and Hep3B) and immortalized human hepatocyte (OUMS29) with sorafenib and/or proteasome inhibitors, including epoxomicin and acetyl-leucyl-leucyl-norleucinal." | ( Harada, M; Honma, Y; Shimizu, S; Takehara, T, 2014) |
| "The treatment of hepatocellular carcinoma (HCC) remains a challenge and the future of cancer therapy will incorporate rational combinations directed to molecular targets that cooperate to drive critical pro-survival signaling." | ( Chen, Y; He, H; Shao, R; Yu, D; Zhang, C; Zhang, H; Zhao, W, 2013) |
| "Chemotherapeutic treatment of hepatocellular carcinoma often leads to chemoresistance during therapy or upon relapse of tumors." | ( Günther, M; Hoehn, M; Marfels, C; Wagner, E, 2013) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| "We evaluated gene therapy targeting hepatocellular carcinoma (HCC) using the herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene system and the tissue inhibitor of metalloproteinase 3 (Timp3) gene." | ( Li, RK; Sung, HW; Wu, J; Xie, J; Yu, BF; Zhang, Y, 2013) |
| "Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) have an extremely poor prognosis and relatively few treatment options." | ( Chen, PJ; Cheng, SQ; Chow, P; Han, KH; Lau, WY; Lee, RC; Leung, T; Poon, RT; Sangro, B, 2013) |
| "Human hepatocellular carcinoma cells BEL-7402 (c-Met-positive) and Huh7 (c-Met-deficient) were treated with different dose of PHA with or without equal dose of Celastrol, and cell growth, cell cycle and apoptosis were evaluated, respectively, by MTT assay, flow cytometry and Caspase3/7 activity." | ( Jiang, HL; Jin, JZ; Liang, J; Lin, GF; Ma, DY; Wu, D; Xu, D; Yu, H, 2013) |
| "Apoptosis resistance in hepatocellular carcinoma (HCC) is one of the most significant factors for hepatocarcinogenesis and tumor progression, and leads to resistance to conventional chemotherapy." | ( Fan, L; Ma, T; Sun, G; Wei, W; Zhong, F, 2013) |
| "Fibrolamellar hepatocellular carcinoma (FL-HCC) and conventional hepatocellular carcinoma (HCC) cases in two consecutive paediatric HCC trials were analysed to compare outcome and derive treatment implications." | ( Aronson, DC; Brock, P; Brugières, L; Childs, M; Czauderna, P; Fabre, M; Maibach, R; McCabe, AJ; Murawski, M; Otte, JB; Perilongo, G; Plaschkes, J; Roebuck, D; Sullivan, M; Weeda, VB; Zimmermann, A; Zsíros, J, 2013) |
| "For patients with advanced hepatocellular carcinoma (HCC) who have failed first-line anti-angiogenic therapy, there is no salvage treatment." | ( Cheng, AL; Cheng, JC; Hsu, C; Hsu, CH; Huang, CC; Huang, KW; Liang, PC; Lin, ZZ; Shao, YY; Wu, YM, 2013) |
| "Advanced hepatocellular carcinoma (HCC) is insensitive to traditional chemotherapeutic approaches, which causes difficulty in the development of novel agents for the treatment of HCC." | ( Huang, N; Yang, X, 2013) |
| "Human hepatoma cell lines were treated with lipopolysaccharide (LPS) or cyclooxygenase-2 inhibitor, Celecoxib, and in vitro proliferation, apoptosis, and cell cycle progression were assessed." | ( Bai, L; Mao, ZY; Su, D; Wang, LJ; Zhang, T, 2013) |
| "For successful therapy, hepatocellular carcinoma (HCC) must be detected at an early stage." | ( Cheng, S; Gao, Y; Guo, S; Han, N; Liu, Y; Qi, J; Rong, W; Wang, H; Wang, L; Wu, F; Wu, J; Xiao, T; Xu, B; Yang, L; Zhang, Y; Zhao, X, 2013) |
| "Our data showed that autophagy helped hepatoma cells to maintain survival under the treatment of no more than 1 mM of eATP." | ( Han, L; Huai, W; Jia, X; Sun, L; Wan, Z; Wei, Q; Yu, C; Zhang, Y, 2013) |
| "Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port." | ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013) |
| "A total of 40 patients with hepatocellular carcinoma treated with transarterial chemoembolization between January 2007 and March 2011 were included." | ( Altundağ, K; Balkancı, F; Bayraktar, Y; Cil, BE; Doğanay Erdoğan, B; Idilman, I; Kav, T; Peynircioğlu, B; Yalçın, S, 2013) |
| "Treatment options for hepatocellular carcinoma using chemotherapeutics at intermediate and advanced stages of disease are limited as patients most rapidly escape from therapy and succumb to disease progression." | ( Berger, W; Grubinger, M; Gucky, T; Haider, C; Jorda, R; Kryštof, V; Miklos, W; Mikulits, W; Řezníčková, E; Rotheneder, H; Strnad, M; Weiss, TS; Zatloukal, M, 2013) |
| "In 38 patients with hepatocellular carcinoma (HCC) after curative treatments and 18 patients with liver cirrhosis, 105 hypovascular nodules that were hypointense at the hepatobiliary phase of EOB-MRI were biopsied and the clinical usefulness of these EOB-MRI findings for the diagnosis of HCC was examined." | ( Hagihara, H; Kobayashi, Y; Kuwaki, K; Nakamura, S; Nouso, K; Ohnishi, H; Shiraha, H; Takayama, H; Toshimori, J; Yamamoto, K, 2013) |
| "Two primary malignant hepatoma cell lines, N1S1 (murine HCC) and HepG2 (human hepatoblastoma) were treated in media containing increasing concentrations of sorafenib with/without (188)Re to assess the cellular toxicities of each treatment alone and in combination." | ( Ardisson, V; Audrain, O; Boucher, E; Clement, B; Edeline, J; Garin, E; Lenoir, L; Lepareur, N; Pracht, M; Raoul, JL, 2013) |
| "Following treatment of the hepatocellular carcinoma cell lines BEL-7402 and QGY-7703 with EGCG, in vitro, EGCG significantly suppressed cell proliferation as detected by MTT assay, induced apoptosis as detected by flow cytometry, dramatically lowered the expression levels of phosphorylated Stat3 proteins (p-Stat3) as determined by immunoblot detection, and inhibited the expression of multiple genes including Bcl-xL, c-Myc, VEGF and cyclin D1 as demonstrated by RT-PCR analysis." | ( Deng, C; Guo, T; Li, Y; Ren, X; Wang, Y; Xu, MX; Yan, E; Yang, L, 2013) |
| "Treatment of hepatoma cells with anti-cancer drugs increased the production of IL-8 and its receptor, as well as the proportion of side population (SP)." | ( An, SY; Han, J; Kim, JB; Kim, JH; Kim, YJ; Lim, HJ; Park, SY; Yang, MG, 2014) |
| "The rates of morbidity and mortality of hepatocellular carcinoma (HCC) have not lessened because of difficulty in treating tumor metastasis." | ( Byambaragchaa, M; de la Cruz, J; Hwang, SG; Yang, SH, 2013) |
| "The well-established Yoshida hepatoma rat model was used and tumor-bearing rats were treated with 1mg/kg/d (LD), 10mg/kg/d (HD) tandospirone or placebo." | ( Anker, SD; Beadle, J; Coats, AJ; Doehner, W; Elkina, Y; Hartmann, K; Mayer, U; Palus, S; Springer, J; Tschirner, A; von Haehling, S, 2013) |
| "In 170 patients with hepatocellular carcinoma cells (HCC), the liver surfaces and resected specimens were intraoperatively examined by using a near-infrared fluorescence imaging system after preoperative administration of ICG (0." | ( Aburatani, H; Fukayama, M; Hasegawa, K; Ishizawa, T; Kaneko, J; Kawaguchi, Y; Kokudo, N; Masuda, K; Midorikawa, Y; Satou, S; Shibahara, J; Tsuji, S; Urano, Y, 2014) |
| "We treated H4IIEC3 rat hepatoma cells with free fatty acids in combination with antioxidants and mitochondrial inhibitors designed to block key events in the progression toward apoptosis." | ( Egnatchik, RA; Leamy, AK; Noguchi, Y; Shiota, M; Young, JD, 2014) |
| "Multidrug resistance (MDR) in hepatocellular carcinoma (HC) significantly impedes the effect of chemotherapy and is considered as a primary reason leading to its recurrences and metastasis." | ( Li, C; Meng, X; Sheng, L; Xiong, M, 2014) |
| "In this study, three hepatocellular carcinoma cell lines were treated with ethyl pyruvate." | ( Chen, K; Cheng, P; Dai, W; Guo, CY; Li, J; Lu, J; Shen, M; Wang, C; Wang, F; Xu, L; Yang, J; Zhang, H; Zhang, Y; Zheng, Y; Zhu, R, 2014) |
| "infusion of fentanyl in patients with hepatocellular carcinoma (HCC) treated by RFA." | ( Ikeda, O; Inoue, S; Kawanaka, K; Nakasone, Y; Tamura, Y; Yamashita, Y; Yokoyama, K, 2014) |
| "Chemotherapy plays a crucial role in hepatocellular carcinoma (HCC) treatment especially for patients with advanced HCC." | ( Chen, W; Luo, M; Qian, H; Qin, J, 2014) |
| "Mice bearing hepatoma or sarcoma allografted tumors were treated with various doses of RGD-rmhTNF-α alone or in combination with doxorubicin (2 mg/kg)." | ( Jiang, C; Li, M; Niu, J; Teng, Y; Wang, H; Zhang, Y, 2014) |
| "All patients with hepatocellular carcinoma were eligible for multimodality therapy." | ( Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M, 2014) |
| "Accurate assessment of viability of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) is important for therapy planning." | ( Choi, SJ; Kim, HS; Kim, J; Lee, JM; Park, H; Seo, J, 2014) |
| "He had been diagnosed with hepatocellular carcinoma (HCC) 1 year prior and had undergone repeated transcatheter arterial chemoembolization and radiotherapy." | ( Ahn, J; Je, D; Jeon, J; Jeong, H; Lee, KH; Park, TK; Yoo, H, 2014) |
| "Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability." | ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014) |
| "Many advanced hepatocellular carcinoma (HCC) cases can be successfully downstaged into the Milan criteria; however, immediate radical therapy cannot be applied to all such patients for various reasons." | ( Jiang, L; Lei, JY; Li, B; Wang, WT; Wei, YG; Wen, TF; Xu, MQ; Yan, LN; Yang, JY, 2014) |
| "We prospectively studied 147 hepatocellular carcinoma patients (97% cirrhotic, 82% Child-Pugh A, BCLC-B 77, BCLC-C 69) treated with sorafenib." | ( Ayuso, C; Bruix, J; Darnell, A; Forner, A; LLarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2014) |
| "Conditioned media from TAMs in hepatoma-bearing mice treated with NCTD or TAMs transfected with pre-miR-214 inhibited survival and invasion of H22 cells." | ( Gao, Y; Huang, X; Lu, S; Wang, X, 2014) |
| "Two human hepatoma (HCC-LM3 and SMMC-7721) and a normal liver (LO2) cell lines were treated with DCA or ADM alone, or in combination." | ( Dai, Y; Huang, G; Liu, J; Qin, W; Sheng, S; Wang, H; Xiong, X, 2014) |
| "Additionally, xenograft hepatocellular carcinoma growth was also effectively inhibited by combined treatment through induction of cell apoptosis in vivo." | ( Chen, T; Fan, C; Fu, X; Li, X; Wong, YS; Zheng, W, 2014) |
| "Early assessment of hepatocellular carcinoma (HCC) response during sorafenib (SO) treatment is challenging, since tumor necrosis, extension and radiological appearance can be inhomogeneous." | ( Bargellini, I; Bartolozzi, C; Masi, G; Mismas, V; Sacco, R; Scionti, A; Vivaldi, C, 2014) |
| "Four hepatoma cell lines, HepG2, HuH7, SNU-387, and SNU-449, were treated with cetuximab or cetuximab plus rapamycin and growth inhibition was evaluated by measuring relative cell viability and cell proliferation." | ( Chen, W; Hu, QD; Liang, C; Liang, F; Liang, TB; Liu, H; Ma, T; Xia, XF; Zhang, Q, 2014) |
| "Multiple modalities for treatment of hepatocellular carcinoma are available, depending on tumor size and number." | ( Imagawa, DK; Reataza, M, 2014) |
| "Patients with advanced hepatocellular carcinoma, treated by transcatheter arterial chemoembolization and sorafenib subsequently, between February 2010 and September 2012 in our hospital, were retrospectively analyzed." | ( Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L, 2014) |
| "The recurrence of hepatocellular carcinoma, the sixth most common neoplasm and the third leading cause of cancer-related mortality worldwide, represents an important clinical problem, since it may occur after both surgical and medical treatment." | ( Cescon, M; Colecchia, A; Cucchetti, A; Festi, D; Marasco, G; Schiumerini, R; Taddia, M, 2014) |
| "The HSVtK gene-specific expression in hepatoma cells as well as the cytotoxicity of the suicide gene system in HepG2 cells provided the basis for the targeted gene therapy of HCC." | ( Gao, R; Lai, Z; Li, C; Niu, K; Qin, Q; Xie, J; Xu, J; Yu, B; Zhang, T, 2014) |
| "Patients suffering from advanced hepatocellular carcinoma can generally be treated only by targeted therapy to achieve a survival rate that lasts a few months more than that achieved with conventional therapy." | ( Lee, CJ; Lin, YY; Liu, JY; Wu, JC; Yue, CH, 2014) |
| "Tumor control of hepatocellular carcinoma by radiotherapy remains unsatisfactory." | ( Cheng, AL; Cheng, JC; Gao, M; Hsu, FM; Liu, WL; Tsai, CL; Tzen, KY, 2014) |
| "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here." | ( Chung, KH; Tang, HC, 2014) |
| "The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear." | ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015) |
| "The treatment of liver injuries or hepatocellular carcinoma (HCC) has been hindered by the lack of efficient drug delivery." | ( Abdelsalam, M; Avritscher, R; Huang, Q; Melancon, MP; Qiao, Y; Recio-Boiles, A; Singhana, B; Vykoukal, J; Wallace, M; Zhao, J, 2014) |
| "The proliferation of hepatocellular carcinoma SMMC 7721 cells treated with feverfew lactone was measured by MTT assay." | ( Gao, B; Gao, JP; Li, J; Li, YY; Lin, P; Liu, ZP, 2014) |
| "ISAHA and SAHA were used to treat HepG2 hepatoma xenograft-bearing mice." | ( Chan, PC; Chang, CA; Chang, CW; Chen, FD; Chiou, SH; Chou, LS; Ho, CH; Hwang, JJ; Lin, WJ; Liu, RS; Wang, HE; Wu, CY, 2015) |
| "For locally unresectable hepatocellular carcinoma (HCC) patients, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment." | ( Choi, JS; Han, KH; Kim, JK; Kim, JW; Kim, KS; Lee, IJ; Park, YN; Seong, J, 2014) |
| "Treatment of hepatoma cells with bortezomib led to an increase in the levels of intracellular reactive oxygen species (ROS)." | ( Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P, 2015) |
| "The human hepatoma cell line HepG2 was treated with 0, 2." | ( Chen, CZ; Hu, YN; Jiang, XJ; Zhang, ZZ; Zhao, W, 2014) |
| "We herein report a case of hepatocellular carcinoma (HCC) with lung metastasis that was successfully treated with transcatheter arterial infusion chemotherapy via the hepatic and bronchial arteries." | ( Chiba, M; Dohmen, T; Fujita, A; Fujiwara, J; Goto, T; Hasegawa, I; Hashimoto, M; Ishioka, M; Kamada, K; Kanata, R; Minami, S; Miura, K; Ohnishi, H; Ohshima, S; Sakai, T; Sato, W; Shibuya, T; Sugimoto, Y; Takahashi, K; Yoshida, T, 2014) |
| "Locoregional therapy for hepatocellular carcinoma (HCC) can be challenging in patients with a transjugular intrahepatic portosystemic shunt (TIPS)." | ( Bhattacharya, R; Chewning, RH; Hippe, DS; Ingraham, CR; Johnson, GE; Kogut, MJ; Kwan, SW; Monsky, WL; Padia, SA; Vaidya, S; Valji, K, 2015) |
| "However, the hepatocellular carcinoma (HCC) risk for ETV-treated patients remains unclear." | ( Doi, Y; Fukui, H; Hagiwara, H; Hamasaki, T; Harada, N; Hayashi, N; Hijioka, T; Hiramatsu, N; Iio, S; Imai, Y; Itoh, T; Kaneko, A; Kasahara, A; Katayama, K; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yamada, R; Yoshida, Y; Yoshihara, H, 2015) |
| "Patients with hepatocellular carcinoma and preexisting infection with hepatitis B and C viruses had higher pre-embolization stiffness, and the post-embolization stiffness of the treated segments in these patients was higher than that in the remainder of the study population." | ( Bas, A; Cantasdemir, M; Gulsen, F; Kabasakal, L; Kantarci, F; Numan, F; Samanci, C, 2015) |
| "In an orthotopic model of hepatocellular carcinoma in BALB/c nude mice, cHAb18 treatment effectively reduced the tumor metastasis in liver and prolonged the survival." | ( Bian, H; Chen, ZN; Feng, F; Nan, G; Sun, XX; Wang, B; Wang, Y; Wei, D; Yang, XM; Yuan, L, 2015) |
| "Out of 265 patients with advanced hepatocellular carcinoma who were treated with sorafenib at our hospital, 45 experienced TACE failure or refractoriness and were included in this study and retrospectively analyzed." | ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014) |
| "Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits." | ( Seong, J; Yoon, HI, 2014) |
| "Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis." | ( Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V, 2014) |
| "Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib." | ( Kimura, T; Kita, R; Nishikawa, H; Osaki, Y, 2014) |
| "The management of hepatocellular carcinoma (HCC) is decided according to evidence-based recommendations generated by international societies: according to these recommendations, the tumour stage, as determined by the Barcelona clinical liver cancer (BCLC) score, divides patients into five prognostic categories, each with a distinct treatment indication." | ( Colombo, M; Sangiovanni, A, 2015) |
| "Adjuvant therapy after resection of hepatocellular carcinoma (HCC) is limited." | ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2014) |
| "Advanced hepatocellular carcinoma (HCC) and chronic hepatitis B infection were diagnosed and treated by twice-repeated transcatheterarterial chemoembolization (TACE) followed by administration of entecavir." | ( Hosoda, Y; Kakita, N; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yamada, Y; Yamasaki, M; Yasui, M, 2014) |
| "PLC/PRF/5 hepatoma cells were pretreated with 500 µmol/l NaHS (a donor of H2S) for 24 h." | ( Chen, J; Feng, J; Hu, F; Pan, W; Wu, H; Zhang, Y; Zhen, Y, 2015) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) is poor and the development of effective treatments for this malignancy, including combination chemotherapy, is required." | ( Baba, A; Kochi, T; Kubota, M; Moriwaki, H; Ohno, T; Shimizu, M; Shirakami, Y, 2014) |
| "At present, the treatment of hepatocellular carcinoma (HCC) is an international problem." | ( Chen, Q; Li, Y; Liu, W; Tang, H; Yang, X; Zhao, X, 2015) |
| "Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib." | ( Choi, HS; Hahm, JS; Jun, DW; Kim, JO; Lee, HL; Lee, KN; Lee, OY; Tae, HJ; Yoon, BC, 2015) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "Chemotherapy resistance of hepatocellular carcinoma (HCC) is still a major unsolved problem highlighting the need to develop novel therapeutic strategies." | ( Abhari, BA; Fulda, S; Liese, J, 2015) |
| "Treatment of advanced hepatocellular carcinoma (HCC) remains challenging, particularly with the limited systemic therapy options." | ( Kalyan, A; Kulik, L; Nimeiri, H, 2015) |
| "Many patients with advanced hepatocellular carcinoma (HCC) develop lung metastasis and available treatments are limited." | ( Huang, A; Shi, Y, 2015) |
| "To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism." | ( Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014) |
| "To investigate the role of miR-20a in hepatocellular carcinoma (HCC) cell radioresistance, which may reveal potential strategies to improve treatment." | ( Chen, L; Ding, Y; Li, Q; Liu, T; Peng, S; Sun, Q; Wang, R; Wang, W; Yang, H; Zhang, Y; Zheng, L, 2015) |
| "Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging." | ( Heo, J; Woo, HY, 2015) |
| "Case 1: A6 4-year-old man with hepatocellular carcinoma (HCC) had received local therapy repeatedly for 20 years." | ( Hijikawa, T; Ishizaki, M; Kaibori, M; Kitade, H; Kon, M; Matsui, K; Yamada, M; Yanagida, H; Yokoigawa, N; Yoshioka, K, 2015) |
| "Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study." | ( Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L, 2015) |
| "A total of 124 hepatocellular carcinomas (HCCs) were treated by RFA after Gd-EOB-DTPA administration." | ( Fujise, Y; Hodozuka, M; Hosho, K; Kakite, S; Kato, J; Kishina, M; Koda, M; Matono, T; Miyoshi, K; Murawaki, Y; Okamoto, T; Okano, J; Oyama, K; Sugihara, T; Tokunaga, S; Yamashita, E, 2015) |
| "EGCG also inhibited self-renewal in hepatoma and colon CSCs, attenuated the expression of stem cell markers and ATP-binding cassette transporter genes, which are putative molecules associated with treatment resistance in CSCs, and decreased the transcription of Nek2 and p-Akt, resulting in the inhibition of Akt signaling." | ( Arakawa, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, Y; Shimada, M; Wubetu, GY; Yamada, S, 2016) |
| "In a hepatoma xenograft model, ISJ pretreatment resulted in significant antihepatoma activity in vivo." | ( Chen, H; Dai, M; Li, X; Shan, L; Sun, Q; Yuan, X; Zeng, H; Zhang, W, 2015) |
| "The use of metformin in patients with hepatocellular carcinoma receiving radiotherapy was associated with higher overall survival." | ( Chang, AR; Han, CJ; Jang, HS; Jang, WI; Kay, CS; Kim, M; Kim, MS; Lee, DS; Lim, JS; Park, HJ; Park, SC; Seo, YS; Yoo, HJ, 2015) |
| "A 65-year-old man was diagnosed with hepatocellular carcinoma 4 years ago, for which he underwent interventional therapy and radiofrequency ablation after the right lobe partial hepatectomy." | ( Gu, T; Jiang, L; Liu, F; Luan, L; Shi, H, 2016) |
| "UDCA suppresses growth of BEL7402 hepatocellular carcinoma cells in vivo, in part through apoptosis induction, and is thus a candidate for therapeutic treatment of HCC." | ( Han, GQ; Huang, Y; Liang, TJ; Liu, H; Qin, CK; Qin, CY; Wei, LL; Xu, HW; Zhang, YZ, 2015) |
| "Overexpression of TRPV2 in H2O2-treated hepatoma cells aggravates the inhibition of Akt and Nrf2, while it enhances the activation of p38 and JNK1 at the early stage of cell death." | ( Gao, C; Huang, J; Huang, R; Li, C; Li, Z; Lin, Z; Liu, J; Ma, W; Yin, S, 2015) |
| "Here we provide models of human hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in vitro and in vivo to evaluate the efficacy of NFC alone and in combination with sorafenib, a kinase inhibitor approved for treatment of HCC." | ( Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF, 2015) |
| "The decisions taken by the Hepatoma Board for the 74 patients were as follows: 1- surgical resection (7 patients), 2- local ablative therapy (LAT) (22 patients), 3- conventional transarterial chemoembolization (TACE) (24 patients), and 4- palliative supportive care (21 patients)." | ( Abdel Malek, MO; Bakheet, AA; Hamza, HM; Makhlouf, NA; Sabry, AM; Seif, HM; Zaky, S, 2015) |
| "Real life management of hepatocellular carcinoma occasionally deviates from guidelines for recommended therapy." | ( Alkhatib, A; Allam, N; Gomaa, A; Rewisha, E; Waked, I, 2015) |
| "Patients with unresectable hepatocellular carcinoma (HCC) cannot generally be cured by systemic chemotherapy or radiotherapy due to their poor response to conventional therapeutic agents." | ( Hirose, Y; Kobayashi, T; Komatsu, M; Kosugi, S; Matsuda, Y; Moro, K; Nagahashi, M; Soma, D; Takabe, K; Tsuchida, J; Wakai, T, 2016) |
| "Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit." | ( Abou-Alfa, GK; El Dika, I; Harding, JJ, 2016) |
| "Human hepatocellular carcinoma cells Huh7 and alveolar epithelial cells A549 were stimulated with either interleukin (IL) IL-1β (1 ng/ml, 24 h) or tumor necrosis factor (TNF) (10 ng/ml, 4 h), and then treated with EtP (2." | ( Juengel, E; Marzi, I; Mörs, K; Omid, N; Perl, M; Relja, B; Wagner, N; Werner, I, 2016) |
| "Advanced hepatocellular carcinoma (HCC) includes a wide spectrum of tumors and patients' prognosis after treatment is highly variable." | ( Adhoute, X; Bayle, O; Beaurain, P; Blanc, JF; Bourlière, M; Bronowicki, JP; Castellani, P; Conroy, G; Edeline, J; Monnet, O; Muller, C; Pénaranda, G; Perrier, H; Pol, B; Raoul, JL, 2016) |
| "Human hepatocellular carcinoma HepG2 cells and normal human liver L-02 cells were treated with different concentrations of guggulsterone (5-100 μmol/L) for 24-72 h." | ( Dang, SS; Gao, N; Jia, XL; Li, M; Li, YP; Shi, JJ; Yang, N; Zhang, X, 2015) |
| "One of the major challenges in the hepatocellular carcinoma (HCC) treatment is its insensitivity to chemotherapeutic drugs." | ( He, C; He, X; Lee, RJ; Li, B; Li, W; Ma, X; Rong, Z; Xiang, G; Xue, H; Yang, T; You, J; Zhao, P, 2016) |
| "Treatment of hepatocellular carcinoma (HCC) is guided by the tumour stage." | ( Colombo, M; Sangiovanni, A, 2016) |
| "The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported." | ( Fujimoto, S; Kimura, T; Miyamoto, H; Muguruma, N; Okamoto, K; Takayama, T; Takeishi, S; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T, 2016) |
| "Treatment of advanced hepatocellular carcinoma (HCC) has reached a plateau after the approval of sorafenib in 2007." | ( Aravind, P; Oikonomopoulos, G; Sarker, D, 2016) |
| "Because the recurrence rate of hepatocellular carcinoma (HCC) is high, even after curative treatments such as hepatic resection and microwave ablation, chemopreventive agents that can effectively suppress HCC recurrence are required." | ( Eguchi, S; Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y, 2016) |
| "Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed." | ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016) |
| "a multidisciplinary approach of hepatocellular carcinoma in a second level hospital with trained professionals permits a diagnosis in early tumoral and functional stages in the majority of patients, and a variety of possible treatments with adequate survival outcomes." | ( Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F, 2015) |
| "Targeted hepatocellular carcinoma (HCC) therapy was carried out to improve the efficacy of liver cancers." | ( Li, J; Yan, M; Zhang, X, 2016) |
| "Three human hepatocellular carcinoma cell lines--HepG2, Hep3B and HuH-7--were pre- and post-treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin." | ( Farmer, RW; Li, Y; Martin, RC; Yang, Y, 2016) |
| "The optimal treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains controversial." | ( Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ, 2016) |
| "The intermediate-stage hepatocellular carcinoma patients who received either TACE-S or TACE-alone treatment were consecutively included into analysis." | ( Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y, 2016) |
| "Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial." | ( Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY, 2016) |
| "The resistance of hepatocellular carcinoma (HCC) to chemotherapy may be mediated by the c-Jun N-terminal kinase (JNK) pathway." | ( Jiang, J; Liu, SP; Liu, XY; Zhang, T; Zhang, X, 2016) |
| "A 74-year-old man diagnosed with hepatocellular carcinoma ensuing in hepatitis C virus infection, who was treated with sorafenib at a daily dose of 400 mg, developed osteonecrosis of the right mandibular body." | ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016) |
| "Honokiol or rosiglitazone treatment in hepatoma cells induced growth inhibition at high dose by sulforhodamine B assay." | ( Chang, YF; Chen, HC; Chi, CW; Hsia, CY; Hsu, HT; Lee, HC; Weng, JW, 2016) |
| "Despite significant progress, advanced hepatocellular carcinoma (HCC) remains an incurable disease, and the overall efficacy of targeted therapy by Sorafenib remains moderate." | ( Cui, SX; Gao, ZH; Qu, XJ; Shi, WN; Song, ZY; Wang, SQ; Yu, XF, 2016) |
| "The treatment efficacy of unresectable hepatocellular carcinoma (HCC) is still not promising." | ( Bao, Y; Dai, Y; Dong, X; Feng, W; Shen, J; Tang, C; Zhang, J; Zheng, Y, 2016) |
| "The cumulative incidence of hepatocellular carcinoma did not differ between LMV-treated and ETV-treated patients (P=0." | ( Ahn, H; An, H; Choe, WH; Jung, YK; Kim, JH; Kim, SG; Kim, SU; Kim, TY; Kim, YS; Lee, JH; Seo, YS; Suh, SJ; Suk, KT; Um, SH; Yim, HJ; Yim, SY, 2016) |
| "In summary, DNC-treated hepatocellular carcinoma cells undergo apoptosis by changing the expression of genes involved in the apoptosis and proliferation processes." | ( Khodi, S; Mohaghegh, M; Montazeri, M; Pilehvar-Soltanahmadi, Y; Sadeghizadeh, M; Sadeghzadeh, H; Zarghami, F; Zarghami, N, 2016) |
| "The majority of hepatocellular carcinoma (HCC) patients is diagnosed in late stages and therefore becomes ineligible for potentially curative treatment such as resection or liver transplantation." | ( Chen, CL; Chen, TY; Cheng, YF; Hsu, HW; Huang, TL; Leung-Chit, L; Ou, HY; Weng, CC; Yu, CY, 2016) |
| "However, hepatocellular carcinoma (HCC) developed about 20 months after the administration of danazol." | ( Baba, K; Itamoto, K; Kobayashi, K; Mizuno, T; Noguchi, S; Okuda, M; Shimokawa Miyama, T, 2016) |
| "Human hepatocellular carcinoma (HepG2) cells were treated with 100-, 200-, 400-, and 600-nM prodigiosin after which morphology of cells, cell number, growth inhibition, survivin expression, caspase-3 activation, and apoptotic rate were evaluated by inverted microscope, hemocytometer, MTT assay, RT-PCR, fluorometric immunosorbent enzyme assay, and flow cytometric analysis, respectively." | ( Esmaeillou, M; Sam, MR; Yenkejeh, RA, 2017) |
| "Treatment options for patients with hepatocellular carcinoma (HCC) are limited, in particular in advanced and drug resistant HCC." | ( Abou Elkacem, L; Bachawal, S; Choe, JW; Devulapally, R; Mullick Chowdhury, S; Paulmurugan, R; Tian, L; Wang, DS; Wang, TY; Willmann, JK; Yakub, BK, 2016) |
| "The lack of effective chemotherapies in hepatocellular carcinoma (HCC) is still an unsolved problem and underlines the need for new strategies in liver cancer treatment." | ( Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J, 2016) |
| "The management of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) is challenging, especially if it is not treatable by surgery or embolization." | ( Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C, 2016) |
| "Thirty patients with unresectable hepatocellular carcinoma were enrolled to groups, depending on whether liver impairment was mild (group I, aspartate aminotransferase and alanine aminotransferase ≤2× upper limit of normal and Child-Pugh score 5 [n = 14] or 6 [n = 2]) or moderate (group II, Child-Pugh score 5-6 and aspartate aminotransferase or alanine aminotransferase >2× to ≤5× upper limit of normal [n = 7] or Child-Pugh score 7 [n = 7]); 22 patients had prior sorafenib treatment." | ( Ikeda, M; Inoue, K; Loembé, AB; Mitsunaga, S; Muro, K; Okusaka, T; Otsuka, T; Saito, I; Sugimoto, R; Tadayasu, Y; Ueno, H, 2016) |
| "After treating the hepatoma cell line 7721 with triptolide(9, 18, or 36 μg/mL) and/or sodium cantharidinate (2, 5, or 10 μg/mL), cell viability assay and apoptosis were examined by MTT and flocytometry, respectively." | ( Dong, Z; Han, L; Ju, Y; Pan, X; Wang, G; Wang, M; Zhou, Y, 2016) |
| "Viability of hepatoma cell line 7721 was inhibited by either the therapy of triptolide and/or sodium cantharidinate (P<0." | ( Dong, Z; Han, L; Ju, Y; Pan, X; Wang, G; Wang, M; Zhou, Y, 2016) |
| "None of the patients had hepatocellular carcinoma before and during antiviral therapy." | ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2016) |
| "Because the patient's hepatocellular carcinoma score was outside the Milan criteria, an allograft from a donor with HCV genotype 3 was accepted as rescue treatment." | ( Canbay, A; Gerken, G; Herzer, K; Paul, A; Timm, J; Treckmann, J; Willuweit, K, 2017) |
| "Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options." | ( Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A, 2017) |
| "Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are not effective." | ( Chen, JC; Chen, YC; Chien, YC; Chuang, HY; Hsu, FT; Hwang, JJ, 2016) |
| "Due to the lack of effective treatment, hepatocellular carcinoma (HCC) is one of the malignancies with low survival rates worldwide." | ( Chen, X; He, Y; Huang, Z; Ke, X; Wen, Y; Zhou, X; Zou, F, 2016) |
| "The treatment responses of sorafenib in hepatocellular carcinoma are modest which may be due to different characteristics of cancer cells or insufficient therapeutic concentrations." | ( Chuang, WL; Lin, ZY, 2017) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) is dismal, underscoring the need for novel effective treatments." | ( Arihara, Y; Hayasaka, N; Kamihara, Y; Kato, J; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Okagawa, Y; Osuga, T; Takada, K; Usami, M, 2016) |
| "As there is currently no superior hepatocellular carcinoma (HCC) model with percutaneous vascular access for transarterial treatments available, the VX2 rabbit model is frequently used for in vivo investigations on liver carcinoma." | ( Brauner, J; Dudeck, O; Jürgens, J; Kalinski, T; Nass, N; Powerski, M; Ricke, J; Schulz, N; Seidensticker, M; Streit, S; Wybranski, C, 2017) |
| "(1) Background: Hepatocellular carcinoma (HCC) is the second leading cause of cancer deaths worldwide, and surgical resection is the main treatment for HCC." | ( Cheng, SB; Huang, YC; Huang, YT; Lin, PT; Liu, HT, 2017) |
| "Long-term prognosis of hepatocellular carcinoma (HCC) remains poor owing to the lack of treatment options for advanced HCC." | ( Chang, Y; Cho, E; Cho, H; Cho, YY; Kang, SH; Kim, YJ; Lee, DH; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2017) |
| "Hepatic resection for hepatocellular carcinoma (HCC) is now established as the treatment most likely to yield the best outcome." | ( Aoki, T; Kato, M; Kubota, K; Shimoda, M; Tago, K, 2017) |
| "We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively." | ( Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017) |
| "The rates of HBsAg loss and hepatocellular carcinoma (HCC) development in HBeAg-negative patients with cirrhosis who continued NA treatment were compared with those who discontinued treatment." | ( Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH, 2017) |
| "Treatment of advanced hepatocellular carcinoma (HCC) remains a challenge due to the high tumor heterogeneity." | ( Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V, 2017) |
| "In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival." | ( Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S, 2017) |
| "When HepG2 hepatoma cells were treated with celecoxib, the expression of the genes in de novo sphingolipid biosynthesis and sphingomyelinase pathway was upregulated and cellular ceramide was elevated." | ( Kim, GT; Kim, JY; Lee, K; Maeng, HJ; Park, TS; Song, JH; Song, YJ, 2017) |
| "At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment." | ( Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K, 2017) |
| "Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge." | ( Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E, 2017) |
| "Apoptosis of human hepatoma cells treated with sorafenib was investigated, and the expression of Jun proto-oncogene (c-Jun) was measured." | ( Haga, Y; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Takahashi, K; Wu, S; Yokosuka, O, 2017) |
| "In our study, human hepatoma SMMC-7721 cell lines were selected and treated with curcumin to detect its effects on the apoptosis and AMPK signaling pathway." | ( Fang, ZY; Li, D; Liu, JS; Xiang, H; Zhang, H; Zhang, YJ, 2017) |
| "Liver fibrosis and hepatocellular carcinoma (HCC) have worldwide impact but continue to lack safe, low cost, and effective treatments." | ( Huang, H; Jiang, X; Li, W; Liu, L; Xu, G; Yue, F; Zou, J, 2017) |
| "Drug treatments for hepatocellular carcinoma (HCC) often fail because of multidrug resistance (MDR)." | ( Dai, H; Li, J; Ling, S; Liu, J; Lu, D; Shan, Q; Song, P; Wen, X; Xie, H; Xu, X; Zheng, S; Zhou, L, 2017) |
| "The efficacious treatment of hepatocellular carcinoma (HCC) remains a challenge, partially being attributed to intrinsic chemoresistance." | ( Chen, RM; Chen, YJ; Chong, QY; Liu, L; Lobie, PE; Ma, L; Pandey, V; Wu, MM; Wu, ZS; You, ML; Zhu, T, 2017) |
| "Curative treatment of patients with hepatocellular carcinoma (HCC) is poor." | ( Dong, L; Hou, N; Li, J; Liu, N; Yan, Y, 2017) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| "However, the role of PP5 in hepatocellular carcinoma (HCC) and whether PP5 may be a viable therapeutic target for HCC treatment are unknown." | ( Chao, TI; Chen, KF; Chen, LJ; Chen, YL; Chu, PY; Hsiao, YJ; Hsieh, FS; Hung, MH; Shih, CT; Tsai, MH, 2017) |
| "For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines." | ( Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2017) |
| "Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear." | ( Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, GN; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C, 2017) |
| "Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor." | ( Itoh, K; Matsueda, S; Morita, M; Muroya, D; Sasada, T; Shichijo, S; Shirahama, T; Yamada, A; Yamaguchi, R; Yutani, S, 2017) |
| "An 81-year-old man with hepatocellular carcinoma associated with alcoholic liver cirrhosis suddenly lost consciousness before transcatheter arterial chemoembolization treatment for his disease and died 5 h after the episode." | ( Hyodo, I; Ishige, K; Noguchi, M; Sakashita, M; Sakashita, S; Sakata, A; Uesugi, N, 2017) |
| "Radioembolization for the treatment of hepatocellular carcinoma (HCC) induces liver volume changes referred to as "atrophy-hypertrophy complex"." | ( Bellendorf, A; Dechêne, A; Goebel, J; Goebel, T; Lazik-Palm, A; Mueller, S; Sulke, M; Theysohn, J; Umutlu, L, 2017) |
| "The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients." | ( Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M, 2017) |
| "advanced hepatocellular carcinoma (HCC) AIM: To explore potential biomarkers of lenalidomide efficacy as second-line therapy for HCC." | ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| "The incidence of hepatocellular carcinoma (HCC) has continued to increase worldwide, and advanced HCC is difficult to treat using the currently available therapeutics." | ( Choi, EK; Hong, SM; Hwang, JJ; Jeong, SY; Ju, EJ; Jung, J; Ko, EJ; Kuroda, S; Lee, JS; Lee, KJ; Park, J; Park, SS; Shin, SH; Song, SY, 2017) |
| "Human hepatocellular carcinoma cells were treated with hyperthermia and ionizing radiation." | ( Cao, DD; Chen, X; Deng, JJ; Lei, JJ; Shi, L; Xu, XM; Yuan, GJ, 2017) |
| "Twenty-two patients with 39 hepatocellular carcinoma lesions were treated with the surefire infusion system." | ( Caridi, T; DeMulder, D; Frantz, S; Kim, AY; Krishnan, P; Lynskey, GE; Spies, JB, 2017) |
| "The management of recurrent hepatocellular carcinoma untreatable with surgical options is based on systemic therapy with sorafenib." | ( Barbera, MA; Brandi, G; Cescon, M; Cucchetti, A; De Lorenzo, S; De Pace, V; Del Gaudio, M; Frega, G; Maroni, L; Neri, F; Palloni, A; Pantaleo, MA; Pinna, AD; Ravaioli, M; Ripoli, MC, 2017) |
| "Among solid tumors, hepatocellular carcinoma (HCC) emerges as a prototypical therapy-resistant tumor." | ( Ahmad, J; Ali, A; Awan, FM; Ikram, A; Janjua, HA; Naveed, AK; Naz, A; Obaid, A, 2017) |
| "To investigate the anti-hepatoma mechanism of α-pinene, HepG2 cell was treated with α-pinene and the change of cell cycle was examined by flow cytometry." | ( Chen, WQ; Li, M; Lu, XS; Wang, F; Xie, JJ; Yang, JB; Yang, MD, 2016) |
| "Angiogenesis plays an important role in hepatocellular carcinoma (HCC), the inhibition of which is explored for cancer prevention and treatment." | ( Akbareian, SE; Atkinson, SJ; Bao, Y; Liu, P; Munsterberg, A; Robinson, SD; Zhou, Z, 2017) |
| "The treatment approach for hepatocellular carcinoma (HCC) depends on the stage and extent of disease, the severity of the underlying liver disease, and the overall performance status of the patient." | ( El-Serag, HB; Johnson, MS; Zhu, AX, 2017) |
| "The study included 44 hepatocellular carcinoma patients who were treated with TACE using DC Bead LUMI." | ( Aliberti, C; Carandina, R; Cillo, U; Fiorentini, G; Guadagni, S; Pizzirani, E; Ramondo, G; Sarti, D, 2017) |
| "Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging." | ( Andreesen, R; Endlicher, E; Ghibelli, L; Hackl, C; Herr, W; Klebl, F; Reichle, A; Schulz, U; Vogelhuber, M; Walter, I; Wiedmann, K; Wiest, R, 2017) |
| "For advanced hepatocellular carcinoma (HCC), surgical treatment after sorafenib induction has rarely been reported." | ( Arima, K; Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Higashi, T; Imai, K; Ishiko, T; Kaida, T; Nakagawa, S; Nitta, H; Okabe, H; Sasaki, Y; Takeyama, H; Taki, K; Tanaka, M, 2018) |
| "Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies." | ( Khan, S; Lee, EW, 2017) |
| "Sorafenib, a multikinase inhibitor for hepatocellular carcinoma treatment, inhibits the Raf/MAPK/ERK signaling pathway." | ( Fei, Z; Lu, M; Zhang, G, 2018) |
| "Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined." | ( Arii, S; Hagiwara, Y; Izumi, N; Kadoya, M; Kaneko, S; Kokudo, N; Kokudo, T; Ku, Y; Kubo, S; Kudo, M; Kumada, T; Matsuyama, Y; Nakashima, O; Sakamoto, M; Takayama, T; Takayasu, K, 2018) |
| "A 73-year-old woman with hepatocellular carcinoma localised to the liver was treated with doxorubicin-loaded drug-eluting beads through transcatheter arterial chemoembolisation (DEB-TACE)." | ( Elsayed, AG; Martin, JM; Pacioles, T, 2018) |
| "Human hepatocellular carcinoma cells (HCCs) were treated with LicA, to detect markers of autophagy and to investigate the mechanisms." | ( Duan, W; Li, C; Lv, W; Niu, Q; Wang, G; Wang, J; Wang, K; Yan, T; Zhang, T; Zhao, W; Zhou, D, 2018) |
| "The detection of hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from a blood sample can be a very powerful noninvasive approach for the early detection and therapy of liver cancer." | ( Pang, Y; Sun, Z; Wang, C; Xiao, R, 2018) |
| "This study included 36 patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization." | ( Abajian, A; Chapiro, J; Duncan, JS; Geschwind, JF; Laage-Gaupp, FM; Lin, M; Murali, N; Nezami, N; Savic, LJ; Schlachter, T, 2018) |
| "The risk of hepatocellular carcinoma (HCC) during antiviral therapy in patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from untreated patients." | ( El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wong, GL; Wong, VW; Wu, CY; Wu, MS; Yip, TC, 2018) |
| "In the present study, it was found that hepatocellular carcinoma (HCC) cell proliferation was inhibited by either bufalin or sorafenib following incubation for 24 h, and the inhibition was enhanced upon treatment with a combination of the two." | ( Chi, H; Meng, Z; Wang, H; Zhang, C, 2018) |
| "Treatment of hepatocellular carcinoma (HCC) cell line with FTI-277 alone showed cell death in a time and dose dependent manner while in combination with alendronate, a synergistic apoptotic effect at 24 h was observed." | ( Channa, IS; Hashim, Z; Ilyas, A; Zarina, S, 2018) |
| "The SMMC-7721 hepatoma cell line was cultured and treated with PTER for different time depending on the experiment." | ( Levenson, AS; Li, K; Liu, ZS; Qian, YY; Yan, HJ; Yuan, YF, 2018) |
| "MATERIAL AND METHODS Hepatoma cell line HepG2 was treated with SIX1 knockdown or/and TAX." | ( Geng, R; Huo, Z; Li, B; Zhang, H; Zhao, S, 2018) |
| "Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC)." | ( Chan, HH; Chang, YC; Chen, YA; Chu, TH; Hu, TH; Huang, SC; Ma, YL; Tai, MH; Wang, EM; Wen, ZH; Weng, WT; Wu, DC; Wu, JC, 2018) |
| "Early identification and treatment of hepatocellular carcinoma is very important for improving the prognosis and survival rate of the patient." | ( Jin, Y; Tian, J; Yang, X, 2018) |
| "A sustained proportion of advanced hepatocellular carcinoma (HCC) patients worldwide received either chemotherapy or sorafenib." | ( Chu, YD; Huang, YH; Hung, CF; Lee, WC; Lin, CC; Lin, KH; Yeh, CT; Yeh, TS, 2018) |
| "Resistance of hepatocellular carcinoma (HCC) to systemic chemotherapy is partially due to presence of drug-resistant cancer stem cells." | ( Chen, Y; Fan, L; He, C; Lee, RJ; Li, B; Li, L; Liu, Y; Ma, X; Xiang, G; Xu, C; Xue, H; Yang, T; You, J; Zhang, X; Zhao, P, 2018) |
| "In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior." | ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018) |
| "Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options." | ( Chai, S; Che, N; Ding, J; Kau, PW; Lee, TK; Lo, CM; Luk, ST; Ma, S; Man, K; Ngan, ES; Tong, M; Zhou, L, 2018) |
| "Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
| "Herein, a synergistic strategy for hepatoma therapy by the combination of tumor microenvironment-sensitive polymer-doxorubicin (DOX) conjugate thermogel, containing a DNA intercalator DOX, and docetaxel (DTX), a microtubule-interfering agent, was proposed." | ( Chen, X; Ding, J; Xiao, G; Xu, W; Zhang, J; Zhang, Y, 2018) |
| "Targeted hepatocellular carcinoma therapy was carried out to improve the efficacy of liver cancer treatment." | ( Duan, W; Liu, Y, 2018) |
| "Main search terms included hepatocellular carcinoma, tyrosine kinase inhibitors, immunotherapy, immune checkpoint inhibitors, sorafenib, regorafenib, lenvatinib, cabozantinib, ramucirumab, and nivolumab." | ( Peck-Radosavljevic, M; Pinter, M, 2018) |
| "The incidence of hepatocellular carcinoma (HCC) in patients with a history of curatively-treated HCC is higher than in patients with no history of HCC even after sustained virologic response (SVR)." | ( Akita, T; Kaneoka, Y; Kumada, T; Maeda, A; Mizuno, K; Sone, Y; Tada, T; Tanaka, J; Toyoda, H, 2018) |
| "Correct staging of hepatocellular carcinoma (HCC) could help physicians to precisely select treatments for patients, such as surgery, chemotherapy, or their combination." | ( Chen, N; Chen, Y; Lou, B; Lv, J; Mao, W; Wang, P; Wang, W, 2018) |
| "Human hepatoma cell lines were treated with 1 and 2 mM melatonin, and functional assays were used to dissect melatonin's antitumor effect in HCC; small-RNA sequencing was performed to identify the microRNAs (miRNAs) involved in the anti-HCC activity of melatonin; and quantitative RT-PCR and Western blotting were used to elucidate how miRNAs regulate melatonin-mediated HCC suppression." | ( Chang, JL; Chen, CC; Chen, CY; Hsueh, C; Li, WS; Lian, JH; Wang, TH; Yeh, CT, 2018) |
| "Treatment outcome for hepatocellular carcinoma (HCC) is related to tumor burden and liver function." | ( Carling, U; Dorenberg, EJ; Line, PD; Røsok, B, 2019) |
| "The most effective treatment of hepatocellular carcinoma is surgical removal of the tumour but there is often recurrence." | ( Berhane, S; Chan, AWH; Chong, CCN; Cucchetti, A; García-Fiñana, M; Johnson, PJ; Kudo, M; Kumada, T; Lai, PBS; Li, LQ; Mazzaferro, V; Roayaie, S; Shi, K; Tada, T; Toyoda, H; Xiang, BD; Zhong, J, 2018) |
| "FHL1 promote paclitaxel resistance in hepatocellular carcinomas cells through regulating apoptosis induced by paclitaxel, suggesting that FHL1 may be a promising molecular target for HCC therapy." | ( Ding, L; Liu, J; Luo, X; Ren, J; Zhang, Y; Zhao, L; Zhou, L, 2018) |
| "We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group)." | ( Ahn, SH; Baatarkhuu, O; Han, KH; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Park, JY; Song, K, 2019) |
| "Prospective data on the risk of hepatocellular carcinoma (HCC) according to dose and duration of aspirin therapy are limited." | ( Chan, AT; Chong, DQ; Chung, RT; Corey, KE; Fuchs, CS; Giovannucci, EL; Ludvigsson, JF; Ma, Y; Meyerhardt, JA; Simon, TG; Zhang, X, 2018) |
| "At present, the treatment of hepatocellular carcinoma (HCC) remains to be a problem globally." | ( Chen, XZ; Li, XJ; Li, YS; Shang, HC; Tang, HB; Tian, GH; Zhang, WK, 2018) |
| "We compared the risk of hepatocellular carcinoma (HCC) and hepatic events in nucleos(t)ide analogue (NA)-treated patients with and without HBsAg seroclearance." | ( Chan, HL; Lam, KL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2019) |
| "From 2009 to 2017, 267 hepatocellular carcinoma patients treated with sorafenib were enrolled." | ( Abe, M; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, Y; Joko, K; Koizumi, Y; Michitaka, K; Ochi, H; Watanabe, T; Yoshida, O; Yukimoto, A, 2019) |
| "The clinical management of advanced hepatocellular carcinoma (HCC) is challenging due to its resistance to chemotherapy." | ( Chen, X; Li, X; Luo, B; Sun, Y; Xu, H, 2019) |
| "For patients with advanced hepatocellular carcinoma requiring sorafenib therapy, co-administration with conventional transarterial chemoembolization did not improve overall survival compared to sorafenib alone." | ( Bae, SH; Cheong, JY; Han, SY; Hwang, J; Kim, BH; Kim, DY; Kim, HY; Kim, YJ; Kwon, OS; Lee, HC; Lee, YJ; Paik, SW; Park, JW; Yeon, JE, 2019) |
| "Most patients with hepatocellular carcinoma (HCC) have lost the chance of radical treatment at the time of their visit, and the prognosis of metastatic HCC is even worse." | ( Han, Z; He, Z; Wang, C; Wang, Q, 2018) |
| "Metastasis of hepatocellular carcinoma (HCC) is usually unrecognized before any pathological examination, resulting in time-taking treatment and poor prognosis." | ( Chen, KC; Hsieh, CL; Maner, RS; Tian, YS; Zulkefli, ND, 2018) |
| "Secondary prevention of hepatocellular carcinoma (HCC) among patients with chronic hepatitis C (CHC) who achieve sustained virologic response (SVR) with interferon-based therapy has been proved effective." | ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS; Teng, W, 2019) |
| "Therapeutic attempts to treat hepatocellular carcinoma (HCC) frequently result in a poor response or treatment failure." | ( Chieti, A; Cigliano, A; Dituri, F; Giannelli, G; Mancarella, S, 2019) |
| "Accurate assessment of hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients receiving entecavir (ETV)/tenofovir disoproxil fumarate (TDF) is likely to play a pivotal role in post-treatment follow-up strategy." | ( An, HY; Heo, NY; Jang, JW; Jin, YJ; Lee, JW; Suh, YJ; You, CR; Yu, JH, 2019) |
| "Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers." | ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS; Yu, SH, 2019) |
| "To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients." | ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019) |
| "Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies." | ( Atkinson, A; Bernasconi, E; Bonnet, F; Dabis, F; Dufour, JF; Fehr, J; Gjærde, LK; Kraus, D; Mauron, E; Neau, D; Peters, L; Rauch, A; Reiss, P; Rockstroh, J; Smit, C; van der Valk, M; Wandeler, G, 2019) |
| "Patients with advanced hepatocellular carcinoma (HCC) will almost always develop acquired tolerance after sorafenib therapy, and the molecular mechanism of sorafenib tolerance remains poorly characterized." | ( Chen, J; Chen, X; Guo, Y; Hong, J; Li, J; Li, M; Liu, J; Ma, Q; Qi, Y; Qian, C; Shan, J; Shen, J; Wang, M; Wu, H; Xu, H; Xu, Y; Yang, Z; Yao, C; Zhang, Q; Zhao, W, 2019) |
| "Human hepatocellular carcinoma cells QGY-7701 were treated with 0, 1, 5, 25 and 125 nmol/L Birinapant for 24, 48 and 72 hours respectively, each experiment 3 wells." | ( Chen, JY; Jiang, PR; Ke, RJ; Lou, EZ; Xie, JG; Zhu, ML, 2018) |
| "Furthermore, hepatoma cells with miR-613 overexpression performed more sensitivity to cisplatin or sorafenib treatment." | ( Li, B; Li, HY; Liu, D; Wang, D; Yang, P, 2019) |
| "The treatment for advanced primary hepatocellular carcinoma (HCC) is sorafenib (SORA), while HCC has become increasingly drug resistant with enhanced aerobic glycolysis." | ( Chen, J; Chen, K; Dai, W; Feng, J; Guo, C; Ji, J; Mao, Y; Wang, F; Wu, J; Wu, L; Xu, L; Yu, Q; Zhang, J, 2019) |
| "Treatment outcomes for hepatocellular carcinoma (HCC) remain unsatisfactory, and effective new therapeutic methods are urgently needed." | ( Cao, Y; Chen, W; Ji, A; Jiang, C; Qiang, G; Wang, Z; Wu, J; Zhang, G, 2019) |
| "Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after transplantation." | ( Andersson, M; Bennet, W; Cahlin, C; Eilard, MS; Geronymakis, C; Lindnér, P; Naredi, P; Rizell, M, 2019) |
| "Optimal therapeutic strategies for hepatocellular carcinoma (HCC) patients are still challenging due to the high recurrence rate after surgical resection and chemotherapy resistance." | ( Adams, A; Bridges, B; Cox, J; Li, Z; Vittal, A; Voss, J; Weinman, SA; Wozniak, A; Zhao, J, 2019) |
| "The increasing worldwide prevalence of Hepatocellular carcinoma (HCC), characterized by resistance to conventional chemotherapy, poor prognosis and eventually mortality, place it as a prime target for new modes of prevention and treatment." | ( Alison Holmes, J; Chung, RT; Dai, CY; Davidovich, A; Domovitz, T; El-Osta, A; Gal-Tanamy, M; Haviv, I; Huang, CF; Kaspi, A; Lavi-Itzkovitz, A; Meirson, T; Nimer, A; Perez, S; Stemmer, SM; Yaari, G; Yu, ML, 2019) |
| "For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization." | ( Boulin, M; Gehin, S; Guiu, B; Pistre, P, 2020) |
| "Systemic therapy of advanced hepatocellular carcinoma (HCC) with the small-molecule multikinase inhibitor sorafenib is associated with large interindividual pharmacokinetic variability and unpredictable side effects potentially requiring dose reduction or treatment termination." | ( Baker, SD; Chen, M; Frisch, F; Hu, S; Koepsell, H; Laufer, S; Neul, C; Nies, AT; Schaeffeler, E; Schwab, M; Sparreboom, A; Winter, S, 2020) |
| "More than two-thirds of patients with hepatocellular carcinoma (HCC) cannot receive curative therapy and have poor survival due to late diagnosis and few prognostic directions." | ( Han, J; Han, ML; Li, C; Li, ZL; Liang, L; Shen, F; Song, YY; Wang, MD; Wu, H; Wu, MC; Xie, Y; Xing, H; Xu, AJ; Yang, T; Yuan, DY; Zhang, H, 2020) |
| "The clinical treatment of hepatocellular carcinoma has been hindered due to the drug resistance and heterogeneity of tumor cells." | ( Bai, L; Chunyang, Z; Dan, W; Guangliang, H; Huanling, G; Jie, L; Manxia, L; Ming, X; Wei, W; Xiangzi, S; Xiaoyan, X; Yang, T; Zhong, C, 2019) |
| "RESULTS The treatment of the hepatoma cell line SMMC-7721 with SDF-1 resulted in enhanced secretion of the angiogenic factors, IL-8 and VEGF, and shows that these stimulatory effects are abolished by PL." | ( Chen, W; Huang, D; Huo, L; Li, J; Lin, Y; Wei, J; Wei, Y; Zhao, C; Zhong, J, 2019) |
| "Cirrhosis and hepatocellular carcinoma onset were the only features associated with treatment failure." | ( Aghemo, A; Alberti, A; Bonfanti, P; Carolo, G; Carriero, C; Centenaro, R; Degasperi, E; Fabris, P; Faggiano, G; Fagiuoli, S; Gatti, F; Giorgini, A; Grossi, G; Lampertico, P; Landonio, S; Lombardi, A; Lomonaco, L; Maggiolo, F; Noventa, F; Paolucci, S; Paon, V; Pasin, F; Pasulo, L; Pozzoni, P; Puoti, M; Romano, A; Rossi, MC; Rovere, P; Russo, FP; Soffredini, R; Soria, A; Spinetti, A; Vario, A; Vinci, M; Zoncada, A, 2019) |
| "In this study, after induction of hepatocellular carcinoma, rats were divided into four groups: groups A and B as healthy or control group and negative untreated cancer group respectively; groups C and D were treated with platinum azido-thymidine (0." | ( Atabi, F; Jassem, RM; Mohammadi, R; Sabokrouh, A, 2020) |
| "Sorafenib (SOR) is currently used for hepatocellular carcinoma (HCC) recurring after liver transplantation (LT) when HCC is unsuitable for surgical/locoregional treatments." | ( Airoldi, A; Antonelli, B; Cesarini, L; Donato, MF; Iavarone, M; Invernizzi, F; Lampertico, P; Maggi, U; Manini, MA; Mazza, S; Rossi, G; Sangiovanni, A; Saverio Belli, L; Zavaglia, C, 2020) |
| "With increasing use of radiation for hepatocellular carcinoma (HCC) through transarterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT), there is concern for increased radiation-related complications when using SBRT after TARE." | ( Buckstein, M; Fischman, A; Hardy-Abeloos, C; Kim, E; Lazarev, S; Moshier, E; Rosenzweig, K; Ru, M, 2019) |
| "The prognosis for patients with hepatocellular carcinoma is poor, partly because of the lack of effective treatment options for those with more advanced disease." | ( Chow, EK; Hooi, L; Lim, JJ; Rashid, MBMA; Toh, TB, 2020) |
| "The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)." | ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020) |
| "This is the second described case of hepatocellular carcinoma associated with sorafenib treatment and leukocytoclastic vasculitis." | ( Belev, B; Bulimbašić, S; Kekez, D; Kocić, L; Pleština, S; Prejac, J, 2020) |
| "MATERIAL AND METHODS We treated hepatocellular carcinoma (HCC) Huh-7 cells and tumor xenograft mice models with celecoxib to test its effects on the tumor." | ( Dai, H; Ma, R; Pan, L; Zhang, S, 2019) |
| "Most patients with hepatocellular carcinoma (HCC) cannot be treated using traditional therapies." | ( Chen, KS; Chen, YW; Chou, FI; Chuang, YJ; Hung, YH; Liao, JW; Lin, YC; Lin, YT; Liu, HM; Peir, JJ; Shih, GW; Yang, CH; Yang, CM, 2019) |
| "A 66-year-old woman with hepatocellular carcinoma and untreated hepatitis C was referred to our hospital." | ( Akahoshi, S; Beppu, T; Chiyonaga, S; Hara, A; Kinoshita, K; Komohara, Y; Motohara, T; Sato, N; Suyama, K; Yuki, H, 2019) |
| "Human hepatoma HepG2 cells were treated with β-naphthoflavone for 3 days, and intracellular labile and total zinc levels were assessed through flow cytometry and inductively coupled plasma atom emission spectroscopy, respectively." | ( Ishida, T; Takechi, S, 2019) |
| "Recruitment of patients with advanced hepatocellular carcinoma and Child-Pugh B for sorafenib treatment and additional pharmacokinetic studies is challenging." | ( Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O, 2020) |
| "Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly." | ( Li, Q; Li, Y; Liang, R; Lin, Y; Liu, Z; Luo, M; Ye, J; Zhang, J; Zhang, Y, 2019) |
| "Eleven hepatocellular carcinoma cell lines and two combined hepatocellular/cholangiocarcinoma cell lines were treated with 0-30 μM lenvatinib." | ( Akiba, J; Kondo, R; Kusano, H; Mihara, Y; Ogasawara, S; Yano, H, 2019) |
| "Patients with hepatocellular carcinoma who were treated with TACE with epirubicin were retrospectively evaluated." | ( Iseki, K; Kobayashi, M; Nakai, M; Ogawa, K; Saito, Y; Sakamoto, T; Sugawara, M; Takekuma, Y; Yamada, T, 2020) |
| "Advanced hepatocellular carcinoma (HCC) portends a poor prognosis; however recent advances in first-line and second-line treatment options should yield significant improvements in survival." | ( Bangaru, S; Marrero, JA; Singal, AG, 2020) |
| "Among patients with hepatocellular carcinoma (HCC), optimal timing of DAA therapy remains unclear." | ( Alavi, M; Danta, M; Dore, GJ; Hajarizadeh, B; He, S; Lockart, I, 2020) |
| "Representative hepatocellular carcinoma (HCC) cell lines and HCC-bearing mice were treated with oncolytic Newcastle disease virus (NDV), alone or in combination with dichloroacetate (DCA, a pyruvate dehydrogenase kinase (PDK) inhibitor)." | ( Chen, A; Dong, J; Li, B; Meng, G; Wei, J; Wu, J; Xu, T; Yu, D; Zhang, H; Zheng, M, 2020) |
| "The main curative treatments for hepatocellular carcinoma (HCC) are surgical resection and liver transplantation, which only benefits 15% to 25% of patients." | ( Lin, LS; Liu, TP; Yang, PM, 2020) |
| "In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE)." | ( Arai, M; Chiba, T; Kanayama, K; Kanogawa, N; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Maruta, S; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A, 2020) |
| "The prediction of hepatocellular carcinoma (HCC) development during nucleotide/nucleoside analog (NA) therapy is clinically important in patients with chronic hepatitis B." | ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y, 2020) |
| "Treatment options for unresectable hepatocellular carcinoma include ablative and transarterial interventions - selective yttrium-90 microsphere transarterial radioembolisation - in addition to the drug sorafenib." | ( Abdel-Rahman, O; Elsayed, Z, 2020) |
| "The efficacy of chemotherapy for hepatocellular carcinoma (HCC) remains unsatisfactory, primarily due to inherent self‑defense mechanisms (e." | ( Chen, RX; Lin, XH; Liu, HH; Ma, M; Zhang, R, 2020) |
| "The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h." | ( Jiang, W; Wang, J, 2020) |
| "The treatment of hepatocellular carcinoma after liver transplantation (LT) is controversial because of its high recurrence rate and low survival rate." | ( Li, H; Li, R; Lu, S; Lu, W; Yang, Z, 2020) |
| "The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure." | ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020) |
| "Studies to evaluate risks of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection treated with the nucelos(t)ide analogues entecavir or tenofovir have produced contradictory results." | ( Ahn, SB; Cho, YK; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, SE; Lee, HY; Oh, H; Shim, JJ; Sohn, JH; Yoon, EL, 2020) |
| "A total of 782 hepatocellular carcinoma (HCC) patients treated with sorafenib were evaluated for sorafenib dosing and its modifications via medical records at baseline and regular follow-up." | ( Chang, UI; Choi, JY; Choi, SW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, SW; Nam, HC; Song, DS; Song, MJ; Sung, PS; Tak, KY; Yang, JM; Yoo, SH; Yoon, SK, 2020) |
| "Hepa1-6 hepatoma-bearing mice were treated with Tan II for 14 d." | ( Bi, F; Tie, M; Wang, K; Zhang, Y, 2018) |
| "In a human hepatoma (C3A) cell line, PCB 105 and 118 induced micronuclei marginally, while with ethanol pretreatment (to stabilize CYP2E1) both compounds induced micronuclei efficiently, and co-exposure to trans-1,2-dichloroethylene (a selective CYP2E1 inhibitor) led to clearly negative results with both compounds." | ( Hu, K; Jia, H; Jin, G; Li, Z; Liu, Y; Song, M; Yu, H, 2020) |
| "For patients with advanced hepatocellular carcinoma after failure of first-line sorafenib monotherapy, second-line axitinib provides modest efficacy with tolerable toxicity." | ( Chao, Y; Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Huang, PH; Hung, YP; Lee, RC; Lin, ZZ; Shao, YY; Shen, YC, 2020) |
| "Patients with FLT3-high hepatocellular carcinoma exhibited a superior OS upon sorafenib treatment." | ( Ding, J; Dong, W; Jin, GZ; Li, J; Li, SC; Liu, D; Liu, H; Pan, CZ; Sun, W; Ta, N; Wang, HY; Wang, ZG; Xu, L; Zhong, W, 2020) |
| "Data from 108 patients with hepatocellular carcinoma treated with RT between 2008 and 2017 were evaluated, of which 47 patients (44%) were treated with proton RT." | ( Brock, KK; El Naqa, I; Eyler, CE; Grassberger, C; Hong, TS; Hwang, M; Noe, B; Pursley, J; Sanford, NN; Wo, JY; Wolfgang, JA; Yeap, BY, 2020) |
| "Most hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage; however, the effect of systemic therapy on advanced HCC remains undetermined." | ( Cao, MQ; Lei, M; Li, KS; Li, XL; Liu, HD; Liu, XF; Shi, WK; Sun, HC; Tang, ZY; Xiao, N; Xu, B; Xu, YF; Zhang, SZ; Zhang, YY; Zhu, XD, 2020) |
| "MATERIAL AND METHODS SMMC-7721 cells (a hepatocellular carcinoma cell line) were treated with different concentrations of oleanolic acid (OA) plus autophagy inhibitor 3-methyladenine (3-MA) (3-MA+OA) or chloroquine (CQ) plus OA (CQ+OA)." | ( Wu, X; Zeng, X; Zhou, W, 2020) |
| "Therapy for human hepatocellular carcinoma (HCC) remains a great challenge for physicians and patients worldwide." | ( Cheng, L; Hou, W; Quan, B; Wu, Q; Yang, J; Zhu, L, 2020) |
| "In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy." | ( Chen, Z; Cheng, Y; De Toni, EN; Reiter, FP; Rong, D; Tang, W; Wang, Q; Wang, S; Wang, X; Wu, F; Zhang, B; Zhang, W, 2020) |
| "The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage that can only benefit from systemic treatments." | ( Gao, Q; Li, M; Lin, YP; Zhang, CH, 2020) |
| "Efficient hepatocellular carcinoma (HCC) therapy remains a significant challenge due to the unsatisfactory targeting efficiency of nanoparticles (NPs) with either a passive targeting or a single active targeting property." | ( He, DX; Huang, C; Huang, W; Liu, Y; Long, J; Tan, XW; Tang, S; Wei, H; Xiang, Y; Yu, CY; Zhou, Y, 2020) |
| "A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c-Met inhibitor tivantinib as second-line treatment significantly prolonged progression-free survival in a subpopulation whose tumor samples highly expressed c-Met (MET-high)." | ( Chiba, T; Furuse, J; Hino, K; Ido, A; Ikeda, M; Izumi, N; Kato, J; Kudo, M; Moriguchi, M; Morimoto, M; Motomura, K; Nakashima, D; Oikawa, T; Okusaka, T; Sato, T; Takayama, T; Tamura, K; Ueshima, K; Yasuchika, K; Yoshiji, H, 2020) |
| "The poor prognosis of hepatocellular carcinoma (HCC) is primarily attributed to its high frequency of recurrence and resistance to chemotherapy." | ( Hu, L; Liao, B; Qiao, L; Shen, W; Shi, C; Xie, F; Yang, J; Zhu, G, 2020) |
| "However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed to show statistically significant improvement." | ( Antoni, C; Diehl, S; Dreikhausen, L; Ebert, MP; Giordano, FA; Li, M; Rahbari, N; Reissfelder, C; Schoenberg, SO; Schulte, N; Sollors, J; Teufel, A; Zhan, T, 2020) |
| "The analysis of hepatocellular carcinoma by radiomics will contribute toearly diagnosis and treatment of tumors and improve survival and cure rates." | ( Sagir Kahraman, A, 2020) |
| "Then, HuH7 cells, a human hepatoma cell line, were incubated in conditioned media of DCA-treated LX2 to investigate the subsequent effect focusing on malignant behaviors." | ( Arihiro, K; Ito, M; Kakimoto, M; Kanno, K; Kikuchi, Y; Kishikawa, N; Kobayashi, T; Miyauchi, M; Nguyen, PT; Otani, Y; Pham, QT; Tazuma, S, 2020) |
| "Systemic therapy for hepatocellular carcinoma (HCC) consisting of the tyrosine kinase inhibitor sorafenib has remained unchanged for over a decade, although results from phase III targeted therapy trials have recently emerged." | ( Card, PB; Knox, JJ; Lim, H; Liu, D; Meyers, BM; Ramjeesingh, R; Tam, VC, 2021) |
| "By comparing hepatocellular carcinoma cell with simple radiation or combined AB-BEZ235-NP therapy, the HCC apoptosis and self-repair level have significant differences in mortality rates and cell migration abilities." | ( Cai, S; Cao, W; Huo, Z; Jiang, Z; Li, A; Liang, Y; Ma, D; Ma, Y; Tang, X; Wu, B; Xie, C; Xu, R, 2020) |
| "Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed." | ( Acosta-Rivera, M; Anderson, J; El-Khoueiry, AB; El-Rayes, BF; Hou, MM; Hsu, C; Kang, YK; Kim, TY; Knox, JJ; Kudo, M; Lim, HY; Matilla, A; Melero, I; Neely, J; Ruth He, A; Sangro, B; Santoro, A; Shen, Y; Tovoli, F; Wisniewski, T; Yau, T, 2020) |
| "Macroscopic vascular invasion in hepatocellular carcinoma (HCC) remains challenging to treat." | ( Cao, F; Chen, Q; Chen, S; Fan, W; Li, W; Qi, H; Qiu, Z; Shen, L; Xie, L; Yuan, H, 2020) |
| "HepG2 and SMMC-7721 hepatoma cells were treated with different concentrations of PF (0, 5, 10, 20 μM)." | ( Gao, Y; Liu, X; Tan, R; Wu, Z; Zeng, F; Zhong, Q; Zhou, Y, 2021) |
| "Pharmacological interventions for hepatocellular carcinoma (HCC) are hindered by complex factors, and rational combination therapy may be developed to improve therapeutic outcomes." | ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020) |
| "The effective treatment of hepatocellular carcinoma (HCC) requires development of novel drug formulations that selectively kill HCC cells while sparing healthy liver cells." | ( Cheng, L; Wang, X; Yuan, J; Zhang, J; Zhong, Z, 2021) |
| "HCC (hepatocellular carcinoma) is a major health threat for the Chinese population and has poor prognosis because of strong resistance to chemotherapy in patients." | ( Luo, J; Si, Z; Tan, X; Tong, JS; Yao, H; Zhang, Z, 2020) |
| "Treatment of DEN-induced hepatocellular carcinoma Wistar rats with the extract caused significant (p < 0." | ( Adebayo, AH; Adelani, IB; Adesina, GO; Edokwe, CB; Metibemu, DS; Oseha, OE; Yakubu, OF, 2020) |
| "The treatment of hepatoma is limited by its poor response to many chemotherapeutic agents." | ( Lian, X; Shu, C; Wu, Y; Yi, X; Zhang, J; Zhu, J, 2021) |
| "Patients with hepatocellular carcinoma (HCC) receiving different treatments might have specific prognostic factors that can be captured in the hepatobiliary phase (HBP) of gadoxetic acid-enhanced magnetic resonance imaging (GA-MRI)." | ( Bae, JS; Han, JK; Kim, JH; Lee, DH, 2021) |
| "However, hepatocellular carcinoma (HCC) shows variable sensitivity to shikonin treatment, and the mechanism for these differences remains unclear." | ( Chen, Q; Hou, L; Liu, J; Liu, Y; Yang, W, 2021) |
| "Sixty-two rats with N1-S1 hepatoma were divided into four groups according to the treatment methods, i." | ( Han, JK; Kim, JH; Lee, HJ; Lee, S; Moon, H, 2020) |
| "In patients with advanced hepatocellular carcinoma (hcc) following sorafenib failure, it is unclear which treatment is most efficacious, as treatments in the second-line setting have not been directly compared and no standard therapy exists." | ( Berry, S; Chan, KKW; Delos Santos, S; Doherty, M; Ko, YJ; Nguyen, A; Udayakumar, S, 2020) |
| "Infiltrative-appearance hepatocellular carcinoma presents a challenge to clinicians as diagnostic criteria continue to evolve and evidence-based treatment guidelines have yet to be established." | ( Dugan, AJ; Fowler, KJ; Furlan, A; Kapoor, H; Nisiewicz, MJ; Owen, JW, 2021) |
| "Chemotherapy of hepatocellular carcinoma (HCC) is facing drug resistance, which leads to unsatisfactory therapeutic effect." | ( Lan, Y; Peng, Y; Shuai, X; Su, Z; Wang, X; Wu, T; Xiao, H, 2020) |
| "The high rates of hepatocellular carcinoma (HCC) recurrence after initially successful curative therapy emphasize ongoing unmet needs to prevent or reduce HCC recurrence." | ( Heo, J; Woo, HY; Yoo, SY, 2021) |
| "68Ga-PSMA expression in hepatocellular carcinoma can influence patient management and potentially guide radionuclide legend therapy." | ( Ahmed, N; Al Kandari, F; Rasheed, R; Usmani, S, 2021) |
| "To evaluate the pathologic outcomes of hepatocellular carcinoma (HCC) treated with Yttrium-90 radiation segmentectomy using glass microspheres prior to liver transplantation and explore parameters associated with pathologic necrosis." | ( Croome, KP; Devcic, Z; Frey, GT; LeGout, JD; Lewis, AR; Lewis, JT; Montazeri, SA; Olson, MT; Patel, TC; Paz-Fumagalli, R; Ritchie, CA; Sella, DM; Toskich, B; Vidal, LL, 2021) |
| "The systemic treatment of unresectable hepatocellular carcinoma (HCC) has been improved throughout the past years." | ( Dietrich, P; Jefremow, A; Kremer, AE; Neurath, MF; Rouse, RA; Siebler, J; Waldner, MJ; Wiesmueller, M, 2020) |
| "However, the effect of adavosertib on hepatocellular carcinoma (HCC) treatment, including sorafenib-resistant HCC, has not been thoroughly studied." | ( Chen, J; Jia, X; Jin, C; Li, Z; Song, P; Song, W; Xie, H; Zheng, S; Zhou, M, 2021) |
| "Treatment of hepatocellular carcinoma (HCC) is currently challenging." | ( Araki, K; Gantumur, D; Hagiwara, K; Handa, T; Harimoto, N; Hoshino, K; Igarashi, T; Ishii, N; Kubo, N; Muranushi, R; Shirabe, K; Tsukagoshi, M; Umezawa, K; Watanabe, A; Yamanaka, T; Yokobori, T, 2021) |
| "The prognosis of hepatocellular carcinoma (HCC) is extremely poor when the condition is diagnosed at the unresectable stage as treatment options are limited." | ( Chun, HJ; Hur, W; Kang, BY; Kim, S; Kim, SM; Kim, WJ; Lee, J; Tak, E; Yoon, SK, 2021) |
| "In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival." | ( Azzaroli, F; Benevento, F; Cabibbo, G; Caturelli, E; Cucchetti, A; Di Marco, M; Farinati, F; Foschi, FG; Gasbarrini, A; Giannini, EG; Guarino, M; Marra, F; Masotto, A; Mega, A; Missale, G; Morisco, F; Nardone, G; Oliveri, F; Pontillo, G; Raimondo, G; Rapaccini, GL; Rodolfo, S; Svegliati-Baroni, G; Trevisani, F; Vidili, G; Zoli, M, 2021) |
| "Children with unresectable hepatocellular carcinoma (HCC) have a poor prognosis and limited treatment options." | ( Bista, R; Goss, JA; Heczey, A; Khan, O; Kukreja, K; Loo, C; Lopez-Terrada, D; Mahvash, A; Masand, P; Nguyen, H; Patel, K; Vasudevan, SA; Whitlock, RS, 2021) |
| "Radical treatments of hepatocellular carcinoma (HCC) with hepatic encephalopathy (HE) can be often difficult due to poor liver function or disturbance of consciousness." | ( Miyasaka, Y; Ohno, T; Okamoto, M; Okazaki, S; Osu, N; Shiba, S; Shibuya, K, 2021) |
| "The age of patients with advanced hepatocellular carcinoma (HCC) eligible for molecular-targeted drug treatment is increasing." | ( Eguchi, S; Fukushima, M; Haraguchi, M; Hashimoto, S; Hidaka, M; Iwatsu, S; Kato, Y; Kinoshita, N; Kugiyama, Y; Matsuo, S; Matsuzaki, T; Miuma, S; Miyaaki, H; Motoyoshi, Y; Nakao, K; Ohba, K; Sasaki, R; Shibata, H; Shigeno, M; Yatsuhashi, H, 2021) |
| "Despite the increasing incidence of hepatocellular carcinoma (HCC) worldwide, current pharmacological treatments are still unsatisfactory." | ( Altomare, A; Cavalluzzi, MM; Gnocchi, D; Lentini, G; Mangiatordi, GF; Mazzocca, A; Rizzi, R; Sabbà, C; Spennacchio, M; Tortorella, C, 2021) |
| "Interference of miR-93 sensitizes hepatoma cells to cisplatin or sorafenib treatment." | ( Li, J; Liu, C; Lu, J; Wang, X; Xu, F; Yang, J; Zhong, X, 2021) |
| "Human hepatoma cells Hep3B and human osteosarcoma cells U2OS were treated with Selinexor." | ( Depping, R; Dunst, J; Kosyna, FK; Landesman, Y; Mandl, M; von Fallois, M, 2021) |
| "Patients with hepatocellular carcinoma were treated on 3 prospective institutional review board-approved trials using baseline and midtreatment ICG to deliver individualized functional response adaptive liver SBRT." | ( Cuneo, KC; Gharzai, LA; Haken, RKT; Hartman, HE; Jackson, WC; Karnak, DM; Lawrence, TS; Maurino, C; Mayo, CS; Mendiratta-Lala, M; Parikh, ND; Schipper, MJ, 2021) |
| "The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges." | ( Cai, L; Cai, X; Ji, L; Liang, X; Lin, Z; Ruan, Y; Tao, L; Wan, Z; Wang, Y; Xia, S; Xu, J; Zheng, J, 2021) |
| "Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant (LT) is challenging." | ( Chan, A; Cheung, TT; Chiu, J; Kwok, GGW; Leung, R; Li, BCW; Lo, CM; Ma, KW; She, WH; Shing, K; Tang, V; Tsang, J; Yau, T, 2021) |
| "The DDS effects were evaluated in a rat hepatoma model using doxorubicin (DOX) treatment." | ( Im, M; Jeon, H; Kim, J; Kim, JH; Lee, BC; Lee, S; Shim, S, 2021) |
| "Additionally, liver hepatocellular carcinoma HepG2 cells treated with nicotine exhibited markedly enhanced proliferation via CYP1A1 expression and Akt activation." | ( Han, JY; Jung, YD; Li, S; Nguyen, TT; Ung, TT, 2021) |
| "The prognosis of hepatocellular carcinoma (HCC) remains unsatisfactory due to limited effective treatment options." | ( Cao, HJ; Chen, TW; Cheng, S; Ding, X; Li, JJ; Li, Z; Ma, N; Ni, QZ; Wang, K; Wang, X; Wang, YK; Xia, J; Xie, D; Xu, S; Zhang, EB; Zhang, F; Zhang, X; Zheng, QW; Zhu, B, 2021) |
| "Treatment of hepatocellular carcinoma (HCC) is challenging as most patients are diagnosed at advanced stage with underlying chronic liver conditions." | ( Khan, AA; Liu, ZK; Xu, X, 2021) |
| "Age, history of hepatocellular carcinoma (HCC), and PRA were identified as independent factors for prognosis after tolvaptan treatment." | ( Enomoto, N; Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Komiyama, Y; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yamashita, K; Yasui, Y, 2022) |
| "It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment." | ( Aoki, T; Arai, T; Atsukawa, M; Fukunishi, S; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Joko, K; Kariyama, K; Kawata, K; Koizumi, Y; Kudo, M; Kumada, T; Nagano, T; Nakamura, S; Nouso, K; Ochi, H; Ohama, H; Okubo, T; Shibata, H; Shimada, N; Tada, T; Tajiri, K; Takaguchi, K; Tanaka, T; Tani, J; Toyoda, H; Tsuji, K; Tsutsui, A; Yasuda, S, 2021) |
| "The landscape of hepatocellular carcinoma (HCC) has changed since the incorporation of sorafenib in 2007 as the first pharmacological treatment for HCC." | ( Iserte, G; Llarch, N; Muñoz-Martínez, S; Reig, M; Sanduzzi-Zamparelli, M, 2021) |
| "Human hepatocellular carcinoma (HCC) is major cancer type due to its poor prognosis even after treatment with chemotherapeutic drugs, which causes a variety of side effects in patients." | ( Bhosale, PB; Ha, SE; Heo, JD; Kim, GS; Kim, HH; Kim, SM; Lee, HJ; Vetrivel, P, 2021) |
| "Patients experiencing hepatocellular carcinoma and treated with 90Y-labeled resin microspheres were included in a retrospective study." | ( Blanc, JF; Bordenave, L; Debordeaux, F; Lapuyade, B; Papadopoulos, P; Pinaquy, JB; Subreville, C, 2021) |
| "Background & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs)." | ( Iwamoto, H; Kajiwara, A; Kamachi, N; Kawaguchi, T; Koga, H; Kuromatsu, R; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Shimose, S; Shirono, T; Tanaka, M; Torimura, T, 2021) |
| "Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options." | ( Ankavay, M; Bandiera, S; Bardeesy, N; Baumert, TF; Bian, CB; Chung, RT; Cocquerel, L; Croonenborghs, T; Crouchet, E; Duong, FHT; Durand, SC; El Saghire, H; Felli, E; Fernández-Vaquero, M; Fuchs, BC; Fujiwara, N; González-Motos, V; Goossens, N; Gunasekaran, G; Heide, D; Heikenwälder, M; Hetzer, J; Heydmann, L; Higashi, T; Hirschfield, H; Hoshida, Y; Jühling, F; Kiani, K; Kim, RS; Koh, AP; Li, S; Lupberger, J; Mahajan, M; Masia, R; Nair, VD; Nakagawa, S; Ono, A; Oudot, MA; Pessaux, P; Pochet, N; Ponsolles, C; Qian, T; Regev, A; Riedl, T; Roehlen, N; Rozenblatt-Rosen, O; Sanchez, R; Saviano, A; Schaeffer, E; Schuppan, D; Schuster, C; Schwartz, ME; Shalek, AK; Sojoodi, M; Song, WM; Straub, BK; Subramanian, A; Sun, X; Tanabe, KK; Thumann, C; Venkatesh, A; Verrier, ER; Wei, L; Zeisel, MB; Zhu, S, 2021) |
| "However, research related to hepatoma treatment using DHI is limited." | ( Cai, M; Chen, RX; Deng, B; Deng, SH; Ding, WJ; Jiang, XL; Liu, B; Tan, ZB; Xu, HL; Xu, YC; Zhang, JZ; Zhang, SQ; Zhang, SW, 2022) |
| "Patients with ruptured hepatocellular carcinoma treated with emergent TAE between January 2001 and December 2019 were retrospectively identified (n = 24)." | ( Andrews, JC; Fleming, CJ; Jundt, MC; Owen, RL; Stockland, AH; Thompson, SM, 2022) |
| "We report a case of hepatocellular carcinoma with a tumor thrombus at the inferior vena cava-right atrium junction and multiple lung metastases after a multiple-course treatment." | ( Liu, X; Yi, Y, 2021) |
| "Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents." | ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021) |
| "The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine." | ( Bieniek, A; Czarnecka, J; Grzanka, D; Kloskowski, T; Nowacki, M; Roszek, K; Wierzbicki, J; Wiśniewski, M; Ziętek, M, 2021) |
| "Cytokeratin 19-positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype characterized by early recurrence and chemotherapy tolerance." | ( Cen, B; Dong, S; Li, H; Lian, Z; Lin, Z; Lu, D; Shen, Y; Tao, Y; Wang, J; Wei, X; Wen, X; Xie, H; Xu, X; Yang, M; Yang, X; Zheng, S; Zhuo, J, 2021) |
| "Heterogeneity of hepatocellular carcinoma (HCC) patients as well as the shortcomings of clinical classifications, randomized clinical trials and cost-effectiveness studies make it difficult to choose between treatment alternatives in this field." | ( Akarca, US; Akhan, O; Bilgiç, S; Bozkurt, MF; Çakaloğlu, Y; Cantaşdemir, M; Çapa Kaya, G; Çermik, TF; Er, Ö; Ilgıt, E; Küçük, NÖ; Numan, F; Parıldar, M; Türkmen, C, 2021) |
| "Patient with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCC), and/or metastatic colorectal cancer (mCRC) who was treated with a dose of Y90 glass microspheres that has been reimbursed in France and who do not oppose use of their personal medical data." | ( Bailly, C; Becker, S; Blanc, JF; Boucher, E; Bouvier, A; Chevallier, P; de Baere, T; Edeline, J; Garin, E; Goupil, J; Guiu, B; Manfredi, S; Mariano-Goulart, D; Mastier, C; Patel, B; Pinaquy, JB; Regnault, H; Rode, A; Sefrioui, D; Sengel, C; Somma, C; Tordo, J; Vibert, E; Vicaut, E, 2022) |
| "The treatment algorithm of advanced hepatocellular carcinoma (HCC) has evolved since the introduction of immunotherapy." | ( Brandi, G; Bruno, R; Carloni, R; De Giglio, A; Di Federico, A; Ricci, D; Rizzo, A, 2022) |
| "Primary and established hepatoma cell lines were exposed to long-term sorafenib treatment to model acquisition of resistance." | ( Becker, D; Binder, H; Breuhahn, K; Castven, D; Czauderna, C; Galle, PR; Hajduk, J; Heilmann-Heimbach, S; Keck, T; Keggenhoff, F; Marquardt, JU; Pereira, S; Schmitt, J; Shah, V; Thorgeirsson, SS; Weinmann, A; Wörns, MA, 2022) |
| "Advanced hepatocellular carcinoma (HCC) remains a highly lethal malignancy, although several systemic therapeutic options are available, including sorafenib (SFN), which has been one of the standard treatment agents for almost a decade." | ( Fujimoto, N; Furuta, Y; Kawasaki, T; Nagaoka, K; Naoe, H; Narahara, S; Oniki, K; Saruwatari, J; Sasaki, Y; Setoyama, H; Tanaka, K; Tanaka, M; Tanaka, Y; Tateyama, M; Tokunaga, T; Watanabe, T; Yoshimaru, Y, 2022) |
| "The surgical treatment for large hepatocellular carcinoma (HCC) remains controversial because of a high risk of recurrence after resection." | ( Cho, EJ; Cho, HJ; Choi, NR; Hong, JH; Hur, MH; Hyun, D; Kim, HC; Kim, J; Kim, JM; Kim, JY; Kim, YJ; Lee, JH; Lee, KW; Lee, YB; Paeng, JC; Park, MK; Sinn, DH; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2022) |
| "Liver cancer, primarily hepatocellular carcinoma (HCC), is highly lethal with limited treatment options." | ( Chang, JC; Chen, D; Chen, MM; Chen, X; Deng, Y; Gan, B; Hang, Q; Liang, H; Liu, X; Ma, L; Martinez, C; Mei, Y; Rosato, RR; Su, X; Sun, Y; Teng, H; Wang, Y; Xie, D; Yao, F; Yap, S; You, MJ; Zhang, M; Zhang, Y; Zhao, Y; Zhu, H, 2021) |
| "It thus remains unclear which hepatocellular carcinoma (HCC) patient subpopulation(s) can benefit from metformin treatment." | ( Cai, P; Cai, Y; Deng, J; Feng, J; Gao, P; Jia, W; Lu, H; Lu, Z; Ma, W; Qu, K; Shu, Y; Sun, Y; Tian, W; Yang, H; Zhang, H; Zhou, Z, 2022) |
| "The treatment landscape for advanced hepatocellular carcinoma (aHCC) is rapidly expanding beyond tyrosine kinase inhibitors (TKIs) in the first-line (1L) setting, with multiple TKIs and immune-checkpoint inhibitors (ICIs) now being evaluated in combination." | ( Aly, A; Feinberg, B; Healey, MJ; Klink, AJ; Marshall, LZ; Seal, B, 2022) |
| "For patients with hepatocellular carcinoma, as well as physicians treating hepatocellular carcinoma, the quality of life that different treatments can offer represents an increasingly important aspect to consider when choosing treatments." | ( Agirrezabal, I; Brennan, VK; Chatellier, G; Colaone, F; Pereira, H; Shergill, S; Vilgrain, V, 2022) |
| "The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly evolved." | ( Harris, WP; King, GG; Wong, KM, 2022) |
| "Adults with confirmed hepatocellular carcinoma who experienced progression after or intolerance to sorafenib treatment received pembrolizumab 200 mg every 3 weeks for ≤35 cycles or until confirmed progression, unacceptable toxicity, withdrawal of consent or investigator decision." | ( Cattan, S; Chan, SL; Cheng, AL; Daniele, B; Edeline, J; Fartoux, L; Finn, RS; Gurary, EB; Knox, J; Kudo, M; Ogasawara, S; Palmer, DH; Sarker, D; Siegel, AB; Verset, G; Verslype, C; Vogel, A; Wang, A; Yau, T; Zagonel, V; Zhu, AX, 2022) |
| "The treatment of hepatocellular carcinoma (HCC) has been dominated by multikinase inhibitors for more than a decade." | ( Cai, L; Cai, X; Chen, J; He, J; Ji, T; Jiang, S; Li, B; Liang, X; Shao, H; Staiculescu, D; Xu, J; Zhao, J, 2022) |
| "When administered to a mouse model of hepatocellular carcinoma (HCC), tTF-EG3287@Liposomes showed prolonged retention and enhanced accumulation in the tumor as well as a superior antitumor effec, compared with tTF-EG3287." | ( Lai, W; Li, M; Liu, C; Liu, J; Luo, F; Luo, X; Wang, L; Wang, S; Xu, P; Yan, J; Zhao, Z, 2022) |
| "175 ruptured hepatocellular carcinoma (HCC) patients treated with hepatectomy were included." | ( Chen, X; Liu, Z; Ndhlovu, E; Xia, F; Zhang, B; Zhu, P, 2022) |
| "Successful hepatocellular carcinoma (HCC) therapy in vivo remains a significant challenge due to the down-regulated expression of the receptors on the surface of tumor cells for compromised active targeting efficiency and cellular uptake of nanoparticles (NPs)-based drug delivery systems (DDSs) and "accelerated blood clearance" and premature unpackaging of NPs in vivo induced by the poly(ethylene glycol)ylation (PEGylation)." | ( He, DX; Huang, C; Ling, XL; Liu, Y; Long, JR; Lv, SY; Wang, YQ; Wei, H; Xu, CH; Ye, PJ; Yu, CY, 2022) |
| "Immunotherapy for hepatocellular carcinoma (HCC) exhibits limited clinical efficacy due to immunosuppressive tumor microenvironment (TME)." | ( Feng, H; Gao, Y; Guo, J; Han, Q; Ji, L; Li, F; Li, M; Li, Y; Sheng, J; Sun, X; Tang, Y; Wang, L; Yu, Z; Zhang, J; Zheng, Y, 2022) |
| "The first-line treatment for advanced hepatocellular carcinoma (HCC) is the multikinase inhibitor sorafenib (SOR)." | ( Abdel-Hamed, AR; Abo-Elmatty, DM; Abulsoud, AI; Al-Noshokaty, TM; Mesbah, NM, 2022) |
| "Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis." | ( Aikata, H; Amioka, K; Ando, Y; Awai, K; Chayama, K; Chosa, K; Imamura, M; Kawaoka, T; Kikukawa, C; Kodama, K; Kosaka, Y; Kubo, K; Murakami, E; Nagata, Y; Nakahara, T; Naruto, K; Ogawa, Y; Okamoto, W; Ono, A; Suehiro, Y; Takahashi, S; Uchida, T; Uchikawa, S; Yamaoka, K; Yamauchi, M; Yoshikawa, Y, 2022) |
| "Chemoresistance is a major obstacle to hepatocellular carcinoma (HCC) chemotherapy." | ( Chen, H; Jiang, L; Li, J; Li, Y; Tan, X; Wang, J, 2022) |
| "Individuals with hepatocellular carcinoma who responded to anti-PD-1 treatment have lower levels of MOESIN lactylation in Treg cells than nonresponding individuals." | ( Chen, Q; Gao, J; Gu, J; Li, X; Liang, Y; Lu, L; Shao, Q; Wang, Q; Wei, S; Xu, X; Zhou, B; Zhou, H; Zhou, J, 2022) |
| "Locoregional treatments for hepatocellular carcinoma (HCC) induce immunogenic cell death and a tumor-specific immune response, but infiltration and activation of immune cells in the liver have not been clearly described." | ( Chun, HJ; Han, JW; Hur, W; Jin, L; Kang, BY; Kim, SM; Kim, WJ; Roh, PR; Sung, PS; Tak, E; Yoon, SK, 2022) |
| "GF treatment induced CDRs in the hepatocellular carcinoma (HCC) Hep3B cell line, but not in others, including HCC cell lines HepG2 and Huh7, and the LO2 hepatocyte cell line." | ( Hua, R; Liu, Y; Shen, Z; Sun, X; Wang, L; Wei, J; Yoshida, S; Zhou, S, 2022) |
| "Among all cancers, hepatocellular carcinoma (HCC) remains a lethal disease with limited treatment options." | ( Ahn, KS; Jung, YY; Sethi, G; Um, JY, 2022) |
| "Treatment of the human hepatoma cell lines, HepG2 and SK-Hep-1, with various concentrations of curcumin revealed a time-dependent and concentration-dependent inhibition of cell proliferation, increased apoptosis, cell cycle arrest at the G0/G1 phase, reduced mitochondrial membrane potential, and reduced expression levels of PI3K, p-PI3K, AKT, p-AKT, GSK-3β, and p-GSK-3β." | ( Bai, C; Chen, J; Cui, X; Su, J; Sun, M; Zhang, X; Zhao, J, 2022) |
| "In this prospective cohort study in hepatocellular carcinoma patients referred for tumor-specific therapy, nutritional status was assessed before and 3 months post-treatment using 4 complementary tools: hand-grip strength (HGS), Liver Frailty Index (LFI), Patient-Generated Subjective Global Assessment (PG-SGA) and skeletal muscle index (L3-SMI)." | ( Bruins Slot, AS; Coppens, BJP; de Bruijne, J; van Beers, MA; van Dijk, AM; van Erpecum, KJ; Verstraete, CJR; Vleggaar, FP, 2022) |
| "To establish the mice model of hepatocellular carcinoma with the administration of a suitable dose of diethylnitrosamine (DEN) and examine the utility of EphA7 and pEphA7 as ideal diagnostic markers in HCC." | ( Kma, L; Priya, S, 2022) |
| "Firstly, hepatocellular carcinoma cells were treated with butorphanol." | ( Guo, P; Hai, L; Hu, Q; Nie, X; Wang, J; Zhao, Q, 2022) |
| "Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly." | ( Barsoum, M; Khan, U; Noginskiy, I; Pak, T; Singh, A; Usta, S; Zahid, S, 2022) |
| "This study enrolled 72 patients with hepatocellular carcinoma who received hepatic arterial infusion chemotherapy using cisplatin at Kurashiki Central Hospital between January 2011 and May 2019." | ( Kayahara, T; Mizuno, M; Morimoto, Y; Okuyama, S; Takabatake, H; Ueno, M, 2022) |
| "The specificity and sensitivity of hepatocellular carcinoma (HCC) diagnostic markers are limited, hindering the early diagnosis and treatment of HCC patients." | ( Hou, Q; Huang, H; Peng, Q; Sun, X; Wei, S; Xiao, Y; Zhang, Z; Zhu, C, 2022) |
| "Liver hepatocellular carcinoma (HCC) is a prevalent cancer that lacks a sufficiently efficient approach to guide immunotherapy." | ( Bian, X; Guo, J; Li, W; Qiu, W; Sun, L; Wang, G; Wang, S; Xiao, R; Zhang, Y; Zhao, S, 2022) |
| "Lenvatinib resistance during hepatocellular carcinoma treatment has become increasingly common in recent years." | ( Guo, J; Huang, D; Xu, Q; Zhao, J, 2022) |
| "At present, the treatment of hepatocellular carcinoma (HCC) is disturbed by the treatment failure and recurrence caused by the residual liver cancer stem cells (CSCs)." | ( Chen, Z; Li, F; Li, Y; Wang, Y; Wang, Z; Xi, X; Xu, L, 2023) |
| "Targeted and immunotherapy drugs for hepatocellular carcinoma (HCC) have been rapidly developed." | ( Miao, TG; Nan, YM, 2022) |
| "Human HCC-LM3 and SK-Hep-1 hepatoma cells were used and treated with or without osthole, irradiation, or their combination; the cell survival, migration, colony formation, DNA damage repair, intracellular lactic acid content, and glycolysis-related glycogen synthase kinase-3β (GSK-3β), p-GSK-3β, AMP-activated protein kinase (AMPK), p-AMPK, mammalian target of rapamycin (mTOR), p-mTOR, glucose transporter-1 (GLUT-1), GLUT-3, and pyruvate kinase isozyme type M2 (PKM2) protein expressions were determined." | ( Huang, H; Xie, ML; Xie, T; Xue, J, 2023) |
| "Human HCC-LM3 and SK-Hep-1 hepatoma cells were used and treated with or without osthole, irradiation, or their combination; the cell survival, migration, colony formation, DNA damage repair, intracellular lactic acid content, and glycolysis-related glycogen synthase kinase-3β (GSK-3β), p-GSK-3β, AMP-activated protein kinase (AMPK), p-AMPK, mammalian target of rapamycin (mTOR), p-mTOR, glucose transporter-1 (GLUT-1), GLUT-3, and pyruvate kinase isozyme type M2 (PKM2) protein expressions were determined." | ( Huang, H; Xie, ML; Xie, T; Xue, J, 2023) |
| "Although immunotherapy of hepatocellular carcinoma using immune checkpoint inhibitors has achieved certain success, only a subset of patients benefits from this therapeutic strategy." | ( Chen, B; Chen, Y; Dai, H; Du, JZ; Fan, K; Huang, Y; Liang, Q; Liao, C; Lin, R; Liu, R; Tang, K; Wang, J; Wu, Q; Yan, X; Zeng, L; Zhu, H, 2023) |
| "Although immunotherapy of hepatocellular carcinoma using immune checkpoint inhibitors has achieved certain success, only a subset of patients benefits from this therapeutic strategy." | ( Chen, B; Chen, Y; Dai, H; Du, JZ; Fan, K; Huang, Y; Liang, Q; Liao, C; Lin, R; Liu, R; Tang, K; Wang, J; Wu, Q; Yan, X; Zeng, L; Zhu, H, 2023) |
| "We describe a 56-year-old male with hepatocellular carcinoma treated with epirubicin chemoembolization." | ( Bacis, G; Baldan, A; Butera, R; Contessa, G; Eleftheriou, G; Fagiuoli, S; Faraoni, L; Gallo, M; Giampreti, A; Lucà, M; Schranz, M, 2022) |
| "We describe a 56-year-old male with hepatocellular carcinoma treated with epirubicin chemoembolization." | ( Bacis, G; Baldan, A; Butera, R; Contessa, G; Eleftheriou, G; Fagiuoli, S; Faraoni, L; Gallo, M; Giampreti, A; Lucà, M; Schranz, M, 2022) |
| "Curative treatment for hepatocellular carcinoma (HCC) is limited to hepatic resection (HR), radiofrequency ablation, and liver transplantation, but the value of particle therapy (PT) as an initial treatment remains unclear." | ( Fukumoto, T; Komatsu, S; Matsuo, Y; Okimoto, T; Omiya, S; Terashima, K; Tokumaru, S; Toyama, H; Yamasaki, N, 2023) |
| "Subsequently, knockdown of FNDC5 in hepatocellular carcinoma cells resulted in their diminished resistance to cell death after chemotherapy with nab-paclitaxel." | ( Cao, J; Cui, W; Liu, H; Pang, J; Shi, G; Zhou, Y, 2022) |
| "An optimal sequential anti-hepatocellular carcinoma (HCC) agent that can be used after failed lenvatinib treatment has not been established." | ( Ahn, SH; Goh, MJ; Kang, W; Kim, BK; Kim, DY; Kim, SU; Kim, Y; Lee, HW; Lee, JS; Park, JY, 2023) |
| "The efficacy of treatment for advanced hepatocellular carcinoma (HCC) has remained limited." | ( Chiou, LL; Chou, HC; Hsu, YC; Lee, HS; Liang, JD; Liu, SY; Sheu, JC; Wang, LF; Weng, MT; Wu, MC; Yang, SF, 2023) |
| "Subsequently, human hepatocellular carcinoma (HCC) cell lines, H22 and HepG2 cells, were treated with quercetin, and BALB/c mice were injected with H22 cells and treated with different concentrations of quercetin." | ( Chen, J; Tian, S; Tian, X; Wang, Y; Wu, R; Xiong, J; Zhang, Z; Zhou, T, 2022) |
| "Sarcomatoid hepatocellular carcinoma (sHCC) is a rare phenotype of HCC with extremely poor prognosis and no established pharmacological treatment." | ( Goto, Y; Hayashi, Y; Muraishi, N; Murayama, A; Tajiri, K; Tanaka, S; Yasuda, I, 2023) |
| "Treatment of hepatocellular carcinoma (HCC) with Y90 radioembolization segmentectomy (Y90-RE) demonstrates a tumor dose-response threshold, where dose estimates are highly dependent on accurate SPECT/CT acquisition, registration, and reconstruction." | ( Gichoya, J; Kokabi, N; Villalobos, A; Wagstaff, WV, 2023) |
| "Historically, high hepatocellular carcinoma (HCC)-related mortality has been, in part, due to lack of effective therapies; however, several systemic therapies have been recently approved for HCC treatment, including regorafenib and ramucirumab." | ( Boeri, M; Chatterjee, A; Coulter, J; Gable, J; Girvan, A; Kim, S; Parikh, ND; Poon, JL, 2023) |
| "To understand how PD inhibited hepatocellular carcinoma (HCC), we studied PD treatments in HCC HepG2 and SK-HEP1 cells, and normal liver HL-7702 cells." | ( Farooq, U; Hu, J; Jehan, S; Li, D; Li, G; Shi, J; Sui, G; Wang, H, 2023) |
| "The chemotherapeutic landscape for hepatocellular carcinomas (HCCs) has changed dramatically with the availability of several treatment options." | ( Fukumoto, T; Goto, T; Kido, M; Kodama, Y; Komatsu, S; Kuramitsu, K; Nakagawa, D; Omiya, S; Shimura, Y; Toyama, H; Ueda, Y; Yamamoto, A; Yanagimoto, H; Yano, Y, 2023) |
| "In mouse models with hepatoma xenografts or with Myc/sgp53-induced liver cancer, dietary fructose enhanced tumor angiogenesis, tumor growth, and metastasis, which could be attenuated by treatment with an inhibitor of SLC2A5." | ( Cai, JL; Chen, JG; Chen, JY; Fang, JH; Wang, ZY; Wu, CH; Zeng, HX; Zheng, JL; Zhuang, SM, 2023) |
| "We report a case of hepatocellular carcinoma evaluated as complete response by combined lenvatinib and radiofrequency ablation therapy." | ( Iwatani, Y; Mimura, D; Oyama, T; Tanaka, K; Yamano, A; Yamano, T; Yano, Y, 2023) |
| "Co-culture of HEV-infected hepatoma cells with PBMCs and treatment with RBV both resulted in a decrease in viral replication, which in combination showed an additive effect." | ( Adenugba, A; Bitterer, F; Geissler, EK; Kupke, P; Schemmerer, M; Schlitt, HJ; Wenzel, JJ; Werner, JM, 2023) |
| "Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development." | ( Iwamoto, H; Kawaguchi, T; Niizeki, T; Shimose, S; Shirono, T, 2023) |
| "The treatment landscape of hepatocellular carcinoma (HCC) has significantly changed over the last 5 years with multiple options in the frontline, second line, and beyond." | ( Abbati, C; Chen, R; Granito, A; Ielasi, L; Stefanini, B; Tonnini, M; Tovoli, F, 2023) |
| "For patients with advanced hepatocellular carcinoma (HCC), hepatic artery infusion chemotherapy (HAIC) is a common and mature treatment, but the safety and efficacy of HAIC combined with lenvatinib for advanced HCC patient treatment remains unclear." | ( Wang, Q; Wang, X; Wen, H; Yuan, W; Yue, W, 2023) |
| "The occurrence of hepatocellular carcinoma after the treatment of chronic hepatitis B is a major problem." | ( Cheng, H; Guo, Y; Tang, K; Wang, H, 2023) |
| "The occurrence rate of hepatocellular carcinoma after the treatment of tenofovir for chronic hepatitis B is lower than that of the treatment of entecavir." | ( Cheng, H; Guo, Y; Tang, K; Wang, H, 2023) |
| "Among cancer-related deaths, hepatocellular carcinoma (HCC) ranks fourth, and traditional Chinese medicine (TCM) treatment is an important complementary alternative therapy for HCC." | ( Lai, Z; Liu, Z; Ma, H, 2023) |
| "Thirty-two patients with hepatocellular carcinoma (HCC) or metastases treated on trials of liver SBRT (30-57 Gy, 6 fractions) and concurrent sorafenib were analyzed." | ( Bissonnette, JP; Chen, J; Craig, T; Dawson, LA; Munoz-Schuffenegger, P; Tadic, T; Velec, M, 2023) |
| "Efficiently synergistic therapy of hepatocellular carcinoma (HCC) by chemotherapeutic drug and photothermal agent remains a considerable challenge." | ( Li, S; Li, X; Luo, H; Mo, C; Mo, Q; Qin, Y; Wang, Z; Yang, F; Yang, J, 2023) |
| "Sorafenib is the first line drug for hepatocellular carcinoma (HCC) therapy." | ( Huang, L; Li, W; Lin, C; Lv, L; Saw, PE; Xu, R; Xu, X; Yang, X; Yao, Y, 2023) |
| "Treatment strategy for hepatocellular carcinoma (HCC) and Vp4 [main trunk] portal vein tumor thrombosis (PVTT) remains limited due to posttreatment liver failure." | ( Cao, GS; Chen, SQ; Gao, K; Guo, JH; Ji, JS; Lau, WY; Li, HL; Li, R; Li, YL; Lu, D; Lu, J; Lu, LG; Lv, WF; Min, J; Ren, WX; Shao, HB; Sun, JH; Teng, GJ; Wang, WD; Wang, WJ; Wu, FZ; Yang, P; Yin, GW; Zhang, FJ; Zhao, Y; Zhu, GY; Zhu, HD, 2023) |
| "Malignant ascites in advanced hepatocellular carcinoma (HCC) is a complex clinical problem that lacks effective treatments." | ( Deng, S; Deng, Y; Hu, Y; Huang, J; Jin, H; Liao, Z; Liu, Y; Lovell, JF; Meng, J; Tian, Y; Tuo, Z; Yang, K; Yang, X; Zhou, Z, 2023) |
| "Traditional treatments for hepatocellular carcinoma (HCC) still lack effectiveness." | ( Chen, X; Geng, J; Guo, Y; Kong, G; Li, Z; Shen, H; Sun, J; Tian, H; Wang, F; Wang, H; Yu, S; Zhang, L; Zhao, Y, 2023) |
| "In vivo, the H22 mouse model of hepatocellular carcinoma was established by treatment with CTD and 5-Fu." | ( Deng, XL; Gao, YM; Hui Li, Y; Ma, SQ; Shi, GT; Wang, HS; Yan, J, 2023) |
| "Two patients with unresectable hepatocellular carcinoma underwent high-resolution digital subtraction angiography (DSA) and perfusion four-dimensional computed tomography during hepatic arteriography (4D-CTHA) before and after administration of lenvatinib treatment." | ( Chanoki, Y; Ito, T; Kunichika, H; Maeda, S; Marugami, N; Matsumoto, T; Minamiguchi, K; Nishiofuku, H; Sato, T; Tachiiri, T; Taiji, R; Tanaka, T; Toyoda, S; Yamauchi, S, 2023) |
| "Pharmacological treatments for advanced hepatocellular carcinoma (HCC) have a partial efficacy." | ( Alchera, E; Baroni, S; Borsotti, C; Carini, R; Clemente, N; Corrazzari, M; Crich, SG; Fiorilla, S; Follenzi, A; Reano, S; Ruggiero, MR; Tasso, F; Walker, G, 2023) |
| "Patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombosis (PVTT) are presently lacking effective treatment options." | ( Duan, X; Ji, X; Li, W; Sun, J; Wang, Q; Xu, Z, 2023) |
| "Advanced hepatocellular carcinoma (HCC) is a formidable public health problem with limited curable treatment options." | ( Jiang, H; Jin, C; Liao, J; Mo, J; Wang, L; Xiang, S, 2023) |
| "The response of advanced hepatocellular carcinoma (HCC) to pharmacological treatments is unsatisfactory and heterogeneous." | ( Briz, O; Marin, JJG; Romero, MR; Sanchez-Martin, A; Sanchon-Sanchez, P, 2023) |
| "Currently, conventional treatments of hepatocellular carcinoma (HCC) are not selective enough for tumor tissue and lead to multidrug resistance and drug toxicity." | ( Aliberti, A; Buonaguro, L; Caputo, TM; Carriero, MV; Celetti, G; Cicatiello, P; Cusano, A; Cusano, AM; Micco, A; Minopoli, M; Principe, S; Ragone, C; Ruvo, M; Tagliamonte, M, 2023) |
| "Considering the lower risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving long-term potent antiviral therapy, models predicting HCC after 5 years of therapy are needed." | ( Chon, YE; Ha, Y; Han, S; Hwang, SG; Kim, KM; Kim, MN; Lee, D; Lee, HC; Lee, JH; Lim, J; Shim, JH, 2023) |
| "The treatment of hepatocellular carcinoma (HCC) is undergoing a historic transformation with the approval of several new systemic therapies in the last few years." | ( Beier, D; Ben Khaled, N; Berger-Thürmel, K; De Toni, EN; Ehmer, U; Geier, A; Kubisch, I; Lange, CM; Mayerle, J; Mörtl, B; Munker, S; Pawlowska-Phelan, D; Philipp, A; Reiter, FP; Rössler, D; Schwade, DF; Teufel, A, 2023) |
| "When treating hepatocellular carcinoma with a portal vein tumor thrombus, the computer retrieves eight databases to find controlled trials on the effects of transcatheter arterial chemoembolization combined with apatinib." | ( Hu, Y; Huang, L; Xu, Z, 2023) |
| "Reduced enzyme activity in hepatocellular carcinoma (HCC) and poor targeting limit the application of enzyme-activating prodrugs, which is also detrimental to the effective treatment of HCC." | ( Chen, W; Chen, Y; Meng, X; Pan, J; Wang, F; Wang, L; Ye, X; Zhang, X, 2023) |
| "Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy." | ( Atsukawa, M; Azemoto, R; Haga, Y; Ikeda, M; Inaba, Y; Inoue, M; Ito, K; Itobayashi, E; Itoh, Y; Itokawa, N; Kanogawa, N; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Maruta, S; Moriguchi, M; Morimoto, N; Nakamoto, S; Nakamura, K; Nakamura, M; Ogasawara, S; Okabe, S; Okubo, T; Ooka, Y; Seko, Y; Shiko, Y; Suzuki, E; Takatsuka, H; Watanabe, S, 2023) |
| "Sorafenib is an oral treatment for hepatocellular carcinoma (HCC)." | ( Cui, M; Fang, Z; Lai, K; Liu, K; Song, M; Yin, M, 2023) |
| "However, the internal situation of hepatocellular carcinoma (HCC) is complex, separate SDT treatment is difficult to play a good therapeutic effect." | ( Chen, Y; Cheng, W; Tian, H; Wang, C; Wang, X; Wu, B, 2023) |
| "Apoptosis resistance of hepatocellular carcinoma (HCC) often leads to treatment failure." | ( Chen, Y; Cheng, W; Shang, H; Tian, H; Wang, C; Wang, X; Wu, B, 2023) |
| "Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC." | ( Bai, Z; Cai, C; Dai, Y; Jia, Y; Li, J; Li, P; Lin, E; Liu, X; Wang, B; Zeng, G; Zhao, J; Zhuo, W; Zou, B, 2023) |